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Substantial evidence from family and twin studies confirms the importance of genes 
in influencing susceptibility to Bipolar Disorder (BPD) and Depression. Genome-
wide association studies have uncovered a few genetic variants of small effect that 
explain only a fraction of the total heritability of these disorders, and linkage studies 
have not been able to identify consistent and replicable findings, possibly due to 
phenotypic complexity and genetic heterogeneity. Large multigenerational families 
work as powerful samples to mapping loci for complex diseases as they segregate 
fewer disease causing genes than a collection of independent nuclear families. These 
fewer genes segregating may also be more highly penetrant and easier to detect in 
linkage studies. 
This study performed a whole genome linkage scan of a large 
multigenerational family from Brazil segregating a severe form of BPD and unipolar 
depression with the aim of localising and identifying genetic variants that contribute 
to the development of BPD. The ‘Brazilian Bipolar Family’ (BBF) is one of the 
largest reported in the literature. Three hundred and eight family members were 
interviewed using the Structured Clinical Interview for DSM-IV Axis I Disorders 
(SCID) and the Kiddie-SADS-Present and Lifetime Version (K-SADS-PL) and three-
hundred and twenty-four family members were genotyped using the Affymetrix 10K 
array. Parametric and non-parametric linkage analyses were performed using four 
hierarchical phenotype models. Four genome-wide significant linkage regions were 
identified on chromosomes 2p23.1-p22.3, 3p24.3-p24.1, 11p15.4, and 12q24.22-
q24.32, and four suggestive linkage regions were identified on chromosomes 1p22.2-
p21.3, 1q21.1-q21.3, 12p13.32-p13.31, and 22q11.21-q12.1, which either conferred 
 III! 
specific risk to BPD, unipolar depression, or provided evidence for a general mood 
disorder liability. 
To determine the role of the identified linkage regions in sporadic bipolar and 
depression cases, I performed a case control association analysis using bipolar and 
depression case control cohorts. None of the linkage regions identified in the BBF 
were found to be associated with BPD or depression. The future aim of this project is 
to determine the functional variants within the identified linkage regions that may be 
contributing to the development of mood disorders in the BBF through sequencing 
analysis, which is already underway. 
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Chapter 1 General Introduction 
1.1 Bipolar Disorder Definition  
Bipolar disorder (BPD) is often now considered to be a spectrum of mood disorders 
that characteristically involve recurrent mania, or milder forms of ‘high’ mood, and 
depressive states (Smith et al., 2011). Disorders within this spectrum display a 
gradation in symptom severity and impairment. The ’classic’ varieties of BPD are 
distinguished in the official nomenclature of Diagnostic and Statistical Manual of 
Mental Disorders Fourth Edition (DSM-IV) (American Psychiatric Association, 1994) 
as Bipolar I Disorder (BPI) and Bipolar II Disorder (BPII), characterised by at least 
one episode of mania and one episode of hypomania respectively. Mania and its less 
severe form hypomania feature elevated or irritable mood associated with a number of 
persistent symptoms; inflated self-esteem or grandiosity, distractibility, flight of ideas 
or racing thoughts, pressured speech, increase in goal directed behaviour, and 
decreased need for sleep. The two forms of mania are almost identically defined 
except mania causes impairment in social, occupational, and personal functioning 
usually requiring hospitalisation, while hypomania does not. Psychotic symptoms, in 
the form of hallucinations and delusions also differentiate between the two, occurring 
in mania but never in hypomania. Although some patients with BPD experience only 
‘highs’ the majority also have major depressive episodes, and oscillations between 
mania or hypomania and depression occur with relatively euthymic periods in 
between. 
Also within the bipolar spectrum are cyclothymia, a persistent mood 
instability, characterised by episodes of hypomania and mild depression lasting for at 
least two years with little interruption, and Bipolar Disorder Not Otherwise Specified 
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(BPNOS), an interesting and nebulous DSM diagnostic category that encompasses 
bipolar symptoms that do not fit into any of the three bipolar DSM categories 
described above. BPNOS includes subthreshold manic and hypomanic episodes that 
do not meet the duration requirement to qualify as actual episodes; manic or mixed 
episodes superimposed on delusional disorder, residual schizophrenia, or psychotic 
disorder not otherwise specified; manic or hypomanic episodes without depressive 
episodes; hypomanic episodes occurring along with chronic depression that are too 
infrequent to qualify as cyclothymia, or; drug induced manic or hypomanic episodes. 
The spectrum of BPD is extended to include schizoaffective disorder, bipolar 
type, referred to herein and after as SAD. Schizoaffective disorder is a perplexing 
mental illness that has both features of schizophrenia, including hallucinations, 
delusions, and distorted thinking, and features of either depression or mania. For a 
diagnosis of schizoaffective disorder to be given psychosis must be experienced for a 
period of two weeks without signs of mania or depression. Gershon et al. (1982) in 
line with Tsuang et al. (1979) advocated the extension of the BPD spectrum to include 
schizoaffective disorders based on observations from family data where over-
transmission of BPD, schizoaffective disorder and unipolar depression was observed 
in families of probands with mood disorders. Schizoaffective disorder has an 
interesting history in the DSM where it was initially considered as a subtype of 
schizophrenia (DSM-I and DSM-II), then as a “Psychotic Disorder Not Otherwise 
Specified,” in DSM-III and as its own separate diagnostic criteria in the revised third 
edition of the DSM in which the depression and mania subtypes were delineated. In 
the current edition of the DSM it is categorised under “Schizophrenia and other 
Psychotic Disorders.” In genetic studies, schizoaffective disorder, bipolar subtype 
(SAD) is often considered a severe subtype of BPD.  
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1.2 Epidemiology of Bipolar Disorder 
It is estimated that broadly defined bipolar spectrum disorders including cyclothymia 
and BPNOS occur with a lifetime prevalence of 5 to 8% (Judd & Akiskal, 2003) with 
some studies citing rates as high as 11% (Angst et al., 2003). This estimate is reduced 
to 1.5% to 3.9% when a narrower definition of bipolarity including only BPI and BPII 
disorder is considered and to approximately 1% when BPI disorder only is considered 
(Grant et al., 2005; Kessler, Chiu, Demler, & Walters, 2005; Weissman et al., 1996). 
These prevalence estimates mirror the increase in symptom severity from BPI 
disorder to subthreshold bipolar symptoms under the diagnosis of BPNOS, with the 
more severe BPI disorder occurring with less frequency in the population. There is no 
evidence of sex differences in the rates of BPI disorder, however, there is evidence 
that women are over-represented in BPII disorder (Arnold, 2003).  
Onset of BPD usually occurs in adolescence or early adulthood, with a mean 
age of onset around 21 years old (Weissman et al., 1996). Subtypes of BPD have been 
associated with different ages of onset. A U.S population based study reported an age 
of onset of 18.2 years for BPI disorder, 20.3 years for BPII disorder and 22.2 years for 
subthreshold hypomania falling under the umbrella of BPNOS (Merikangas et al., 
2007). Further, it is suggested that there are three peak ages of onset for BPD, 
occurring in adolescence between 14 and 18 years old, in early adulthood between 25 
and 27 years old, and in adulthood between 40 and 46 years old (Bellivier et al., 2003; 
Leboyer, Henry, Paillere!Martinot, & Bellivier, 2005).  
The recurrent nature of manic and depressive symptoms in BPD makes it a 
very debilitating disease. The World Health Organisation reports BPD as the seventh 
cause of years lost due to disability worldwide, outranking all cancers and primary 
neurologic disorders, such as epilepsy and Alzheimer's disease, primarily because of 
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its early onset and chronicity across the lifespan (Mathers, Fat, & Boerma, 2008). 
BPD is also a leading cause of premature mortality due to suicide with reports of 40 
to 45% of sufferers attempting suicide and 15 to 20% completing suicide (Osby, 
Brandt, Correia, Ekbom, & Sparen, 2001).  
 
1.3 Heritability of Bipolar Disorder 
1.3.1 Family Studies 
Family studies address whether a disorder clusters in families by comparing the 
prevalence of the disorder among first-degree relatives of affected probands (cases) to 
the prevalence in the general population or among relatives of unaffected probands 
(controls). They also attempt to clarify the genetic overlap between clinical disorders 
or subtypes of a disorder by following their co-segregation in families (Sham, 1996). 
It is important to keep in mind that while family studies support the possibility that 
genes influence a disorder, they cannot establish the role of genes or estimate the 
magnitude of their influence, as familiality may be caused by environmental, genetic, 
and gene-environment interactions.  
Family studies consistently point to the role of genetics in the aetiology of 
BPD. Approximately 20 family studies confirm that first-degree relatives of probands 
with BPD have a 5 to 10 fold increase in risk of developing BPD compared to 
relatives of controls. The increased heritability is not however limited to BPD, as a 
three fold increase in the risk of developing unipolar depression is also reported in 
first degree relatives of probands with BPD compared to controls indicating that it 
does not “breed true” (Jones, Kent, & Craddock, 2002).  
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The overlap between bipolar spectrum disorders has been partially clarified by 
family studies. The main question being, are BPD subtypes distinct entities or are they 
all variants of the same disorder with similar familial patterns of segregation? Some 
studies have reported the risk of BPI disorder to be elevated in the families of BPII 
probands, the risk of BPII disorder to be elevated in the families of BPI probands, and 
the risk of unipolar depression to be similar in families of BPI and BPII probands 
(Smoller & Finn, 2003), thus suggesting that the two bipolar subtypes are similar, 
while other studies have reported that the risk of BPII disorder to be high among 
families of BPII probands only (Heun & Maier, 1993), suggesting that it is a distinct 
disorder. The risk of BPI disorder in the relatives of schizoaffective probands has also 
been reported to be elevated (Andreasen et al., 1987) and vice versa where the risk of 
schizoaffective disorder has been reported to be elevated in the relatives of BPD (and 
schizophrenia) probands  (Kendler et al., 1993a) attesting to the relatedness of the 
disorders.  
The co-segregation of cyclothymia with the ‘classic’ subtypes of BPD is 
documented by a few studies that report the clustering of BPI, BPII, and cyclothymia 
in families (Akiskal & Akiskal, 1992; Klein, Clark, Dansky, & Margolis, 1988). 
However, no published studies address the familial overlap between subthreshold 
manifestations of bipolar disorder and BPI or BPII disorder.  
1.3.2 Twin Studies 
Twin studies compare the concordance rates of a disorder between monozygotic (MZ) 
and dizygotic (DZ) twins in an attempt to untangle the genetic determinants of disease 
from other familial factors. Under the assumption that shared environmental 
influences on MZ twins are not different from shared environmental influences on DZ 
twins, higher concordance rates in MZ twins are taken to reflect genetic influences. 
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Additive genetic influences, shared familial environment (e.g. social class, parents’ 
rearing style), and specific environment (e.g. stressful life events) are used to estimate 
heritability, defined as the proportion of phenotypic variance attributed to genetic 
influences, using model fitting (Sham, 1996).  
Twin studies have repeatedly documented that the concordance rates for BPD 
are significantly greater among MZ twins than among DZ twins. The three largest 
recent twin studies have reported a concordance rate of 38.5% to 43% for MZ twins 
compared with 4.5% to 5.6% for DZ twins (Kendler, Pedersen, Neale, & Mathé, 
1995; Kieseppa, Partonen, Haukka, Kaprio, & Jouko, 2004; McGuffin et al., 2003). 
Further, estimates of BPD heritability from these studies are high: 93% estimated by 
Kieseppa et al. (2004) in a population based study of 38 monozygotic twins in 
Finland, 85% estimated by McGuffin et al. (2003) in a hospital study of 67 twin pairs 
in the UK, and 83% estimated by Kendler et al. (1995) in a population based study of 
35 twins in Sweden. The three studies attributed the remaining variance in liability to 
BPD, an estimated 7%, 15%, and 17% respectively, to specific non-familial 
environmental factors. These findings suggest that most of the familiality of BPD 
could be accounted for by additive genetic effects with no contribution from shared 
family environment.  
1.3.3 Adoption Studies 
Adoption studies compare the rates of a disorder in biological family members to 
those in adoptive family members to distinguish genetic from environmental 
influences on a disease.  If biological family members resemble each other more than 
adoptive family members then the disorder is influenced by genetics, and if adoptive 
family members resemble each other more than biological family members then the 
disorder is influences by environmental factors. Two adoption studies found the 
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biological parents of adopted-away children with BPD had a higher frequency of 
affective illness (BPD, unipolar depression, schizoaffective disorder, and 
cyclothymia) than adoptive parents (Mendlewicz & Rainer, 1977; Wender et al., 
1986) and one study showed no evidence of a genetic effect (von Knorring, 
Cloninger, Bohman, & Sigvardsson, 1983). It is important to note, however, that BPD 
adoption studies are based on small samples and are therefore regarded as 
inconclusive.  
 
1.4 The Definition of Bipolar Disorder in Genetic Research 
The definition of BPD in genetic research is a debated topic. Some authorities, e.g. 
Baldessarini (2000) and Soares & Gershon (2000) advocate using narrowly defined 
BPD, mainly BPI disorder and/or SAD in genetic research as perhaps being more 
familial than more broadly defined mood disorders. Under this view, sub-dividing 
BPD into clinically homogenous groups that are reliably assessed either through 
clinical history or an assessment instrument is performed with the aim of defining a 
‘tighter’ phenotype for genetic studies (McMahon & Schulze, 2005). The familial 
aggregation of early onset BPD (particularly pre-pubertal-onset) (Geller et al., 2006), 
episode frequency (Fisfalen et al., 2005), psychosis (Potash et al., 2001), polarity at 
illness onset (Kassem et al. 2006), rapid cycling (Saunders, Scott, McInnis, & 
Burmeister, 2008), co-morbid alcohol abuse or dependence (Schulze, Hedeker, Zandi, 
Rietschel, & McMahon, 2006) are consistent with genetic influences and make them 
informative sub-phenotypes for BPD studies.  
Sub-dividing BPD into more homogenous groups using endophenotypes or 
phenotypes that are intermediate between the clinical presentation of the disorder and 
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its genetic underpinnings has received some attention recently. Research based on 
endophenotypes looks for genes for simple, presumably monogenic, traits that 
accompany the illness and probably contribute to its pathology. The idea here is to 
reduce the complexity of disorders such as BPD to more elementary forms 
(MacQueen, Hajek, & Alda, 2005). Endophenotype that are associated with the illness 
in the population, have been proven to be heritable, and are manifested regardless of 
whether or not the illness is active are regarded as suitable. In BPD, promising 
endophenotypes include abnormal regulation of circadian rhythms, response to sleep 
deprivation, behavioural response to psychostimulants and other medications, event 
related potentials, increase in white matter hyperintensities and biochemical 
alterations in peripheral mononuclear cells have been proposed (Lenox, Gould, & 
Manji, 2002). However, to date no widely accepted endophenotype for BPD has been 
discovered.  
As opposed to sub-dividing BPD into smaller more homogenous groups, other 
authorities advocate including more prevalent subtypes of BPD mainly in the form 
hypomania to facilitate the quest for gene discovery (Akiskal, 2007). This latter view 
comes with the conviction that all manifestations of BPD are dimensionally rather 
than categorically different and therefore possess similar aetiological underpinnings.  
 
1.5 Models of Bipolar Disorder Inheritance 
A range of models of BPD inheritance have been suggested in the literature, including 
single major locus models, oligogenic and polygenic models, multifactorial models 
and mixed models, which will be discussed in this section.  
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1.5.1 Single Major Locus 
Classic Mendelian single locus inheritance assumes that a single genetic defect 
inherited in a dominant or recessive mode of disease transmission is sufficient to 
cause disease. Under this model several factors modify the effect of the major locus 
and render its inheritance pattern more complex; reduced penetrance in which not all 
individuals carrying the deleterious gene express the disease; pleiotropy where a 
single genetic mutation could be responsible for variable phenotypic expressions; 
phenocopies, defined as phenotypes arising from environmental agents that mimic the 
effects of a mutation in a gene, and; genetic heterogeneity, which refers to situations 
in which a disease results from a single locus but different loci operate in different 
families (Ott, 1999). The premise, however, remains that a single locus with a major 
effect causes disease.  
In BPD a single major locus inheritance model has been shown to be 
mathematically incompatible with available family and twin data (Craddock, Khodel, 
Van Eerdewegh, & Reich, 1995). To date, no single gene inherited in a dominant, 
recessive, or intermediate mode has been shown to explain BPD inheritance 
(Craddock and Forty, 2006). The exception being two segregation analyses that 
suggest BPD could result from single gene mutations (Rice et al., 1987; Spence et al., 
1995). However, segregation analyses tend to be very sensitive to mode of 
ascertainment, which is almost impossible to allow for correctly (Suarez, Hampe, & 
Van Eerdewegh, 1994) and are seldom based on large enough datasets to account for 
the large number of parameters required to model complex diseases (Ott, 1999), so 
interpretation of these two findings should be conducted with caution.  
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1.5.2 Polygenic Inheritance 
Polygenic inheritance in which multiple genes at different loci contribute to disease 
susceptibility has been suggested as a likely theory for BPD inheritance (Purcell et al., 
2009; Sklar et al., 2011). Under this model, the effects of the genes are additive and 
mutually independent and the phenotype results from the sum of the risk alleles 
(McGuffin, 1991). Here one assumes the presence of an underlying quantity or 
liability to develop the disorder, if it exceeds a certain threshold an individual 
becomes affected. This model of inheritance, originally postulated by Falconer, 
(1965) assumes that liability to disease has a normal distribution and the proportions 
of affected individuals in the population are those whose liability exceeds some 
threshold. For example, if we assume that multiple BPD causing genes are 
segregating in the population, and bipolar symptoms are only observable with the 
cumulative effect of twenty risk alleles, then affected individuals would be those who 
carry twenty or more risk alleles and unaffected individuals would be those who carry 
a range of risk alleles, up to nineteen, without developing BPD symptoms. Under a 
highly polygenic disease where many genetic variants of small effect are involved in 
disease susceptibility, each affected individual may carry a unique set of risk alleles 
so that any two affected individuals are highly unlikely to carry the same combination 
of risk alleles (Visscher, Goddard, Derks, & Wray, 2011). 
The variation in symptom severity observed in patients with BPD is 
compatible with a polygenic model of inheritance with multiple thresholds of liability 
(Reich, Cloninger, & Guze, 1975), where more severe subtypes of BPD occur at more 
extreme thresholds, i.e. larger quantities of the same underlying genetic liability. Thus 
affected individuals with bipolar spectrum disorders would lie beyond the first 
threshold, e.g. of twenty risk alleles, and individuals affected with more severe forms 
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of BPD would exceed a more extreme threshold, e.g. of thirty risk alleles for BPII 
disorder and forty risk alleles for BPI disorder (Figure 1.1)  
  
Figure 1.1 The liability threshold and multiple threshold models. The figure on the left 
depicts a liability threshold model in which a disease results when a critical underlying 
liability threshold is exceeded. The figure on the right depicts a polygenic multiple 
threshold model under which different thresholds lead to different subtypes of BPD. 
This models holds that the greater the number of risk alleles one has the greater the 
severity of the disease. A gradation in the underlying disease liability similar to that 
observed in the clinical manifestations of the disease is from subthreshold mania and 
hypomanic, to BPII disorder to BPI disorder. Graph adapted from Kelsoe et al. (2003). 
 
1.5.3 Multifactorial Inheritance 
The multifactorial inheritance model proposes that genes and environmental factors 
combine to cause disease. The environmental factors in question could be due to 
familial environment (e.g. low socioeconomic status), specific environment (e.g. 
death of a spouse), gene-environment correlations and/or gene-environment 
interactions. The role of the latter two in susceptibility to psychiatric disorders has 
received increasing attention in recent years. In gene-environment correlations, genes 
act by influencing the probability that an individual will be exposed to a life event. 
For example, McGuffin, Katz, & Bebbington (1988) found not only an increased rate 
of depression among relatives of depressed probands but also an increased reporting 
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of life events. This finding was replicated by several studies that showed life events 
aggregated in families (Kendler, Neale, Kessler, Heath, & Eaves, 1993b; Rijsdijk et 
al., 2001). Other studies, however, did not find significant difference between the 
number of threatening life events experienced by the siblings of individuals with 
depression and the siblings of healthy controls (Farmer et al., 2000).  
In gene-environment interactions, also referred to as ‘genetic control of 
sensitivity to the environment,’ coined by Kendler (1998), genes modify the 
pathogenic effects of the environment to make an individual more or less vulnerable 
to disease. So far gene-environment interactions have only been tested on the level of 
candidate genes. In a landmark study, Caspi et al., (2003) explored gene-environment 
interactions in the Dunedin birth cohort and found a functional polymorphism in the 
promoter region of the serotonin transporter gene (5-HTT) moderated the influence of 
stressful life events on depression. Similarly, a valine to methionine substitution 
polymorphism in the BDNF gene was found to moderate the effects of stressful life 
events on the propensity to develop depressive (but not manic) episodes in BPD 
patients (Hosang et al., 2010). The role of gene-environment correlations and 
interactions in BPD, particularly mania is not well studied. However, based on 
empirical findings the inheritance of BPD could be expressed as follows: 
 
BPD phenotype = genotype + environment + gene-environment correlation + gene-
environment interaction 
1.5.4 Mixed Model of Inheritance 
The mixed model of inheritance, which refers to the effect of one or more major loci 
and oligogenes (few genes) or polygenes on disease susceptibility (Faraone, Tsuang, 
& Tsuang, 1999) has received some support in BPD. Cystic fibrosis is a good 
 13 
example of a disease driven by mixed inheritance. A mutation in the CFTR gene 
causes cystic fibrosis, however, phenotypic variations observed in patients depend on 
a discrete number of alleles at different loci (Badano & Katsanis, 2002). BPD is 
proposed by Ewald, Kruse, & Mors (2003) and Ewald et al. (2005) to occur due to 
dominant risk at a major locus operating with a number of risk and modifying genes 
inherited in a recessive mode at other loci. This suggestion is based on the authors’ 
identification of a number of recessively inherited loci that segregate with BPD in 
pedigrees from Denmark and Cuba together with findings from the literature that 
implicate dominantly inherited loci in BPD. The presence of a major locus that is co-
inherited or modified by recessively inherited risk was not however examined, so the 
suggestion remains speculative.  
1.5.5 Epistasis  
The Epistasis model suggests that a system of interacting genes may be liable in BPD 
with interactions between genes of small effect or between genes of small effect and a 
major locus (Craddock & Forty, 2006). Consequently, standard statistical methods 
that treat disease loci as if they were independent of each other may not have 
sufficient power to detect genes of modest effect. The simultaneous consideration of 
multiple genomic loci in linkage analysis has yielded convincing results of the 
applicability of epistatic models to complex disorders in general, for example in type 
1 diabetes Cox et al., (1999) employed a locus interaction model to demonstrate that 
accounting for locus interactions increased evidence for linkage (to chromosome 15) 
from marginal to significant, and in BPD Fullerton, Donald, Mitchell, & Schofield 
(2010) identified three significant linkage peaks and four gene interaction clusters in a 
study of 65 Australian extended BPD pedigrees, thus emphasising the role of genetic 
interactions in BPD aetiology.  
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1.6 Molecular Genetic Investigation of Bipolar Disorder 
The evidence for a genetic contribution to BPD from family, twin and adoption 
studies spurred numerous efforts to localise and identify the genetic variants that 
contribute to the development of BPD using whole genome linkage and association 
studies, and more recently whole genome sequencing. These methods although 
methodologically different offer complementary tools for understanding the genetic 
architecture of complex diseases, and are all necessary for gaining insight into the 
pathophysiology of diseases with implications for genetically informed therapeutics 
and disease prevention. 
1.6.1 Linkage Studies 
Linkage is very often the first stage in the molecular genetic investigation of a 
disorder. It is used to identify genomic region(s) that may contain disease genes (or 
loci) by following the co-segregation in informative pedigree(s) of the disease of 
interest and genetic markers such as microsatellites or single nucleotide 
polymorphisms (SNPs) with known locations in the genome (Sham & McGuffin, 
2002). A large number of nuclear pedigrees or a small number of multigenerational 
extended pedigrees with multiply affected members are studied with the aim of 
mapping genetic variants with comparatively large effect sizes typically extending 
between 5 to 20 centiMorgans (cM). By definition linkage is the tendency of genes to 
be transmitted together from parent to offspring more often than expected, thus 
representing a departure from Mendel’s law of independent assortment. Linkage is the 
main topic of this thesis and will be discussed thoroughly in chapter 3.  
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1.6.1.2 Linkage Findings in Bipolar Disorder 
Over 40 whole genome-linkage studies have been published for BPD with no major 
and consistent ‘hits’ found and multiple regions of the genome implicated in the 
disorder. Three meta-analyses have been performed in an effort to make sense of the 
large, and potentially perplexing data. The first by Badner & Gershon (2002) 
combined data from seven whole genome scans for BPD. The authors used a method 
derived from Fisher’s approach to combining p-values with a correction for the size of 
the linkage regions included. They found two significant susceptibility loci for BPD 
on chromosomes 13q and 22q. A second and more extensive meta-analysis studied 
linkage statistics from eighteen BPD whole-genome scans and found no genome wide 
significant regions and only reported suggestive linkage on chromosomes 9p, 10q, 
14q, and 18 (Segurado et al., 2003). The most recent major combined analysis by 
McQueen et al. (2005) was a ‘mega-analysis’ since it used the original genotype data 
from eleven BPD genome studies including 5,179 individuals from 1,067 families. 
The study found significant linkage to chromosome 6q for BPI disorder and 
chromosome 8q for BPI and BPII disorders. In addition, several consortia have 
combined data across multiple sites in an attempt to identify “truly” positive linkage 
regions. Lambert et al., (2005) combined data from the UK and Ireland and found 
support for regions on chromosome 9p21, previously identified in the meta-analysis 
by Segurado et al. (2003) and 10p14-21. Schumacher et al., (2005) found evidence for 
linkage on chromosomes 6q24 and 4q31 using combined data from Spanish, 
Romanian and Bulgarian families and proposed these two previously identified 
regions should be considered confirmed BPD susceptibility loci.  
Many more linkage regions have been implicated in BPD. Linkage peaks 
identified with genome wide significance (defined by LOD scores greater or equal to 
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3.0) in independent studies are presented in Table 1.1. Only regions supported by 




Region Publication Phenotype Model Sample Maximum LOD 
4p16 Blackwood et al. (1996) BPI, BPII Dominant  Large Scottish Pedigree MLOD=4.8  
Herzberg et al. (2006) BPI NPL Costa Rica, Colombia LOD=4.18 5q33-q34 
Jasinska et al. (2009) BPI NPL Costa Rica, Colombia LOD=4.90 
6q16.3 Dick et al. (2003) BPI, BPII, SAD, or UP ASP NIMH-II LOD=3.61 
6q22 Middleton et al. (2004) BPI, SAD NPL Portuguese  LOD=3.24* 
6q23-q24 Venkon et al. (2005) BPI, BPII, SAD, UP Recessive Västerbotten MLOD=3.25 
8p21 Park et al. (2004) BPI, SAD Dominant Large Pedigree LOD=3.46 
9q31 Park et al. (2004) BPI, BPII, SAD,UP,SAD Recessive Large Pedigree LOD=3.55 
9q31-q33 Venkon et al. (2005) BPI, BPII, SAD, UP Recessive Västerbotten MLOD=3.70 
10p12 Rice et al. (1998) BPI, BPII, SAD ASP  NIMH-I MLOD=3.40 
10q22.2 Rice et al. (1998) BPI, BPII, SAD ASP  NIMH-I MLOD=3.47 
11p11 Middleton et al. (2004) BPI, SAD NPL Portuguese LOD=4.27* 
12q21.33-q24.23 Morissette et al. (1999) BPI, BPII, SAD, or UP NPL Québec LOD=3.63 
12q24.32 Ewald et al. (2002) BPI, BPII, SAD NPL Two Danish families LOD=3.42 
13q31 Detra-Wadleigh et al. (1999) BPI, BPII, SAD, or UP ASP U.S pedigrees LOD=3.50 
16p13.11 Mérette et al. (2008) BPI, BPII, UP NPL Eastern Quebec LOD=3.87* 
16p13.11 Ross et al. (2008) BPI, BPII Dominant NIMH-all LOD=3.20 
17q25.3 Dick et al. (2003) BPI, BPII, SAD ASP NIMH-II LOD=3.63 
18q21-23 Stine et al.(1995)  BPI, BPII, SAD, or UP Dominant U.S pedigrees LOD=3.51 
21q22 Straub et al. (1994) BPI, BPII, SAD, or UP Dominant Large U.S Pedigree LOD=3.41 
22q11-12 Potash et al. (2003) 
Kelsoe et al. (2001) 
Psychosis 








Table 1.1. Significant Linkage peaks identified in independent BPD studies. BPI=bipolar I disorder, BPII=bipolar II disorder, SAD=schizoaffective 
disorder, bipolar type, UP=Unipolar Depression, NPL=non-parametric linkage, MLOD=Multipoint LOD score. An asterisk denotes NPL scores that 
had been converted to LOD scores using LOD=NPL2/4.62 (Ott, 1999). Although these regions are not inclusive of all the significant linkage findings 
reported in the literature, they are linkage peaks that have been confirmed by subsequent linkage studies and are presented to demonstrate the 
variability in linkage findings reported in the literature. 
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1.6.2 Association Studies  
Genetic association studies are used to evaluate the relationship between genetic 
variants and the risk of developing disease by comparing individuals with a disease 
(cases) with unaffected individuals (controls) from the same population for 
differences in genotype or allele frequencies. They are based on linkage 
disequilibrium (LD), which refers to the non-random association between alleles at 
adjacent genetic loci such that certain combinations of alleles are more likely to occur 
together on a chromosome than other combinations of alleles. If we consider two 
biallelic markers, AG and CT, there are four possible combinations of alleles or 
haplotypes, AC, AT, GC, and GT. Under linkage equilibrium, the alleles in a 
haplotype are randomly associated with each other and the population frequency of 
each haplotype is equal to the frequencies of the alleles it contains. For example, the 
population frequency, P ,of haplotype AC would be simply defined as follows  
PAC =PAPC  
Where PA is the population frequency of allele A at marker AG and PC is the 
population frequency of allele C at marker CT. Linkage Disequilibrium refers to 
deviations from the expected haplotype frequencies in the population due to the non-
random association between alleles at adjacent loci. As such when an allele at one 
locus is found to occur more often than expected by chance with another allele at 
another locus, the frequency of that haplotype is increased (Ardlie, Kruglyak, & 
Seielstad, 2002) (Figure 1.2).  
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Figure 1.2 Linkage equilibrium and linkage disequilibrium in two biallelic markers. 
Linkage equilibrium occurs when all the observed haplotypes follow the expected 
population frequencies, which in this example are 25% for each haplotype. Linkage 
Disequilibrium occurs when deviations from the expected frequencies are observed in 
the population.  
 
An important distinction between linkage and LD needs to be made. Two genetic loci 
are linked if they are transmitted from parent to offspring more often than expected 
under independent assortment. They are in LD if across the population as a whole 
they are found together on the same haplotype more often than expected. An 
association between a specific polymorphism (e.g. SNP) and disease susceptibility 
allele(s) indicates that the two are so close together that they are rarely separated by 
meiosis. Two loci in LD will also be in linkage but not vice versa. Because linkage 
extends over large regions of the genome it detects genes of major effect, LD on the 
other had occurs over relatively small genetic distances, generally not extending over 
regions of one centiMorgan in outbred populations and is therefore used to map 
susceptibility genes with small effect sizes (Reich et al., 2001)  
Until recently association studies have been limited to identifying candidate 
genes thought to influence disease susceptibility because of what is known about their 
neurochemistry and/or mechanisms of drug action and positional candidate genes 
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implicated because they lie within significant linkage peaks. Serretti & Mandelli, 
(2008) reviewed published case control association studies conducted until 2007 and 
reported that candidate genes that have been consistently associated with BPD fall 
into four different pathway; the serotonin (5HTT and TPH2), the dopamine (DRD4 
and DTNBP1), the glutamate (DAOA and DTNBP1) and cell growth and/or 
maintenance pathways (NRG1, DISC1 and BDNF). While these and many more 
candidate and positional genes have been associated with BPD, none have been 
unambiguously identified as causal. 
1.6.2.1 Genome Wide Association Studies 
Genome wide association studies (GWAS) at the level of individual genotyping have 
only become feasible with the advent of microarray technology that allows 
genotyping of hundreds of thousands of single nucleotide polymorphisms (SNPs) in a 
single experiment. Based on the “common disease, common variant” hypothesis, 
GWAS assume that many genes of small effect, but high minor allele frequency, 
contribute to the liability of common diseases. In fact, most common variants 
identified from GWAS for a wide range of diseases confer relatively low risk to 
disease with odds ratios of 1.1 to 1.5 (Bodmer & Bonilla, 2008).  
Association methods are compromised by allelic heterogeneity or differences 
in marker allele frequencies due to population stratification, which refers to the 
problem of hidden, or cryptic, sub-populations being represented in case and control 
groups. It can lead to false positive results as allele frequencies may differ between 
cases and controls irrespective of disease status. As long as cases and controls are 
well matched for broad ethnic backgrounds and measures are taken to exclude 
individuals whose genome wide association data reveal substantial differences in 
genetic background, population stratification can be overcome. Several tools currently 
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exist to detect and adjust for population stratification, which are primarily based on 
principal component analysis (Price et al., 2006; Zheng, Freidlin, & Gastwirth, 2006). 
Assessing population stratification and correcting any differences is part of the 
primary analysis of most GWAS undertaken. 
1.6.2.2 Genome Wide Association Findings in Bipolar Disorder 
The first GWAS study of seven common disorders, of which BPD was one, was the 
Wellcome Trust Case Control Consortium study (2007). To the disappointment of 
many this only revealed one major "hit" in BPD, which was a SNP on chromosome 
16p12 (Burton et al., 2007). This disappointment was carried through when a second 
large GWAS failed to identify any SNPs with genome wide significance in BPD 
(Sklar et al., 2008). Subsequent analyses yielded significant evidence for association 
to a few genes including CACNA1C, a gene located on chromosome 12p13 which 
encodes an L-type, alpha-1C subunit of a voltage-dependent calcium channel protein, 
which mediates the influx of calcium ions into the cell in response to membrane 
depolarisation, and ANK3, a gene located on chromosome 10q21 involved with cell 
motility, activation proliferation, contact and the maintenance of specialised 
membrane domains and is known to modulate the activity of neuronal sodium 
channels (Ferreira et al., 2008; Smith et al., 2009). More recently, The Psychiatric 
Genomic Consortium collaboration (PGC) across more than 200 scientists in 65 
institutions and 19 countries, and 11,974 cases and 51,792 controls for BPD published 
a report identifying a new intronic variant in ODZ4, located on chromosome 11q14.1, 
which according to the authors is involved in cell surface signaling and neuronal 
pathfinding. The study also confirmed the role of CACNA1C in BPD (Sklar et al., 
2011). These results are a step forward towards unravelling the genetic determinants 
of BPD. However, to date the identified loci only explain 1 to 2% of the disease 
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liability (Badner et al. 2011). Further, GWAS have only identified few common risk 
variants in BPD. Is that a reflection of the limited number of such variants in BPD, or 
are GWAS not larger enough. The answer seems to be yes and no. On the one hand, 
the challenge of GWAS remains to be one of sample size. Using large enough 
samples to perform replication studies to achieve unequivocal significance while 
accounting for population stratification and multiple testing remains a priority. On the 
other hand, emerging views hold that complex disorders are actually highly 
heterogeneous with many uncommon mutations having large effects (Cirulli & 
Goldstein, 2010) and recent advances in next-generation sequencing technologies 
should help unravel their genetic architecture. 
1.6.3 Copy Number Variants (CNVs) 
CNVs are genomic deletions and duplications that range in size from one kilobase 
(kb) to several megabases (Mb). They may be rare causal mutations or common 
variants, which increase susceptibility to disease. CNVs have been reported in 
psychiatric phenotypes such as autism, mental retardation, and schizophrenia 
(O’Donovan, Craddock, & Owen, 2009). The overall number of CNVs is reported to 
be greater in individuals with schizophrenia compared with controls, and a number of 
specific rare CNVs have been associated with schizophrenia, for example deletions at 
chromosomes 1q21.1, and 15q13.3, 22q11 as well as deletions of the gene encoding 
the synaptic neural adhesion molecule, neurexin (Kirov et al., 2009). Further, studies 
show the risk of disease associated with CNVs far exceeds that associated with most 
common variants identified from GWAS. For example, three rare deletions at 1q21.1, 
15q11.2 and 15q13.3 associated with schizophrenia have odds ratios estimated at 2.7, 
11.5 and 14.8 (Stefansson et al., 2009), substantially higher than odds ratios for 
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common SNPs associated with schizophrenia estimated at below 1.3 (Purcell et al., 
2009).  
The role of CNVs in the aetiology of BPD is yet to be determined. Emerging 
evidence suggests they influence risk for BPD. A study by Zhang et al. (2008) found 
singletons deletions greater than 100 kb in length are present in 16.2% of BPD cases 
in contrast with 12.3% of controls and a meta-analysis of multiple psychiatric 
disorders showed a 16p11.2 micro-duplication to be associated with BPD. 
Nevertheless, CNVs appear to contribute less to the susceptibility to BPD than to 
schizophrenia. Variants influencing BPD seem to be smaller, less likely to be 
deletions, and have smaller effect sizes (Grozeva et al., 2010; McQuillin et al., 2011).  
Currently, the role of CNVs in unaffected individuals is not clearly 
understood. Larger CNV studies need to be undertaken, particularly in control 
populations, to determine the average rate and size of CNVs in unaffected individuals. 
Without knowledge of the affect of CNVs in a control population, conclusions about 
their role in the aetiology of disease cannot be accurately determined. Molecular 
studies of CNVs are needed to clearly understand how each individual CNV may give 
rise to disease.  
1.6.4 Sequencing Studies 
The recognition that common genetic variants captured using GWAS only explain a 
minor fraction of the genetic risk of most diseases spurred renewed interest in rare 
variants and rare CNVs as plausible in disease aetiology and with more reasonable 
costs, sequencing approaches have recently become the poster for uncovering the 
missing heritability in complex diseases, particularly rare disease causing variants. 
Today whole genome sequencing offers a comprehensive collection of rare variants 
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and structural variation for study and is believed to be the future of molecular genetic 
investigation of disease.  
Given that rare and common genetic variants likely contribute to the genetic 
architecture of BPD, linkage, association, and sequencing methods are needed to map 
the full range of BPD susceptibility. Putting already established common variants 
from GWAS studies together with findings on rare and structural variants from 
sequencing studies on the verge of delivery to the scientific world will shed more 
light on the genetics under pinning of BPD and related disorders. 
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1.7 Differences and Similarities Between Bipolar Disorder and 
Unipolar Depression 
The term unipolar depression refers to three disorders; Major Depressive Disorder 
Major (MDD), dysthymia, and depression not otherwise specified, which vary in 
severity and duration. MDD is characterised by persistent negative emotions and 
thoughts that coexist with disturbances in sleep, energy, and motivational behaviour. 
It results in perseverative and intrusive thoughts of death, suicide and guilt. For an 
individual to receive a diagnosis of a major depressive episode on the basis of the 
DSM-IV at least five of the following symptoms must be present for a minimum 
period of two weeks accompanied by either depressed mood or loss of interest or 
pleasure: increased/decreased appetite, insomnia/hypersomnia, psychomotor 
agitation/retardation, fatigue/loss of energy, feelings of worthlessness and 
inappropriate guilt, reduced concentration, suicidal behaviour, and anhedonia. 
Dysthymia, on the other hand, is a chronic, less severe, form of depression that 
persists for a period of at least two years and depression not otherwise specified is any 
form of depression that does not fall into the two other forms of depression described.  
Kraepelin originally perceived BPD and unipolar depression as a single 
construct of manic-depressive illness (Angst & Marneros, 2001). The proposal that 
unipolar depression and BPD should be divided was originally put forward by 
Leonhard (1959) and seems to be gaining widespread acceptance based on evidence 
from genetic studies. However, a degree of genetic overlap between BPD and 
unipolar depression is evident. There is consistent evidence of an increase in the 
frequency of both BPD and unipolar depression in the close relatives of individuals 
with BPD and as much as a three-fold increase in the average risk of MDD is reported 
in relatives of individuals with BPD compared to controls (Jones et al., 2002; 
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McGuffin & Katz, 1989; Merikangas & Yu, 2002). However, the opposite is not true; 
relatives of individuals with MDD do not have significantly more BPD than the 
relatives of controls (Winokur, Coryell, Keller, Endicott, & Leon, 1995). One 
explanation is proposed by the multiple threshold model, an extension of the liability 
threshold model (see section 1.52) that holds the two disorders exist on the same 
continuum of liability but are caused by different quantities of the same underlying 
genetic liability. Under this model all affected individuals lie beyond the first 
threshold for being affected with unipolar depression, those who exceed a more 
extreme threshold are diagnosed with BPD, and those who exceed an even more 
extreme threshold are diagnosed with schizophrenia (Kelsoe et al.,2003) (Figure 1.3).  
 
Figure 1.3. The multiple threshold model of mood disorders and schizophrenia. The 
figure on the left depicts a liability threshold model in which a disease results when a 
critical underlying liability threshold is exceeded. The figure on the right depicts a 
polygenic multiple threshold model under which different thresholds lead to different 
disorders. This models holds that the greater the number of risk alleles one has the 
greater the severity of the disease. A gradation from unipolar depression, to BPD to 
schizophrenia is shown. Graph adapted from Kelsoe et al. (2003). 
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McGuffin et al. (2003) refuted the multiple threshold model in an analysis based on 
twins ascertained from the Maudsley hospital twin register via probands who received 
a diagnosis of BPD or MDD. The authors proposed an alternative correlated liability 
model, which assumes that there are three sources of variance (additive genetic, 
shared environmental, non-shared environmental) and allows testing for common 
factors that affect both MDD and BPD and specific factors that may affect one 
disorder alone. McGuffin et al. (2003) presented evidence that a correlated liability 
model with both overlapping genetic effects on mania and depression and genetic 
effects specific to mania provided a good fit. In this study, the overlapping genetic 
effects on mania and depression were estimated at approximately 29%, indicating that 
most genetic liability to mania (approximately 71%) was specific to bipolarity (Figure 
1.4).  
 
Figure 1.4. Path diagram for a correlated liability model. The correlation between 
depression and mania is partitioned into additive genetics (A), common environmental 
(C), and specific environmental (E) in Cholesky decomposition for A, C, and E there are 
both common factors affecting the disorders and specific factors affecting the second 
disorder only. The effect of common additive genetic factors AC on the first disorder is 
represented by the path coefficient aC, and the effect on the second disorder is 
represented by a!C. The effect of specific additive genetic factors, AS on the second 
disorder is represented by the path coefficient AS. L indicates liability.  
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Support for a shared genetic liability between BPD and unipolar depression from 
molecular genetic studies is limited to a few linkage regions and unconfirmed 
candidate genes. Compared with BPD and schizophrenia a few genome wide scans of 
unipolar depression as the main phenotype are conducted and there have been no 
meta-analyses undertaken. In the last years, the first GWAS in MDD were published. 
None reported genome wide significant results and their top hits were difficult to 
replicate (Lewis et al., 2010; Muglia et al., 2010; Shyn et al., 2011; Sullivan et al., 
2008; Wray et al., 2010).  
One region of interest that emerges from linkage studies is on chromosome 
12q23-q24, which was implicated in BPD by four genome wide significant signals  
(Curtis et al., 2003; Maziade et al., 2001; Morissette et al., 1999; Venken et al., 2005) 
two pedigrees that segregated both BPD and an autosomal dominant skin disorder, 
Darier's disease (Green et al. 2005), a large sibling pair genome scan of unipolar 
depression (McGuffin et al. 2005), and a whole genome linkage scan of 1,890 
individuals from 110 Utah pedigrees with a strong family history of major depression 
(Abkevich et al., 2003). A second region is on chromosome 2q33-q36 has been 
reported in families from a Northern Swedish Isolated population with BPD or 
unipolar depression (Venken et al., 2005), which overlaps with a linkage signal on 
2q33.1 found in 81 families identified by probands with recurrent, early-onset, MDD 
(Zubenko et al. 2003). Furthermore, candidate gene studies have confirmed some 
overlap in the candidate genes associated with BPD and unipolar depression. . For 
example, Brain Derived Neurotrophic factor (BDNF) (Groves, 2007), P2X 
purinoceptor 7 gene (P2RX7) (McQuillin et al. 2009), and GRIK4 (Paddock et al., 
2007; Pickard et al., 2006) have been reported in both BPD and depression. However, 
to date their roles have not been confirmed in either unipolar depression or BPD.  
 29 
1.8 Differences and Similarities Between Bipolar Disorder and 
Schizophrenia 
BPD and schizophrenia are generally considered distinct nosological entities. 
However, the two disorders share psychotic features in common and are 
epidemiologically similar, both show no gender differences, and have similar 
population prevalences and age of onset distributions. BPD and schizophrenia have 
been reported to ‘breed true’ (Frangos, Athanassenas, Tsitourides, Katsanou, & 
Alexandrakou, 1985; Gershon et al., 1982). However, families in which multiple 
cases of BPD and schizophrenia co-occur challenge the Kraepelinian dichotomy and 
premise that families segregate either BPD or schizophrenia. The fact that relatives of 
probands with BPD and schizophrenia are at an increased risk for schizoaffective 
disorder and unipolar depression (Kendler et al, 1993b; Maier et al., 1993) and that 
relatives of probands with schizoaffective disorder are at an increased risk for BPD, 
unipolar depression and schizophrenia (Rice et al., 1987) question the diagnostic 
divide between mood disorders and schizophrenia. A twin study of 77 MZ and 89 
same sex DZ twins recruited through probands with schizoaffective symptoms 
indicated, using an analysis unconstrained by traditional diagnostic hierarchies (that 
is, the principal that schizophrenia “trumps” mood disorder in diagnosis), that there 
are common genes that confer susceptibility to both BPD and schizophrenia as well as 
genes that are specific to each of these disorders. The study also found that the genetic 
liability to schizoaffective disorder was entirely shared in common with schizophrenia 
and BPD (Cardno, Rijsdijk, Sham, Murray, & McGuffin, 2002). This study was based 
on the correlated liability model described in section 1.7 
Molecular genetic studies have shown some genes common to both BPD and 
schizophrenia supporting a BPD-schizophrenia overlap. Chromosomes 1q42, 10p11-
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16, 13q32, 18p11 and 22q11-13 have been linked to both disorders with overlapping 
or convergent evidence (Baron, 2002). In addition, a genome wide linkage scan using 
families with BPD or schizophrenia, ascertained through probands with 
schizoaffective disorder, demonstrated significant linkage at 1q42 and suggestive 
linkages at 22q11 with equal contribution to the LOD score from ‘schizophrenia’ and 
‘bipolar’ families (Hamshere et al., 2005). Further, a number of candidate genes have 
been shown to influence susceptibility to BPD and schizophrenia. The ‘disrupted in 
schizophrenia’, DISC1, locus at 1q42 is implicated in schizophrenia, BPD, and 
schizoaffective disorder by linkage studies and evidence for allelic association at 
polymorphisms at this locus are reported in schizophrenia, BPD, and schizoaffective 
disorder (Craddock, O’donovan, & Owen, 2005). Neuregulin 1 (NRG1), one of the 
first confirmed genes conferring susceptibility to schizophrenia, initially identified in 
33 Icelandic families and later replicated in Scottish, Welsh, and Chinese families has 
been shown to have a similar effect with BPD (Farmer, Elkin, & McGuffin, 2007). 
Genetic variation at the COMT gene, which lies on locus 22q11, is shown to confer 
susceptibility across the psychosis spectrum in both BPD and schizophrenia. More 
recently, the PGC, in a combined GWAS analysis of schizophrenia and BPD found 
strong association evidence for SNPs in CACNA1C and in the region of NEK4-
ITIH1-ITIH3-ITIH4 (Sklar et al., 2011), indicating their involvement in both 
disorders. 
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Chapter 2 Subjects 
This chapter outlines the structure and phenotypes found in a single large 





Figure 2.1. Map of Brazil (left top) highlighting South East Brazil, shown in greater 
detail in the bottom right. Most family members were recruited from Senhora De 
Oliveira, a small municipality in Minas Gerais, or São Paulo and Vitória where some 
family members moved. The red arrows point to the locations visited by the research 
team to recruit the family.   
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2.1 Subjects for the Whole Genome Linkage Study: The Brazilian 
Bipolar Family (BBF) 
The Brazilian Bipolar Family (BBF) is a five-generation family of 639 members, 57 
of whom are confirmed to be deceased. The family originates from Senhora de 
Oliveira, a small Brazilian municipality located in the state of Minas Gerais in South 
Eastern Brazil. Senhora De Oliveira has a population of approximately 6000, 
according to a 2004 estimate, and was founded in 1695  (Wikipedia). 
The area is relatively underdeveloped with no paved roads leading to the town 
and little in the way of formal healthcare available. Three hundred and thirty family 
members (49% males and 51% females) were recruited by three psychiatrists from the 
University of São Paulo between 2006 and 2008 from Senhora de Oliveira and 
surrounding cities in the state of Minas Gerais, São Paulo in the state of São Paulo, 
and Vitória in the state of Espírito Santo. The majority of the family still resided in 
Senhora de Oliveira or nearby cities, where they are widely known to be “eccentric 
and crazy.” A subset of the family, mainly young professionals from the third 
generation moved with their nuclear families to either São Paulo or Vitória (Figure 
2.1).  
2.1.1 Family Ascertainment 
The BBF was ascertained through a 45-year-old female proband with severe BPI 
disorder who was treated by one of the psychiatrists involved in the study. The 
grandparents of the proband (201, 200) are reported to be first cousins, and although 
deceased, the proband’s grandmother (200) has hospital records indicating she suffered 
from BPI disorder, and the proband’s grandfather (201) is suspected of being on the 
bipolar spectrum. The children, grandchildren, and great grandchildren of 201 and 200 
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represent Branch 1 of the BBF (the descendents of 409, 408 and 411, 410). Following 
the collection of Branch 1, Branches 2 and 3 were collected simultaneously. Branch 2 
of the family, the descendents of 411 and 410, consists of eight siblings of 200, their 
children, grandchildren, and great grandchildren. According to family members, all of 
the siblings of 200 exhibited symptoms of mania and/or depression in their lifetime. 
Branch 3 of the family, the descendents of 409 and 408, is comprised of the siblings of 
201, their children, grandchildren, and great grandchildren (Figure 2. 2).  
Recruitment of Branch 1 was conducted in a systematic order; the proband 
helped recruit other family members beginning with first-degree relatives who in turn 
helped identify their relatives. In addition to the help of a number of especially 
motivated and co-operative family members in constructing the structure of BBF, 
genealogical records obtained from a local church in Senhora de Oliveira were 
available to confirm family relatedness dating back eight generations. 
 
Figure 2.2. BBF branches ascertained through proband 1 indicated in the figure with an 
arrow. Branch 1 is related to Branch 2 through individual 201 and to Branch 3 through 
individual 200.  
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2.2 Ancestry Analysis of the BBF 
The Brazilian population is known for its admixture, with a genetic background of 
three parental populations: European, African, and Brazilian Native Amerindians, and 
a wide range of diverse ancestry patterns in-between (Lins, Vieira, Abreu, 
Grattapaglia, & Pereira, 2010). The BBF members self reported mixed Southern 
European ancestry and this was confirmed by the interviewers. However, as genetic 
data was available and because admixture can be hard to identify at interview, 
analysis of the ancestry of the BBF was conducted using principal components, as 
implemented in EIGENSOFT version 3.0 (Price et al., 2006) (see chapter 6 section 
6.3.2.3). SNPs from fourteen BBF members, genotyped by deCODE genetics on the 
IlluminaHuman 610 QuadBeadChip (comprising 610,000 SNPs), were combined with 
SNP genotypes from the HapMap samples for individuals of Northern and Western 
European, Tuscan Italian, Japanese, Chinese, Mexican, Luhya, Massai, Yoruba and 
African American ancestry (Gibbs et al., 2003). The datasets were merged using 
PLINK version 1.07 (Purcell et al., 2007) after asymmetric and uncommon SNPs 
between the data sets were removed using a number of batch scripts. A total of 70,000 
SNPs present in all population datasets and the BBF were used in the analysis. The 
principal components were plotted to visualise the BBF clustering with reference to 
the HapMap populations, which revealed that the BBF clustered more closely with the 
Northern and Western European and Tuscan Italian populations thus confirming the 
family’s self reports of ancestry (Figure 2.3). 
 35 
 
Figure 2.3. The graphs show the first four principal components (PC) from the EIGENSOFT ancestry analysis based on data from fourteen 
Brazilian Bipolar Family (BBF) members and ten HAPMAP populations. The first four principal components (PC1, PC2, PC3, and PC4) are 
plotted and show the BBF clustering more closely with the Northern and Western European (CEU) and Tuscan Italian (TSI) populations. 
Also shown in the graph are populations with African Ancestry from Southwest USA (ASW), Chinese from Beijing and Denver Colorado 
(CH), Japanese from Tokyo Japan (JPT), Luhya from Webuye Kenya (LWK), Mexican from Los Angeles, California (MEX), Massai from 
Kinyawa Kenya (MKK) and Yoruba from Ibadan, Nigeria (YRI). 
 36 
Delineating the ancestry of the BBF was necessary to inform the linkage and case-
control replication analyses that were going to be performed in the study and any 
conclusions that were going to be drawn from the findings of those studies in 
reference to published works. The analyses were not conducted using the Affymetrix 
10K array data (comprising 10,000 SNPs) available for all BBF members because 
after asymmetric and uncommon SNPs between the BBF 10K data and the HapMap 
populations were removed an insufficient number of SNPs was available to perform 
the EIGENSOFT ancestry analysis. Pursuing the ancestry analysis further using 
alternative methods was not regarded as necessary given that analysis of the fourteen 
BBF members confirmed the reports of ancestry provided by the family and the 
interviewers. 
 
2.3 Diagnostic Procedures 
2.3.1 The Structured Clinical Interview for DSM-IV Axis I Disorders  
All family members aged 17 years or older were given a face-to-face semi-structured 
interview, using the Portuguese version of the Structured Clinical Interview for DSM-
IV Axis I Disorders (SCID) (Del Ben, Rodrigues, & Zuardi, 1996) to systemically 
evaluate the presence of any current and/or lifetime Axis I psychiatric disorders. The 
SCID interview began with basic questions about demographics (e.g. age, marital 
status), educational history, and work history, followed by six sections on mood 
episodes, psychotic symptoms, differential diagnosis of psychotic disorders, 
differential diagnosis of mood disorders, substance-use disorders, anxiety disorders, 
somatoform disorders, eating disorders, and adjustment disorder. Participants were 
asked to report the presence or absence of DSM-IV diagnostic criteria with Yes or No 
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answers. The psychiatrists typically asked participants to elaborate on each answer 
with details of thoughts, feelings, and behaviours, where appropriate. Each criterion 
was rated as either absent or sub-clinically present with a negative (-), or as clinically 
present with a positive (+). Inadequate information for a positive or negative rating 
was coded with a question mark (?). Reaching a satisfactory response to SCID items 
sometimes entailed seeking corroborating information from other family members as 
well as challenging the participants’ answers with more questions. On rare occasions, 
and given the tendency of bipolar patients to deny manic symptoms, the psychiatrists 
made clinical judgments regarding the presence of particular symptoms, even when 
the participants denied their presence.  
2.3.2 The Kiddie-SADS-Present and Lifetime Version (K-SADS-PL) 
Family members between the ages of 5 and 16 years old were administered the 
Portuguese version of Kiddie-SADS-Present and Lifetime Version (K-SADS-PL) 
(Brasil & Bordin, 2010), a semi-structured interview designed to assess current and 
past episodes of psychiatric disorders including major depression, bipolar disorder, 
dysthymia, cyclothymia, schizoaffective disorder, schizophrenia, attention-deficient 
hyperactivity disorder, and anxiety disorders, in children and adolescents according to 
DSM-IV criteria by interviewing the parent(s) and the child or adolescent. After 
information on the child or adolescent’s general health, school functioning, peer and 
family relationships, and developmental milestones was collected, a screening 
interview surveying the primary symptoms of the different psychiatric disorders 
covered by the K-SADS-PL (e.g. increased goal directed activity, racing thoughts, 
decreased mood) was completed for current and most severe past episodes 
simultaneously. Each symptom was scored using either a zero to 3 point rating scale, 
where zero indicated no information was available, 1 indicated symptom was not 
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present, 2 indicated sub-threshold level of symptomology, and 3 indicated symptom 
was present and met criteria, or a zero to 2 point rating scale, where zero implied no 
information was available, 1 indicated the symptom was not present, and 2 indicated 
the symptom was present. Parent(s) and child reports were scored and a final 
summary rating for each item was achieved by including both sources of information. 
In cases of discrepant parent-child accounts, the interviewing psychiatrist used 
information available from other family members, as well as best clinical judgment to 
make a summary rating.  
If the child or adolescent had clinical manifestations of symptoms associated 
with a particular diagnosis, a diagnostic supplement (either affective disorders, 
psychotic disorders, anxiety disorders, behavioural disorders, or substance disorders 
and other disorders supplement) appropriate to the symptoms displayed was 
administered as directed by the ‘Skip out’ criteria in the interview to aid the 
interviewer in making current and past DSM-IV diagnoses.  
2.3.3 Scoring the Diagnostic Interviews 
In total three hundred and eight interviews were completed by the BBF members, and 
only five eligible family members refused an interview. The interviewing 
psychiatrists and myself independently scored the diagnostic interviews and reviewed 
available clinical and hospital records before making independent diagnoses. 
Discrepancies in diagnoses were discussed extensively and reviewed by two 
independent psychiatrists who scored the diagnostic interviews in question and 
examined clinical records before making independent conclusions. A final diagnosis 
based on the consensus was used. Occasionally, additional patient information 
required to confirm diagnoses and was provided via telephone conversations with 
family members. 
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2.4 Diagnostic Profile of the BBF 
A spectrum of mood disorders is manifested in the BBF with variable severity and 
duration, ranging from severe BPI cases requiring repeated hospitalisations to cases 
experiencing single depressive episodes with moderate severity. In total 111 (36%) 
interviewed family members received a mood disorder diagnosis. Forty (13%) family 
members fulfilled criteria for BPI, BPII, or SAD, which increased to 52 (16.9%) when 
bipolar spectrum disorders including BPNOS and cyclothymia were considered. Sex 
differences in the rates of mood disorders were observed in the BBF with a higher 
percentage of women (62.9%) reporting mood disorders than men (37.1%). These 
differences were maintained even when only BPI and SAD were considered as 
affected, with 61.3% women and 38.7% men reporting severe BPD episodes. 
Unipolar depression segregated in the BBF with a high prevalence as 17.3% of 
family members received a diagnosis of major depressive disorder, or dysthymia. This 
lifetime prevalence, however, is difficult to interpret as estimates of lifetime 
prevalence of depression in the general population vary considerably between studies. 
For example the life time prevalence of depression was estimated to be 4.4% in the 
U.S multi-site Epidemiological Catchment Area Study (ECA) (Weissman et al., 
1988), 8.56% in the general population of five European countries (Ayuso-Mateos et 
al., 2001) and 17.1% by the U.S National Co-morbidity Survey (Kessler et al., 1994).  
Thirty-one percent of those affected with a mood disorder in the family 
exhibited co-morbid anxiety disorders, predominantly generalised anxiety and panic 
disorder. The prevalence of co-morbid anxiety did not, however, significantly differ 
from the prevalence of primary anxiety disorders reported in the family (13.2%) (!2= 
0.01, p-value=0.93, df=1). In addition, alcohol abuse, defined as continued drinking 
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despite social, legal, or interpersonal problems, was reported by 21.6% of family 
members affected with mood disorders. This prevalence rate is above that reported in 
the general population, which ranges from 8.8 to 17.8% (Hasin, Stinson, Ogburn, & 
Grant, 2007). However, no significant differences existed between co-morbid alcohol 
abuse among family members affected with mood disorders and alcohol abuse among 
family members unaffected with mood disorders, 20.3% of whom reported alcohol 
abuse (!2= 1.0, p-value=0.32, df=1). 
In addition to mood disorders, diagnostic procedures revealed one family 
member had schizophrenia, four family members were classed as mentally retarded, 
six suffered with adjustment disorder, two reported severe symptoms of premenstrual 
dysphonic disorder, five children were diagnosed with Attention Deficient 
Hyperactivity Disorder, and one child was thought to be on the autistic spectrum. In 
terms of physical disorders, the BBF had higher than expected rates of thyroidism 
(7.8%), type I diabetes (10.1%) and Parkinson’s disease (2.6%).  
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2.4.1 Age of Onset of Mood Disorders in the Family 
Reliable information regarding age of onset was available for 104 out of 111 affected family members. The average age of onset for all mood 
disorders was 29.6 years old (SD=±13.2) ranging from 7 to 85 years old (Figure 2.4).  
Figure 2.4. Histogram of age of onset by clinical diagnosis including bipolar I disorder (BPI), bipolar II disorder (II), bipolar disorder not otherwise 
specified (BPNOS), cyclothymia, dysthymia, major depression (MDD), recurrent major depression (RMDD) and schizoaffective disorder, bipolar 
type (SAD). 
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2.4.2 Paediatric Mood Disorders 
In the BBF children as young as 7 years old received diagnoses of BPD (Figure 2.4). 
The research team was divided over such diagnoses for children under the age of 
twelve, mainly because identifying BPD in children is generally challenging and 
distinguishing BPD from Attention Deficit Hyperactivity Disorder (ADHD) and 
disruptive behaviour is sometimes difficult (Leibenluft & Rich, 2008). While adults 
have distinct periods of depression and mania that last for weeks or months, children 
have rapid cycling manic and depressive episodes that occur daily, sometimes 
simultaneously.  
In general, paediatric BPD is the centre of debate among psychiatrists and 
British child psychiatrists tend to be more conservative with assigning paediatric BPD 
diagnoses than their American counterparts (Dubicka, Carlson, Vail, & Harrington, 
2008; Post et al., 2008). However, some research suggests that paediatric BPD may 
not be rare, but only difficult to diagnose (Chang, 2009) and paediatric BPD might be 
a distinct subtype with a high familial loading (Bellivier et al., 2003). In the BBF, 
eleven children were under consideration for paediatric bipolar disorders. After 
consulting an experienced child psychiatrist, who reviewed the K-SADS-PL and 
interview notes, five children received diagnoses of BPNOS (two 7 year olds, one 9 
year old, and one 10 year old), one received a diagnosis of BPII disorder (11 years 
old), and the remaining children were diagnosed with ADHD. 
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2.5 Phenotype Models 
Bipolar disorder, SAD, and unipolar depression share common clinical features that 
are often indistinguishable. The similarities between the disorders extend to the 
genetic level, as family studies demonstrate their co-aggregation in families and 
molecular genetic studies suggest a “spectrum” of associated disorders with unique as 
well as overlapping genetic liabilities (Jones, Kent, & Craddock, 2002; McGuffin et 
al., 2003). These factors made deciding what should be classed as “affected” in the 
BBF difficult, especially that the nature and strength of genetic influences observed in 
a study may vary substantially depending on how precisely or how broadly the 
phenotype is defined (McGuffin & Sargeant, 1991). 
For these reasons, we elected to use a hierarchical approach to affectedness. 
Three phenotypic models with widening groups of diagnoses classed as affected were 
constructed for the analyses: a narrow, broad, and super model, in addition to a 
depression only model. The narrow affection model included family members that 
fulfilled DSM-IV criteria for BPI, BPII, or SAD. The broad model included family 
members in the narrow model in addition to family members who fulfilled DSM-IV 
criteria for BPNOS and cyclothymia. The super model included family members in 
the broad model in addition to family members who experienced at least one episode 
of major depression of at least moderate severity (MDD) as defined by DSM-IV, or 
fulfilled diagnostic criteria for dysthymia. Finally, family members were included in 
the depression model if they had a history of dysthymia or experienced one episode of 
major depression (Table 2.1). 
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Phenotype Model Co-Morbid Disorders  
Diagnosis Narrow Broad Super Depression Psychosis Anxiety 
BPI 24 24 24  19 10 
BPII 15 15 15   3 
SADB 1 1 1  1  
BPNOS  10 10  3 1 
Cyclothymia  2 2    
RMDD   28 28 1 10 
MDD   29 29  9 






























Table 2.1. Phenotype models by number and percentage of affected family members and 
co-morbid psychosis and anxiety disorders. The total number of family members 
affected with a mood disorder is 111. The total number of interviews conducted is 308. 
The diagnoses are bipolar I disorder (BPI), bipolar II disorder (BPII), schizoaffective 
disorder, bipolar type (SAD), bipolar not otherwise specified (BPNOS), cyclothymia, 
recurrent major depressive disorder (RMDD) , one episode of major depressive disorder 
(MDD), and dysthymia. 
 
Family members with mood disorders not fulfilling the particular diagnostic 
requirements for the phenotype model under study were labelled with affection status 
“unknown” in the analyses (as well as one schizophrenic individual, and seventeen 
very young children who provided blood samples but were not interviewed). 
Genotypes for individuals set as “unkonwn” are only used to infer missing parental 
genotypes and to provide haplotype phasing information (Terwilliger & Ott, 1994), 
which may increase the informativeness of the data. Individuals who were 
interviewed and did not receive any mood disorder diagnoses were labelled as 
“unaffected” in the analyses.  
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2.6 Anticipation in the BBF 
The average age of onset of mood disorders significantly decreased in successive 
generations of the BBF with a mean age of 39.5 years old (SD±15.0) in the second 
generation compared with 31.7 years old (SD±11.3) in the third generation, 19.4 years 
old (SD±9.4) in the forth generation, and 14.0 years old (SD±3.6) in the fifth 
generation (Table 2.2). This suggests anticipation, a phenomenon characterised by 
earlier disease onset or increase in disease severity in successive generation, which was 
first described by Mott in 1910 in the offspring of “insane” parents being affected with 
disease earlier than their parents. Although anticipation has a molecular basis involving 
trinucleotide and other repeat expansion in certain disorders, apparent anticipation can 
occur for other reasons including ascertainment bias (Asherson et al., 1994; Penrose & 
Watson, 1945). 
Anticipation was examined by comparing the age of onset in the second, third, 
fourth, and fifth generations of the pedigree. The first generation, most of whom are 
deceased, were excluded from the analysis due to insufficient information regarding 
age of onset. The differences in ages of onset were analysed with the ANOVA test. 
There were significant differences between the groups (p-value=0.013, F=1.87) 
suggesting anticipation was present. Assessment of disease severity across the 
generations was unfeasible as accurate measures of severity such as episode frequency 
were only available for a limited number of affected family members. 
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Generation  
Diagnosis I II III IV V 
BPI  8 12 3 1 
BPII  2 7 5 1 
SADB      
BPNOS  1 4 6  
Cyclothymia   1   
RMDD  8 15 5  
MDD 1 3 17 7 1 
Dysthymia   2   
Unaffected 1 26 86 88 17 
Total 2 48 144 114 20 










Age of onset Range N/A 15-65 13-56 7-40 11-18 













Table 2.2. Age of onset for affected BBF members across the five generations. The 
diagnoses are bipolar I disorder (BPI), bipolar II disorder (BPII), schizoaffective 
disorder, bipolar type (SAD), bipolar not otherwise specified (BPNOS), cyclothymia, 
recurrent major depressive disorder (RMDD) , one episode of major depressive disorder 
(MDD), and dysthymia. 
 
 
Figure 2.5. Age of onset distribution of mood disorders across the five generations of the 
BBF. Age of onset is graphed against its frequency in the family. 
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Table 2.2 and Figure 2.5 show the pattern of apparent anticipation. However, several 
sources of bias can mimic anticipation and need to be addressed before drawing 
definitive conclusions about the occurrence of anticipation in the BBF. Primary among 
these for the BFF may have been the differential availability of medical care for the 
younger generations versus the second generation who lived mostly in the isolated 
village of Senhora de Oliveira with sparse medical facilities, whereas later generations 
moved to nearby cities where psychiatric care was more readily available. As can be 
seen from Figure 2.5 some second generation family members received first time 
diagnoses aged 60 years or older, suggesting recall bias, as they may have forgotten 
the exact date their symptoms first emerged. Of note is that the clinical interview 
conducted in this study focused on the first appearance of mood episodes and most 
severe episodes encountered by family members rather than first episodes diagnosed. 
In addition, BBF members were known in their village for being “crazy and eccentric” 
and older family members described being weary of passing on “the madness” to their 
children. This awareness of disease could have lead to increased alertness in the 
parents and an earlier diagnosis in their children. The environmental stressors 
associated with an individual being raised by an affected parent could also have an 
effect on early onset of disease. Further, most family members in generations four and 
five were diagnosed and treated by our psychiatrists as a consequence of being 
interviewed for the study, and the BBF was ascertained through proband 1, whose 
child committed suicide aged 17 years during a manic episode. This introduces an 
ascertainment bias as described by Penrose & Watson (1945), who dismissed 
anticipation as an ascertainment artefact altogether.  
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2.7 Inbreeding in the BBF 
The BBF is characterised by extensive inbreeding occurring over successive 
generations. Six instances of consanguinity exist between first-degree cousins; two in 
Branch 1, one in Branch 2, one between Branches 1 and 2, and two between Branches 
1 and 3. In addition, two marriage loops in which siblings from unrelated families 
marry siblings from Branch 1 of the BBF exist. A section demonstrating the 
complexity of family relatedness in Branch 1 of the BBF is shown in Figure 2.6. 
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Figure 2.6. Consanguinity and marriage loops in Branch 1 of the BBF. Consanguinity loops are demarcated by two parallel lines and marriage loops 
are indicated with asterisks. Family members affected with a mood disorder are demarcated in black, unaffected in grey, and unknown in white. 
Symbols crossed by a line represent deceased individuals.  
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Reports on the health effects of inbreeding focus mainly on its impact on reproduction, 
childhood mortality, and rare Mendelian diseases. For a long time inbred families or 
isolated populations have been effective in detecting the causes of rare recessive 
diseases using homozygosity mapping, which hypothesises the presence in large 
inbred pedigrees, such as the BBF, of homozygous segments that are inherited by 
descent from a common ancestor. The idea being that homozygous affected 
individuals whose parents are related most likely receive a common haplotype without 
recombination from a single founder allowing linkage information to be gained from 
all presumed non-recombinant meioses all the way from the original founder 
haplotype to the affected children (Kruglyak & Lander, 1995). However, the usability 
of inbred families and isolated populations is extended to complex disease. Some 
studies have show that inbreeding has an effect on numerous multifactorial as well as 
Mendelian diseases and have emphasised the benefits of studying inbred families with 
common diseases. For example, a study found inbreeding caused an increase in 
homozygosity at many genetic loci with small deleterious effects on homeostatic 
pathways resulting in increased disease risk for blood pressure, unipolar depression, 
BPD, asthma, gout, and peptic ulcer (but not type 2 diabetes) in three genetic isolates 
from neighbouring islands in Middle Dalmatia, Croatia (Rudan et al., 2003).  
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2.8 The Brazilian Bipolar Family Subfamilies 
2.8.1 Branch 1 Subfamilies 
Branch 1 was divided into 12 subfamilies for the purpose of analysis as will be 
discussed later. This Branch of the BBF is densely affected with an array of mood 
disorders that vary in type and severity. A total of 214 individuals were interviewed 
from Branch 1. Assortative mating, or the tendency for individuals with similar 
phenotypes to mate more frequently than expected is common among people with 
mood disorders (Mathews & Reus, 2001) and occurs frequently in Branch 1. 
Assortative mating could partially account for the high incidence of consanguinity in 




Key to Subfamilies 1-19. Eight disorders are included in the subfamily diagrams; 
bipolar I disorder (BPI), bipolar II disorder (BPII), cyclothymia, bipolar not otherwise 
specified (BPNOS), schizophrenia, recurrent major depressive disorder (RMDD), one 
episode of major depressive disorder (MDD), and dysthymia. Available DNA is 
demarcated with a plus (+).   
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Subfamily 1. The parallel lines between 205 and 204 indicate a consanguineous marriage 
between two first cousins. 205 is a member of Branch 2 of the BBF and is suspected of 
being on the BPD spectrum and 204 had numerous hospitalisations due to puerperal 
mania. 205 and 204 are the parents of the largest sibship in the Branch 1 comprised of 
16 children, presented in subfamilies 1 to 3. This subfamily predominantly segregates 
BPII disorder. 58 is the only member of the family with BPI disorder. 
 
Subfamily 2. Continuation of the children of 204 and 205. All BPI cases in this subfamily 
were hospitalised due to psychotic mania. Individual 48 had severe BPI that necessitated 
over 15 hospitalisations and 10 altercations with the police to date. Individual 42 does 
not have an official SCID diagnosis, however, the interviewing psychiatrist noted he was 
hyperthymic during the interview.   
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Subfamily 3. Continuation of the children of 204 and 205. Both individuals 175 and 179 
were hospitalised on numerous occasions and reported visual and auditory 
hallucinations. Individual 179 had altercations with the law, as he tried to kill his wife, 
180, on several occasions. Non-paternity was determined for individual 183. Individual 
30 does not have an official SCID diagnosis, however, the interviewing psychiatrist 
noted he was hyperthymic during the interview. 
 
Subfamily 4. Individual 15 experienced a severe manic episode at 17 years old with 
psychotic symptoms, followed by numerous depressive episodes and currently only 
experiences hypomanic episodes (no medication). Individual 17 experienced 
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Subfamily 5. Individual 217 had a history of severe mania and died in a psychiatric 
hospital due to complications from diabetes. Individual 344 was receiving treatment for 
recurrent depression at the time of interview; however, psychiatrists suspect he might 
be on the bipolar spectrum (although he vehemently denied that). Individual 104 was 
diagnosed with BPNOS aged 10 years old.  
 
 
Subfamily 6. Individual 1 is the proband. Her manic episodes got worse after the suicide 
of her son, 29, who killed himself during a manic episode aged 17 years old. Individual 2 
was hospitalised twice due to severe manic episodes and experienced over 20 episodes of 
debilitating depression.  
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Subfamily 7. The parallel lines indicate consanguineous marriages between first cousins. 
Individual 63 is the youngest family member with a bipolar spectrum diagnosis. He 
presented with a mixed episode over a week during the psychiatrists’ visit, oscillating 
between dysphoria, anger, impulsiveness and euphoria. Individual 98, aged 17 years old 
during the interview, reported multiple episodes of severe depression.  
 
 
Subfamily 8. Individual 71 is the only BBF member with schizophrenia, paranoid 
subtype. He was diagnosed aged 37 years old. Individual 68 experienced multiple 
episodes of psychotic depression.  
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Subfamily 9. A marriage loop occurs in this subfamily, as two brothers (74 and 383) 
marry two sisters (75 and 288). Individual 75 experienced rapid cycling mania with 
psychosis. She built a church in her farm to practice her healing powers on town’s 
people. Her symptoms increased after her son, 93, attempted suicide by climbing an 
electricity pole during a severe manic episode and lost complete function of one of his 
legs. Individual 93 was in a manic episode during the interview. Individual 92 is 10 years 
old. He is suspected of being on the bipolar spectrum based on information from his 
father. His mother denied he experienced any mood symptoms. He jumped out of the 
window to avoid meeting with the visiting psychiatrist.  
 
 
Subfamily 10. The parallel lines indicate consanguineous marriages between first 
cousins. Individual 84 was hospitalised five times with severe manic episodes and 
psychosis. She has not experienced more episodes following treatment with Lithium. 
Individual 86 is deaf. Her mother reported 86 experienced periods of happiness and 
periods of crying and refusing to go to church that lasted no longer than a week, she 
received a diagnosis of BPNOS as the duration and severity of her symptoms was 
ambiguous. 
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Subfamily 11. Individual 94 was hospitalised twice with severe psychotic mania and 
reported more than 10 episodes of depression. Her moods stabilised with Lithium. 
Individual 100 experienced multiple severe depressions and was hospitalised for a severe 
depressive episode for 20 days. He has been euthymic since starting on Lithium 
treatment. Individual 110 reported being diagnosed with depression aged 17 years old. 
Due to family history, he was prescribed Lithium by the study psychiatrists and his 
symptoms markedly improved.  
 
 
Subfamily 12. Individual 123 was hospitalised eight times with manic episodes and 
extreme aggressive behaviour. He inappropriately called his daughters to his bed when 
manic. His symptoms markedly improved with the introduction of Lithium. Individual 
135 is a 6-year-old boy described by the visiting psychiatrist as odd and socially 
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2.8.2 Branch 2 Subfamilies 
Branch 2 of the BBF is the least densely affected. None of the family members 
experienced severe symptoms warranting hospitalisation and none of them reported 
psychotic symptoms. Of note is that ascertainment of Branch 2 of the BBF was the 
least successful, as a large number of its members were either not contactable or 
refused participation in the study. Only 25 interviewed family members belong to this 
Branch. A pedigree diagram and description of each subfamily is presented next. 
 
Subfamily 13. The parallel lines indicate consanguineous marriage between first cousins. 
This subfamily is not very densely affected, with two individuals, 475 and 468 reporting 
one episode of depression each. Individual 417 is suspected of being BPI based on 
information from family members and town’s people.  
 
 
Subfamily 14. Individual 405 denied having any mood episodes, however, his son and 
grandson insisted he had periods of elated mood and renewed vigour as well as periods 
when he avoided family members and refrained from speaking. Individual 886 is 
suspected of being autistic.  
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2.8.3 Branch 3 Subfamilies 
Branch 3 is the most out-bred of the BBF branches, with no consanguinity or marriage 
loops reported within the branch. In comparison to Branch 1, affected individuals in 
this branch do not exhibit psychotic symptoms. A total of 92 interviewed family 
member belong to this Branch. A pedigree diagram and description of each subfamily 
is presented next. 
 
Subfamily 15. Individual 859 suffers from recurrent episodes of severe depression. 
Individual 799 experienced two episodes of depression, the first of which lead to 
voluntary hospitalisation for 90 days.  
 
 
Subfamily 16. Individual 706 has hospital records indicating he suffered from BPI 
disorder. He committed suicide by shooting himself. Individual 711 experiences non-
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psychotic mixed episodes. Individual 654 committed suicide at the age of 22. Individuals 
702 and 703 presented with manic episodes but no depressive episodes.  
 
Subfamily 17. Individual 603 was described as hyperthymic during the interview. She 
revealed she had numerous extra-marital affairs and had 2 children with another man 
(not part of this study).  
 
Subfamily 18. Individual 684 described short periods of irritability, agitation, and 
hypomania of moderate severity. Individual 681 was depressed during the interview, 
which was his first depressive episode aged 57 years old. Individual 901 received fulfilled 
K-SAD criteria for BP NOS, aged 7 years old.  
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Subfamily 19. Individual 739 was hospitalised five times after trying to kill himself 
during severe depressive episodes. Individual 745 had two episodes of depression that he 
received treatment for. The Diagnostic interview revealed he might have experienced a 
mixed episode, however, the interview was inconclusive.  
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Chapter 3 Linkage Introduction 
3.1 Linkage and Recombination  
In order to understand the principles of linkage analysis, it is necessary to appreciate 
how recombination occurs during meiosis. Each individual’s genetic material is made 
of 23 homologous pairs one inherited from the mother and one inherited from the 
father, so that each gene is present in duplicate (except those on the X and Y 
chromosomes). During meiosis the homologous chromosomes crossover and exchange 
DNA segments in a process called recombination. In recombination a portion of the 
maternal homolog recombines with the paternal homolog to form a hybrid 
chromosome. This leads to the formation of gametes that possess non-recombinant 
and recombinant chromosomes that contain new combinations of alleles (Terwilliger 
& Ott, 1994).  
Two genes that are on the same chromosome, transmitted from either the 
individual’s father or the individual’s mother, will be transmitted together unless a 
crossover point separates them. The closer the two genes are together, the less likely 
that a crossover point will occur between them and the more likely that they will be 
transmitted together (Sham & McGuffin, 2002). However, recombination events 
occur unevenly in the human genome. Certain “hotspots” are favoured sites of 
recombination, while areas in the vicinity of centromeres, are “recombination 
deserts”, in which few corssovers ever take place. Typically, 80% of the 
recombination occurs in 10 to 20% of chromosomal sequence, with the exception of 
chromosome 19 which has a much lower density of hotspots (Myers et al. 2005). 
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Linkage is the main method of mapping disease loci in families. It tests the co-
segregation between a disease locus and a genetic marker or markers such as 
microsatellites, multiallelic markers comprised of short, repeating sequences of DNA, 
or biallelic Single Nucleotide Polymorphisms (SNPs). Two methods of linkage 
analysis are used, parametric linkage and non-parametric linkage.  
 
3.2 Parametric Linkage Analysis 
Parametric linkage is a statistical method used to determine if a disease and marker 
locus co-segregate in families. Determining linkage would suggest that the disease 
locus is present in the region of the chromosome containing the marker. Parametric 
linkage analysis requires the specification of a disease transmission model, which 
details the mode of disease inheritance (e.g. dominant, recessive, or co-dominant), the 
disease allele frequency and the penetrance of the disease. Additional parameters such 
as marker allele frequencies, recombination rates between the marker loci, and the 
mutation rates at the marker loci are also specified, although the latter is often 
assumed to be zero (Schmidt, 2006).  
3.2.1 The Recombination Fraction  
The recombination fraction is the main measure of interest in parametric linkage 
analysis. It is the proportion of gametes that are recombinant with respect to two loci 
and is usually denoted as Theta (!). It reflects the probability of recombination 
between two loci at meiosis. Two loci are said to be linked if during meiosis, 
recombination occurs between them with a probability of less than 50%. Conversely, 
two loci are said to be independently assorting, if during meiosis recombination 
occurs between them with a probability of 50%. The genetic map is based on the 
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recombination fraction between markers, where one Cenitmorgan (cM) corresponds 
to the occurrence of crossing over between two markers one time in a hundred. 
Delineating the recombination frequency between a disease locus and a maker with a 
known location on the genetic map allows an approximate localisation of the disease 
gene. Further, if additional markers in the region are examined then the disease gene 
can be narrowed down to a small region where the markers show no recombination 
with the disease locus (Sham and McGuffin, 2002).  
3.2.2 The Logarithm of the Odds (LOD) Score 
To evaluate the statistical significance of the recombination fraction (!) between two 
loci, the logarithm of the odds (LOD) score is used. The LOD score compares the 
likelihood of the data under the assumption of linkage (! is less than 0.5) to the 
likelihood of the data under the assumption of no linkage (! is equal to 0.5) and could 
be expressed as follows: 
 
 
Where R is the number of recombinant meioses, NR is the number of non-
recombinant meioses and N is the total number of meioses.  
If we consider a simple three-generation pedigree (Figure 3.1) where a double 
heterozygote (MmDd) father for a marker locus (Mm) and a dominant disease locus 
(Dd) mates with a double recessive homozygote (mmdd) mother for the same loci. 
Calculating the recombination fraction between the two loci is possible, and relatively 
straightforward, when phase, or the physical relationship between the two loci on the 
homologous chromosome(s) is known. If the two loci are co-inherited from the same 
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parent and are therefore physically present on the same homolog they are in coupling 
phase, with the opposite being repulsion phase (Ott, 1999).  
By inspecting the illustrated pedigree we are able determine the linkage phase 
of the second-generation father, which is indicated by the vertical bar in his genotype 
separating maternal (left side of bar) from paternal alleles; D and M alleles are on one 
homologous chromosome and d and m are on the other. Both sets of alleles D M and 
d m are in coupling phase. Based on the inferred linkage phase we could determine 
with confidence that in the third generation five children are non-recombinant and 
two children are recombinant. The recombination fraction between the disease and 
marker locus is the total number of recombinant offspring divided by the total number 
of offspring, which is 2/7=0.29. Thus the gene or locus for disease D and marker M 
appear to be loosely linked with a recombination fraction of 0.29, suggesting that the 
disease and marker locus are approximately 29 cM apart.  
 
Figure 3.1 The father in generation II with DdMm genotypes is doubly heterozygous. It 
can be deduced that the alleles transmitted from the two grandparents to this parent are 
DM and dm. The ‘coupling’ of D and M and that of d and m, are known as the phase of 
the genotype. Five children are non-recombinant (NR) as they inherit the same genotype 
combinations as those transmitted in the previous generation and two children are 
recombinant (R) as they inherit genotypes that are unlike those transmitted in the 
previous generations.  
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To evaluate the statistical significance of this finding, the LOD score is calculated as 
follows: 
 
By convention, a LOD score greater or equal to 3.0 is considered as significant 
evidence for linkage. It indicates 1000 to 1 odds that the linkage observed did not 
occur by chance. On the other hand, a LOD score less than -2.0 is considered as 
evidence to exclude linkage (Morton, 1955). Accordingly, the LOD score achieved 
from pedigree 3.1 neither confirms linkage between the disease and the marker locus, 
nor excludes it entirely.  
In reality, phase is usually ambiguous due to incomplete pedigree information 
or inability to determine which two alleles were received by a double heterozygote 
parent from the maternal or the paternal gametes. Deducing the number of 
recombinant and non-recombinant offspring becomes difficult and calculating the 
LOD score becomes more arduous. To illustrate, if phase information for the double 
heterozygote father in pedigree 3.1 was unknown because genotypic information from 
the grandparents was unavailable or difficult to interpret because they are both 
heterozygotes, two outcomes from the segregating disease and marker loci would be 
considered depending on whether paternal alleles D and m were on one homologous 
chromosome and d and M on the other, or paternal alleles D and M were on one 
homologous chromosome and d and m on the other. In the first instance, and as 
demonstrated in pedigree 3.2 (a), we would have two non-recombinant and five 
recombinant offspring yielding a recombination fraction of 0.71, and in the second 
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instance we would have five non-recombinant and two recombinant offspring (b) 
yielding a recombination fraction of 0.29.  
 
 
Figure 3.2. The father in generation II with DdMm genotypes is doubly heterozygous. 
Genotypes are not available for the grandparents, so the alleles transmitted from the two 
grandparents to this parent are of unknown phase. In a) two children are non-
recombinant and four children are recombinant. In (b) five children are 
nonrecombinant and two children are recombinant. . 
 
To calculate the LOD score the following formula would be used:  
 
Similar to pedigree 3.1, the LOD score achieved from pedigree 3.2 neither confirms 
linkage between the disease and the marker locus, nor excludes it entirely. This 
example demonstrates that with unknown phase calculating the LOD score becomes 
more difficult as all of the parent to offspring allele transmissions must be considered. 
The inclusion of extended families with missing genotypes, which is often the case in 
pedigree analyses, complicates the LOD score calculations even further as the number 
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of possible recombinant versus non-recombinant offspring combinations increases. In 
practice LOD score statistics are calculated for a range of recombination fractions. 
3.2.3 Maximizing the Recombination Fraction 
In parametric linkage a LOD score statistic is calculated for a range of recombination 
fractions (e.g. !=0.0 to ! =0.3) reflecting every possible offspring outcome observed 
from the pedigree data. The recombination fraction achieved under the maximum 
LOD score reveals the best estimate of the recombination fraction, which is 
approximately proportional to the distance between the marker and disease locus. This 
is known as maximising the recombination fraction (Table 3.1). Tracing the 
recombination fraction between the disease locus and multiple loci with known 
locations in the genome allows the positioning of the disease gene or locus on the 
genetic map with some accuracy (Dawn Teare & Barrett, 2005).  
 
Recombination Fraction Marker Genetic Location 
0.0 0.01 0.02 0.1 0.2 0.3 
1 40.0 2.94 2.23 2.21 1.49 1.10 0.73 
2 44.0 2.71 2.70 3.50 1.18 1.50 0.90 
3 48.0 2.30 4.04 2.90 1.54 1.44 0.65 
4 50.0 2.93 2.90 1.90 0.98 0.90 0.59 
 
Table 3.1. Example output from parametric linkage analysis using four markers with an 
inter marker distance of 4 cM at theta (!) values of zero, 0.01, 0.02, 0.1, 0.2 and 0.3 
indicating the disease and locus gene are in the same location, 1 cM apart, 2 cM apart, 10 
cM apart, 19 cM* apart, and 27* cM apart respectively. The LOD score for marker 3 is 
maximised at a recombination fraction of 0.01 and the LOD score for marker 2 is 
maximised at a recombination fraction of 0.02 indicating that the disease locus is 1 cM 
away from marker 3 and 2 cM away from marker 2.  Considering a LOD score of 3.0 as 
indicative of significant linkage, only markers 2 and 3 meet that threshold and therefore 
are used to localise the disease gene. 
 
                                                
* Converted to genetic distance using the Kosambi function. 
* Converted to genetic distance using the Kosambi function.!
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It is important to note that when the recombination fraction is small, the genetic 
distance and the recombination fraction are approximately equal. In practice 
geneticists treat them as equal for recombination fraction values of 0.1 or less. 
Recombination fraction values greater than 0.1, as demonstrated by the example in 
Table 3.1, are usually converted to genetic distance using either the Haldane or 
Kosambi function (see Chapter 4 section 4.5.4.4). 
3.2.4 The Disease Transmission Model 
Parametric linkage was originally developed to map genes in simple Mendelian 
diseases with known genetic parameters (disease allele frequency, dominance 
relationship between normal and disease alleles, penetrance values) under a single 
locus two allele model defined by the formula: 
 
Where the population prevalence of the disease Kp is a function of the allele 
frequencies of the ‘normal’ allele and the ‘disease’ allele denoted by p and q 
respectively and three penetrance parameters denoted by ƒ1, ƒ2, and ƒ3 for the 
penetrance of zero, one, and two disease alleles respectively. Penetrance refers to the 
probability of being affected with a disease given a certain genotype. The penetrance 
set determines to what degree the phenotypic information of unaffected individuals is 
used for the linkage analysis (Terwilliger & Ott, 1994). The penetrance of ƒ1, also 
known as the phenocopy rate, is the percentage of sporadic cases in the population 
under study that are affected with the disease not due to genetic predisposition, but 
due to some unspecified environmental factor or to genes at other locations (not under 
study) (Ott, 1999).  
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Parametric linkage methods have been successful in identifying genes for 
dominantly inherited monogenic diseases such as Huntington’s disease and 
recessively inherited diseases such as cystic fibrosis, but have been less successful 
when applied to genetically complex diseases.   
3.2.5 Parametric Linkage Analyses in Complex Diseases 
In complex diseases, such as BPD, where the mode of inheritance is not known 
assumptions about the disease allele frequency expected in the population; the disease 
penetrance, and the expected phenocopy rate are made. It is therefore common to 
analyse the data under several possible transmission models. This approach is called 
the maximized maximum LOD score (MMLS) (Greenberg, 1989), or mod score 
approach (Clerget-Darpoux, Bonaïti-Pellié, & Hochez, 1986). It typically involves 
analysing the data under a dominant and a recessive model and varying the penetrance 
parameters to include full penetrance, incomplete penetrance, or age-related 
penetrance. The robustness of this method has been verified by simulation studies, 
which show that maximising the LOD score over a range of transmission models, and 
subsequent correction for multiple testing, does not substantially decrease the power 
to detect linkage, compared with what one would find if the true mode of inheritance 
was used (Goldin & Weeks, 1993; Greenberg, Abreu, & Hodge, 1998). Authorities 
still contend that parametric linkage methods (as opposed to non-parametric methods) 
offer the highest power to detect linkage, when a genetic model that approximates the 
true mode of disease inheritance is specified (Abreu, Greenberg, & Hodge, 1999; 
Durner & Greenberg, 1992), and especially when the LOD score is maximised over 
several inheritance models. 
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3.2.6 Two-Point Parametric Linkage 
The LOD score method described thus far is referred to as two-point linkage. It is 
carried out as a sequence of pair-wise comparisons calculating the recombination 
fraction between a disease locus and each of a number of markers. It is not affected by 
marker location anomalies, marker allele frequency misspecifications, or genotyping 
errors. Two-point linkage is, however, prone to error if the disease model is 
misspecified. Here misspecifying a dominant trait as a recessive trait or vice versa 
will strongly reduce the maximum LOD score and consequently the power to detect 
linkage. In addition, misspecifying the penetrance or disease allele frequency can 
result in overestimation of the recombination fraction where the LOD score maximum 
occurs, as non-penetrant cases may be misclassified as recombinants (Risch & 
Giuffra, 1992).  
3.2.7 Multipoint Parametric Linkage 
Estimating the position of the disease locus relative to a number of closely spaced 
markers with known location in the genome is known as multipoint linkage. The 
multipoint LOD score (MLOD) is defined as: 
 
 
Where !0 represents a specific genetic model, x represents the location of the disease 
locus on a specific marker map and x=" refers to the null hypothesis of no linkage, 
i.e. the disease locus is not located on the marker map. Here linkage is usually 
expressed as a function of chromosomal positions measured in cM, as opposed to the 
recombination fraction in two-point methods. Multipoint linkage is in general more 
efficient than two-point linkage, as all relevant marker data are used simultaneously to 
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estimate the position of a disease susceptibility gene (Lander & Green, 1987). 
However, it is crucial that marker allele frequencies and the order of markers on the 
genetic map be correct as multipoint linkage simultaneously analyses several markers 
and therefore relies on the correct marker position and marker allele frequencies to 
locate the position of the disease locus on the genetic map. Errors in any of these 
parameters could result in misallocation of the disease susceptibility locus, or 
complete exclusion of linkage (Göring & Terwilliger, 2000). 
3.2.8 Locus Heterogeneity and Heterogeneity LOD Score  
Locus heterogeneity is the phenomenon of two or more independently acting loci each 
causing the same disease phenotype. Thus, if we perform linkage analysis with a 
marker located near one of these disease loci, some families will show linkage, 
whereas other families will show independent assortment of disease and marker and 
the combination of families will result in a reduction of the linkage signal, and may 
lead to failure to detect true linkage altogether (Abreu, Hodge, & Greenberg, 2002). 
To address locus heterogeneity, an admixture parameter alpha (!), which reflects the 
proportion of families linked to a particular locus can be incorporated into the LOD 
score analysis to allow for heterogeneity between investigated families, where an 
alpha of 1 indicates all members of a family show evidence of linkage to the locus 
under investigation, and an alpha of zero indicates that none of the family member 
show evidence of linkage. A heterogeneity LOD score (HLOD) is calculated thus 
allowing the detection of linkage even if some families under investigation do not 
have a genetic form linked to the locus of interest (Durner & Greenberg, 1992). The 
HLOD score assumes there are two categories of families in the data under 
investigation, some with ! =0.5 and some with ! less than 0.5, with a proportion ! of 
the families segregating the disease gene (! > 0) and a proportion of the families not 
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segregating the disease gene (!=0) and is calculated as follows: 
 
 
As with LOD scores the HLOD is maximised over disease models, and the maximum 
HLOD score achieved is taken to reflect the best estimate model of disease 
transmission. It is common practice in linkage to calculate both the LOD score and 
the HLOD score, and a more significant score under heterogeneity is taken to indicate 
locus heterogeneity.  
In the investigation of large multigenerational families, within family 
heterogeneity might be possible. LOD scores achieved using the entire pedigree can 
be compared to LOD scores achieved when the pedigree is broken into smaller units. 
Splitting a large pedigree into smaller components reduces information, for example 
of phase and recombination events and therefore reduces power. However, if the 
disease allele is common, and intra-familial heterogeneity is present, LOD scores may 
actually increase when the pedigree is divided (Badner, Gershon, & Goldin, 1998). 
The proficiency of HLOD scores to accurately detect linkage has been shown to be in 
par with the that of LOD score analysis and a good deal of evidence indicates it is a 
powerful and robust tools for detection of linkage in the presence of heterogeneity 
(Hodge, Vieland, & Greenberg, 2002).  
3.2.9 Allelic Heterogeneity  
Allelic heterogeneity refers to the presence of different mutations within the same 
susceptibility locus so that different disease alleles at the same locus could each cause 
the same disease phenotype. An example of this is cystic fibrosis for which a number 
of different mutated alleles within the CF transmembrane conductance regulator gene 
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(CFTR) have been isolated and shown to contribute to the cystic fibrosis phenotype 
(Tsui, 1992). Contrary to the effect of locus heterogeneity on linkage, allelic 
heterogeneity does not impede linkage analyses (its effect is more pronounced in 
association methods of gene mapping). 
 
3.3 Non-Parametric Linkage 
As discussed, parametric linkage relies on the specification of a disease inheritance 
model and with the majority of complex diseases the underlying genetic model is 
difficult to estimate. As such, the use of non-parametric approaches has become 
commonplace in the linkage analysis of complex diseases and has proven to be 
successful in mapping disease loci for a number of complex diseases such as 
osteoarthritis (Hashimoto, Ochs, Komiya, & Lotz, 1998). The power to detect linkage 
using non-parametric methods has been reported to be equivalent to that of a LOD 
based method conducted under the correct inheritance model (Kruglyak, Daly, Reeve-
Daly, & Lander, 1996). 
The method is based on the idea that family members inherit the same alleles 
from a common ancestor at the disease locus (due to lack of recombination fraction 
between the disease and marker locus). Therefore, at a marker locus close to a 
disease-causing locus affected family members should share more marker alleles or 
haplotypes that are identical-by-descent (IBD), i.e. have the same DNA sequence and 
are inherited from a common ancestor, than would be expected under random 
Mendelian segregation. IBD is distinguished from identity-by-state (IBS), which 
occurs in unrelated as well as related individuals, and simply refers to the sharing of 
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genotypically identical alleles that are not inherited from the same ancestor. Of course 
if two alleles are IBS they are definitely IBD but the converse is not necessarily true.  
Assigning IBD status to affected family members is necessary for most NPL 
approaches (some rely on IBS). For example, consider the pedigrees in Figure 3.3, the 
siblings in pedigree (a) with marker genotypes 1/2 and 1/1 share allele 1 IBD (and 
IBS of course) because the latter child received a 1 allele from each parent one of 
which is IBD with the 1 allele the first child received. In pedigree (b) the siblings 
share two alleles IBS and one allele IBD as they must have received the same 1 allele 
from the father. There is no information about the IBD status of the maternally 
derived alleles because there is no way to differentiate the 1 alleles from each other. 
In pedigree (c) the siblings share zero alleles IBS and IBD and in pedigree (d) they 
share both alleles IBS and IBD. Pedigree (e) is more complicated in the sense that 
because both parents and children are heterozygous, each with genotype 1/2 we 
cannot tell whether there are two alleles IBD or none. If the children were 
homozygous (i.e. 1/1 each, 2/2 each or 1/1 and 2/2) then IBD status would be more 
easily determined as one allele IBD if they were both 1/1 or 2/2 and zero alleles IBD 
if they were 1/1 and 2/2. Determining IBD allele sharing is easier when all parental 
alleles are distinguishable from each other, due to extremely polymorphic markers, as 
in pedigrees c and d.  
    
Figure 3.3. Affected sibling pairs with fully typed parents. Distinguishing Identical-By-
State (IBS) from Identical-By-Descent (IBD) status in nuclear families with affected 
sibling pairs and fully typed parents. Distinguishing IBS from IBD is facilitated by the 
use of polymorphic makers. Adapted from Terwilliger and Ott (1994).   
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NPL approaches map disease susceptibility loci by looking for excess sharing of 
marker alleles or haplotypes among affected sibling pairs (ASP) and affected pedigree 
members (APM) (Terwilliger & Ott, 1994).  
3.3.1 Affected Sibling Pairs 
Originally non-parametric linkage methods were devised entirely for use in nuclear 
families with known parental genotypes and were most commonly based on affected 
sibling pairs (ASP). Here the probability of siblings sharing zero, one or two marker 
locus alleles that are IBD is !, " and ! under the assumption of no linkage. Hence 
the average number of alleles shared at a marker locus that is unlinked to the disease 
in ASP is ", regardless of gene frequency or mode of disease inheritance (Sham & 
Zhao, 1998). The presence of linkage at a disease locus would lead to departure from 
this average and could be tested using the mean IBD test (Blackwelder & Elston, 
1982), which evaluates the null hypothesis that the proportion of IBD allele sharing is 
equal to " by comparing the observed number of alleles shared IBD with the expected 
number. Assuming that IBD is known for certain and that in a sample of affected 
sibling pairs n0 denotes sharing zero alleles IBD, n1 denotes sharing one allele IBD, 
and n2 denotes sharing two alleles IBD and N is the total number of affected sibling 
pairs, then the NPL test statistic could is defined as follows: 
 
In the ASP method the statistical analysis is simple as it only considers affected 
sibling pairs with available parental genotypes. The method becomes more 
complicated with extensions to include un-genotyped parents in the analyses or when 
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it is difficult to distinguish IBD from IBS (e.g. Figure 3.3 pedigree e) usually as a 
consequence of using markers that are not polymorphic enough to ensure that all 
parental alleles are distinguishable from each other (e.g. SNPs). In these instances 
NPL is determined using the prior and posterior probabilities of IBD sharing between 
sibling pairs. The prior probability is conditional only upon the relationship between 
the two siblings and is !, " and ! for sharing zero, one or two marker alleles that are 
IBD and the posterior probability is conditional on the genotype information only. For 
example, consider the pedigree in Figure 3.4 the mother is un-genotyped; she could 
have either genotype 1/3 or genotype 2/3. The posterior sharing probabilities for the 
siblings depend on the probabilities of these two maternal genotypes. If the mother is 
1/3 the siblings share zero alleles IBD, however, if the mother is 2/3 they share one 
allele IBD. So we need to know the probability that a mother drawn form the 
population has genotype 1/3 versus 2/3. Using the Hardy Weinberg equilibrium where 
the probabilities (P) are P(1/3)=2P(1)P(3) and P(2/3)=2P(2)P(3) would determine the 
most likely maternal genotype. Here the posterior probability depends on the assumed 
allele frequencies (Cordell, 2004).  
                          
Figure 3.4. Nuclear family with unknown maternal genotype. The maternal genotype 
must be either 1/3 or 2/3, which depends on the population genotype frequencies 
assumed for the maker frequencies in the analysis.  
 
To calculate the NPL, a maximum Likelihood score (MLS) could be calculated and is 
defined as follows: 
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Where Z0, Z1 Z2 represent the maximum likelihood estimates of the posterior 
probability of zero alleles IBD, one allele IBD, and two alleles IBD over the 
likelihood of the prior probability (Cordell, 2004). 
3.3.2 The Affected Pedigree Member Method 
The Affected Pedigree Member (APM) method considers all affected family members 
in nuclear and extended pedigrees. Whittemore and Halpern (1994) introduced two 
non-parametric linkage statistics, NPLpairs and NPLall that are commonly used in 
extended pedigrees. The tests are based on the posterior probability of IBD allele 
sharing (based on the genotype data given the family relationship) compared with the 
expected prior probability of IBD sharing (based on the individuals relationship only). 
Observed IBD allele configurations for affected family members are assigned scores 
on the basis of family relationships and frequency of the marker alleles in the 
population. The scores for all IBD configurations possible in the pedigree are summed 
and a normalised score is calculated under the assumption of no linkage. The NPL test  
for pedigree i could be defined as  
 
Where S is the sum of IBD configuration scores, µi and !i are the mean and standard 
deviation of all possible IBD configurations calculated on the basis of family 
relationships regardless of whether they are compatible with the observed genotypes. 
NPLpairs tests compute IBD scores for pairs of affected family members, while NPLall 
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tests compute scores for arbitrary groups of affected family members. The NPLall test 
is complicated given that the number of possible IBD configurations grows rapidly 
with number of individuals considered. For example, three IBD configurations are 
possible in two individuals, sixteen in three individuals, and 624,889 in seven 
individuals (Whittemore and Halpern, 1994).  
3.3.3 Are Non-parametric Linkage Approaches Truly ‘Model Free’? 
NPL methods that depend on the specification of marker allele frequencies to calculate 
the probabilities of IBD sharing among family members, such as NPLpairs and NPLall 
are not entirely ‘model free.’ They are only model free in the sense that they do not 
rely explicitly on disease model parameter specifications, i.e. estimations of 
penetrance, phenocopy rate, and mode of disease transmission are not required for the 
analysis. However, they have implicit model assumptions inherent in the scoring 
functions and weighting parameters employed by the NPL test statistic used (Kong 
and Cox, 1997; Farrall, 1997; Kruglyak, 1997) and rely as discussed on the population 
marker allele frequencies specified in the analyses.  
NPLpairs and NPLall have been the topic of debate in terms of the power they 
possess to detect linkage in single-locus, multi-locus, nuclear and multigenerational 
families. The consensus, based on multiple simulations comparing different ways of 
scoring allele sharing between affected relatives, holds that NPLall tests tend to 
perform better and therefore detect linkage when the underlying mode of disease 
transmission is dominant (Kruglyak, 1997), while NPLpairs tests tend to perform 
better, and therefore detect linkage, when the underlying mode of disease 
transmission is recessive. The jury is still out with regard to diseases with additive 
genetic inheritance, as some statistical geneticists attribute better power to detect 
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linkage when the underlying genetic model is additive to NPLall test statistics, while 
other attribute it to NPLpairs (Whittemore and Halpern, 1994). Of note is that all of the 
assumptions made regarding the power of different NPL tests, depend to a large 
extend on the size of the simulated data, the type of family under study (nuclear vs. 
multigenerational) and the density of the genetic map used and are therefore not 
necessarily applicable to all datasets.  
3.3.4 Affected Only NPL Designs 
NPL statistics are usually conducted using genotypes from affected family members 
only. The rationale behind this is that affected family members contribute most of the 
linkage information and elimination of unaffected family members does not usually 
cause a severe loss of power. Moreover, in more complex diseases individuals 
classified as unaffected may eventually develop the disease at a later stage making the 
designation of a family member as ‘unaffected’ more uncertain than the designation of 
a family member as ‘affected.’ Therefore looking only at the phenotype of affected 
individuals avoids mistakenly assigning a low risk genotype to individuals in whom 
the mutation in not yet penetrant (McPeek, 1999). Even though NPL tests score 
affecteds only, genotype information from unaffected family members, particularly 
siblings, is used to infer missing parental genotypes, thus making inferences about 
IBD sharing more precise.  
 
3.4 Whole Genome Linkage Significance  
A LOD score of 3.0 (p-value=0.0001) is conventionally used to indicate significant 
linkage and denotes the likelihood of the observed pedigree data (including 
information on pedigree structure, phenotypes, and marker genotypes) is 1000 times 
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higher under linkage than under independent assortment, and a LOD score of -2 is 
used to indicate significant evidence against linkage (Morton, 1955). This convention 
was challenged by Lander and Kruglyak (1995) who contended to keep the chance of 
encountering a false positive at no more than 5% or once in 20 genome scans, one 
must impose a more stringent LOD score of 3.3 (p-value = 4.9 x 10-5) for whole-
genome linkage and a LOD score of 1.86 (p-value=1.7 x 10-3) as suggestive of 
linkage. The stringency of the proposed significance levels are the source of constant 
debate in the literature since they are based on the assumption of a dense marker map 
with no missing data.  
3.5 Linkage Studies of Large Multi-Generational Families  
When the genetic component of a disease is caused by multiple distinct genes/loci 
with major effect, the power to detect linkage is reduced due to locus heterogeneity. 
Studying large multigenerational families has been proposed as a means of reducing 
heterogeneity, as they are more genetically homogeneous and probably segregate 
fewer disease-causing genes/loci than a collection of independent nuclear families. 
The caveat is, however, that in common diseases, extended families may feature intra-
familial heterogeneity, proportional to the size of the pedigree, caused by genes 
introduced by marrying in-spouses. In this case, the loss of power to detect linkage 
due to heterogeneity is compensated by the increase in genetic information available 
for analysis and heterogeneity must be accounted for in appropriate test statistics. 
Dividing a pedigree into its nuclear constituents would be beneficial in this situation. 
Locus heterogeneity could also be attributed to loosely defined disease phenotypes or 
the use of multiple subtypes of a disease that might themselves be diseases with 
distinct causes, each with a distinct genetic component. Because large families usually 
segregate more severe and clinically similar forms of a disease, they are considered 
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ideal candidates for linkage studies (as well as isolated populations). In addition, 
penetrance may be more appropriately defined in a large pedigree where information 
on anticipation, imprinting, and other factors are likely to be more available 
(Blackwood & Muir, 2001) and because the probability that a major disease gene is 
segregating in a large family is increased, affected individuals have a lower probability 
of being phenocopies compared to affected individuals in the general population 
(McInnes et al., 1996). Large families are also more environmentally homogenous, 
and offer more genetic information that enables estimation of gametic phase for un-
genotyped family members.  
On the flip side, large families are extremely difficult and expensive to collect 
and come with analytic difficulties inherit in their size and complicated structures. 
Enormous computational difficulties are reported by most large family linkage studies 
that resort to breaking large pedigrees into smaller, more “manageable” units for 
analysis.  
 
3.6 Genetic Markers in Linkage Studies 
In order to be useful for mapping disease genes, marker loci must be highly 
polymorphic so their segregation in families can be tracked accurately. When a parent 
passes a locus to an offspring determining whether it is recombinant or non-
recombinant depends to a large extent on whether the parent is a double heterozygote, 
i.e. heterozygous at each of the two loci under study. Similarly, distinguishing IBD 
from IBS allele sharing between siblings or affected family members is more easily 
and accurately accomplished when the investigated markers are highly polymorphic. 
For these reasons microsatellite markers were used in linkage studies for more than 
two decades. The high polymorphism rates of these loci and low cost PCR procedures 
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made them attractive. However, more recently, SNPs gained popularity as genetic 
markers in linkage studies (Figure 3.5).  
 
Figure 3.5. Microsatellites are multiallelic markers comprised of short, repeating 
sequences of DNA. The repeat motif is typically two to four base pairs long. The alleles 
of a microsatellite markers differ from each other in the number of repeat units. A 
tetranucleotide is shown in the graph with 2, 3, and 4 repeats. SNPs are biallelic and 
comprise changes in a single base pair. Mapping disease genes using microsatellites lost 
favour to SNPs only due to the ability to genotype SNPs at large volumes.  
 
Although biallelic and therefore less polymorphic than microsatellite markers, the 
high abundance of SNPs, occurring every 100 to 300 base pairs along the 3-billion-
base human genome, coupled with the advent of highly automated, cost effective 
genotyping platforms, meant that their low informativeness could be offset by the 
ability to genotype them in large numbers. It is reported that a marker density of one 
SNP every 4.5 cM, which requires approximately 700 to 900 polymorphic SNP 
markers for whole genome coverage, has the same information content as 
approximately one microsatellite every 10 cM, which requires between 300 and 400 
microsatellite markers for whole genome coverage. This substitution is, however, 
only workable if the minor allele frequency of the SNPs used is 20% or above 
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(Kruglyak, 1997). Studies comparing the performance of SNP arrays to 
microsatellites have shown that current SNP genotyping arrays (e.g. Affymetrix 10K 
array) offer higher genomic coverage, have greater information content (due to large 
numbers), and produce lower genotyping errors than microsatellite markers. Several 
studies that have re-analysed existing microsatellite linkage scans with denser maps of 
SNPs have found either suggestive or significant linkage missed by the initial scans 
(John et al., 2004; Middleton et al., 2004). The variability in linkage data due to use of 
microsatellites versus SNP markers is a contributor to the inconsistency of linkage 
findings due to differences between the two genetic maps.  
An issue arising from SNP maps concerns LD, as dense SNP maps are more 
likely to contain markers with strong LD than microsatellite maps. Given that linkage 
is conducted under the assumption of linkage equilibrium, LD could potentially be 
problematic in multipoint linkage analyses as unaccounted for LD may increase false 
positive rates especially when parental genotypes are missing (Scott, Schmidt, 
Ashley-Koch, & Schmidt, 2005) as haplotype frequencies can be incorrectly inferred. 
LD could be accounted for by correcting LOD scores for inflation due to tight LD 
between SNPs or alternatively SNPs with high LD could be treated as one single 




Chapter 4 Materials and Methods 
4.1 Sample Collection 
Following the diagnostic interviews, interviewers obtained 30ml of whole blood that 
was collected in 4 X 7.5 ml (EDTA containing) monovettes. The blood samples were 
labelled, gently mixed, and stored frozen upright in a -20°C freezer pending 
extraction. Interviewers collected saliva derived DNA from twelve family members 
who refused to give blood using the Oragene saliva collection system and extraction 
kits (DNA Genotek Inc., Ontario, Canada). This is a robust non-invasive method of 
DNA collection that preserves the DNA for several months prior to extraction with no 
significant loss of yield. All bar five participants provided a blood or saliva sample 
following the interview, and twenty-five participants, seventeen of whom were under 
the age appropriate for interview (younger than 5 years old) provided a blood or 
saliva sample without completing an interview. Sufficient information was attained 
from first-degree relatives regarding the psychiatric history of family members who 
were not interviewed but provided blood or saliva samples (were taken to be 
unaffected by the interviewers but were assigned “unknown” status in the analyses). 
Overall there were three hundred and twenty four samples available for DNA 
extraction.  
 
4.2 DNA Extraction  
Genomic DNA was isolated from whole blood and saliva usually within two days of 
sampling by laboratory technicians at the Federal University of São Paolo using 
standard procedures. DNA samples were sent to King’s College London on dry ice 
via express international mail for genotyping.  
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4.3 Affymetrix GeneChip!  Mapping 10K Array2.0 
Genotyping was conducted using the Affymetrix 10K microarray, which works on the 
principle of allele-specific hybridisation between DNA samples and 25-mer 
oligonucleotide probes. Each SNP is interrogated in both the sense and anti-sense 
strands with 40 different 25-mer oligonucleotides represented in five probe quartets 
that are tiled onto the microarray. Each probe quartet includes a perfect match for 
allele A (PMA), a perfect match for allele B (PMB), a one base pair (bp) mismatch for 
allele A (MMA) and a one base pair mismatch for allele B (MMB) (Wang et al. 1998) 
(Figure 4.1).  
 
 
Figure 4.1. Scanned hybridisation signal intensities for a single SNP on the microarray. 
Three individuals are shown, one for each genotypic group (AA, AB and BB). Forty 
unique probes, twenty on the sense strand and twenty on the anti-sense strand represent 
each SNP on the microarray, and each probe is present in millions of copies. A 
hybridisation signal in only visible for the perfect match probes to allele A (PMA) for the 
AA homozygote, and for the perfect match probe to allele B (PBMB) for the BB 
homozygote. Figure from Affymetrix 10K mapping manual. 
 
In this manner, the 10K SNP microarray allows the simultaneous interrogation of 
11,555 SNPs distributed throughout the genome, with a mean inter-SNP distance of 
210 kilobases (Kb) and average SNP heterozygosity of 0.37 (Kennedy et al., 2003). 
The SNPs on the 10K microarray were not selected on the basis of putative 
functionality or as informative ‘tagging’ SNPs. Rather computer predicted fragment 
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lengths based on Xba I enzyme restriction sites upstream and downstream of SNPs 
were used to select SNPs from the SNP Consortium repository in January and 
September 2001. This procedure identified 55,605 SNPs from which a subset of 
11,555 was identified using selection criteria designed to ensure accuracy and 
reproducibility of the microarray assay (Holden, 2002).  
4.3.1 The GeneChip® Mapping 10K 2.0 Assay Protocol  
The BBF samples were processed according to the GeneChip® Mapping 10K 2.0 
Assay Protocol, which was preformed over four days and followed eleven stages; 
DNA preparation, restriction enzyme digestion, ligation, PCR, purification and 
elution, quantification, fragmentation, labelling, hybridisation, washing staining and 
scanning, and finally data retrieval and genotype calling (Figure 4.2).  
 
Figure 4.2 Overview of the GeneChip® Mapping 10K Assay protocol. Figure from 
(http://www.affymetrix .com) 
 
Three hundred and twenty-four BBF samples were genotyped using this protocol. 
With every batch of samples genotyped, a reference DNA sample provided by 
Affymetrix was processed as a positive control to test the accuracy with which the 
protocol was completed and a sample of molecular biology grade water was 
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processed as a negative control in all the steps leading to labelling and hybridisation 
to assess the presence of contamination in the reactions. Three batches of 92 BBF 
samples were processed in this manner after initially processing three batches of 22 
samples at a time. Some samples were run in duplicates (n=18). In our laboratory, we 
have 2 Affymetrix® GeneChip® Fluidics Stations (each containing 4 modules) which 
meant that a maximum of 8 microarrays could be washed and stained at a time. 
Therefore, three rounds of washing and staining were completed in one day after 
which the microarray were scanned together. The steps of the protocol are presented 
next. 
Step 1: Genomic DNA Preparation 
BBF DNA samples were quantified using a NanoDrop fluorospectrometer, which 
measures the amount of ultraviolet (UV) light that is absorbed as it passes through an 
aqueous solution. Concentrations of the DNA solution can be estimated by comparing 
the proportion of light passing through a blank (I0) (water), relative to that which 
passes through the solution in question (I). From this two statistics are calculated, 
transmittance (T) and absorbance (A): 
T=I/I0 A= - Log10 T 
The absorbance statistic enables the concentration of DNA to be estimated when UV 
light is passed through at 260 nm; the wavelength absorbed by nucleic acid. To assess 
DNA purity, the intensity of absorbance of the DNA solution at 280nm; the 
wavelength absorbed by protein is estimated and the ratio 260:280 is used as a purity 
measure. A DNA sample with a 260:280 ratio of 1.8 is considered to be pure and free 
from protein contamination and a DNA sample that has a 260:280 ratio lower than 1.8 
is said to be contaminated with proteins. The majority of BBF samples (n=280) were 
free from contaminants, however, a subset of samples scored below 1.4 indicating 
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protein contamination, most probably heme. These samples were cleaned using a 
standard phenol-chloroform and proteinase K DNA purification procedure. 
Following, two rounds of phenol-chloroform and proteinase K cleanup only 24 
samples were usable. In total 304 samples were carried through to step 2 of the 
protocol.  
Step 2: Restriction Enzyme Digestion 
Genomic DNA (250ng at 50ng/µl) was digested with 10 units of the restriction 
enzyme Xba I in the following reaction; 10.5µl H2O, 2µl 10X NE buffer, 2µl BSA at 
1mg/ml, 0.5 XbaI at 20U/µl, for 2 hours at 37°C in the thermal cycler, followed by 
enzyme inactivation for 20 minutes at 70°C. This step of genomic fractionation is 
necessary to reduce the chances of cross-hybridisation and therefore non-specific 
allele signaling in subsequent steps. 
Step 3: Ligation 
The digested DNA fragments were ligated to Xba adaptors (Affymetrix, Santa Clara, 
CA) that recognise the cohesive four base pair (bp) overhangs, using T4 DNA Ligase 
in the following reaction; 1.25ul Adapter Xba I at 5uM, 2.5ul X10 T4 DNA Ligase 
buffer, 1.25ul T4 DNA Ligase at 400,000U/ml and 20ul digested DNA, for 2 hours at 
16°C in the thermal cycler, followed by an enzyme inactivation step for 20 minutes at 
70°C. All DNA fragments resulting from restriction enzyme digestion, regardless of 
size, are substrates for adaptor ligation. Ligated DNA was diluted 4X with water 
(25µl Ligated DNA and 75µl of water).  
Step 4: Polymerase Chain Reaction (PCR) 
A generic primer provided by Affymetrix that recognises the Xba I adapter sequence 
was used to amplify the adapter-ligated DNA fragments in a PCR reaction. Fragments 
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in the size rage 250-1000 bp are preferentially amplified; this narrow size range of 
amplicons reduces the complexity of the genome and allows allele-specific 
hybridisation of the samples to the probes on the microarray.  
In this step, 90µl of PCR master mix containing 10µl PCR buffer, 10µl dNTPs 
(2.5mM each), 10µl MgCL2 (25mM), 7.5µl PCR Primer Xba (10µM), 7.5µl 
AmpliTaq Gold (5U/µl) and 50.5µl H2O,was mixed with 10µl of DNA. Each sample 
was amplified independently in four separate reactions to produce sufficient product 
for hybridisation to one microarray. The PCR reaction entailed cycling three steps: 
denaturation, primer annealing, and DNA synthesis, under the following conditions: 
 
Temperature Time Cycles 









72oC 5 minutes 1 
 
Following the completion of the PCR, 3µl of each PCR product, mixed with 3µl of 
Gel loading dye, were run on 2% Agarose gel (prepared by adding 10g Agarose to 
500mL TBE heated in the microwave until the Agarose was completely dissolved and 
the solution was clear and mixed with12µl of Ethidium Bromide) at 120 Volts for 1 
hour to check that sufficient amplification of each sample in the correct size range had 
occurred. The samples were stored at -20 until the next day.  
Step 5: PCR Purification and Elution with QIAGEN MinElute 96 UF PCR 
Purification Plate  
 
The PCR products were purified to remove excess primers, unincorporated dNTPS. 
The four PCR reactions for each sample were pooled into one well of the MinElute 
plate (QIAGENInc., Hilden, Germany) (total 400µl amplified DNA product per well) 
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and dried down using a vacuum, which was maintained at approximately 800 mbar 
for five hours. Once the wells were dry, the PCR products were washed by adding 
50µl of molecular biology grade water, and dried completely using the vacuum for 
approximately two hours. This step was repeated twice for a total of three water 
washes, after which the MinElute plate was removed from the vacuum and tapped on 
a stack of absorbent paper to remove any liquid remaining on the bottom of the plate. 
The resulting DNA products were reconstituted in 40µl of EB buffer and shaken on a 
plate shaker at 1000 rpm for 5 minutes. Purifying the PCR products took 
approximately 7 hours to complete as opposed to the expected 1 hour 50 minutes 
suggested by Affymetrix. I suspect that was the case because a suboptimum vacuum 
was used to complete this step. The samples were stored at -20 for completion of the 
protocol the next day. 
Step 6: Quantification of Purified PCR Product 
A UV spectrophotometer was used to quantify the purified PCR products. A forty-
fold dilution (4µl purified PCR product diluted in 156µl of molecular grade water) 
was prepared in an optical plate and read at an absorbance of 260nm. The PCR 
products were quantified in triplicate and a water blank was included as a measure of 
accuracy. The purified PCR products were normalised to concentrations of 20µg per 
45µl solution by adding more EB buffer and then transferred to a new plate in 
preparation for fragmentation. In cases where there were less than 45µl of DNA 
available, EB buffer was added to a final volume of 45µl, irrespective of 
concentration.  
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Step 7: Fragmentation 
To allow sufficient hybridisation of the DNA molecules to the microarray probes, the 
purified PCR products were fragmented to approximately 50bp to 100bp using 
Deoxyribonuclease I (Affymetrix), an endonuclease, which was diluted and added to 
45µl of purified PCR product and 5µl of fragmentation buffer (Affymetrix). The 
samples were fragmented in a pre-heated thermal cycler at 37°C for 30 minutes, 
followed by 95°C for 15 minutes. Following the completion of the program, 4µl of 
each fragmented PCR product mixed with 4µl gel loading dye, was run on a 4% pre-
cast gel at 120 Volts for one hour to ensure fragmentation occurred successfully. The 
size of fragments was on average less than 180 bp (Figure 4.3).  
 
Figure 4.3. A typical example of fragmented PCR products from the BBF run on 4% gel 
at 120 Volts for one hour. The average fragment size is less than 180 bp.  
Step 8: Labelling 
The fragmented DNA products were end-labelled with biotin using Terminal 
Deoxynucleotide Transferase (TdT, Affymetrix) to allow attachment of florescent 
molecules during the staining procedures that follow. The biotin was prepared in a 
master mix containing 14µl TdT buffer (5X), 2µl GeneChip! labelling reagent at 
(5mM) and 3.4µl TdT. Aliquots of 19.4µl master mix were added to 50.6µl of 
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fragmented DNA and the reaction was heated at 37°C for 2 hours, followed by 95°C 
for 15 minutes.  
Step 9: Target Hybridisation 
The microarrays were taken out of the cold room where it was stored at 4°C, and left 
on the bench for approximately 30 minute to equilibrate to room temperature. This 
was done to prevent the microarray rubber septa from cracking, a major cause of 
unwanted leaking during hybridisation. Biotin labelled DNA was added to 190µl 
hybridisation mix containing 12µl 12X MES stock, 13µl DMSO, 3µl X50 Denhardt’s 
solution, 3µl EDTA (0.5M), 3µl Herring Sperm DNA (10mg/ml), 2µl X1 
oligonucleotide control reagent, 3µl Human Cot-1 (1 mg/ml), 1µlTween-20 (3%), and 
140µl Tetramethyl Ammonium Chloride (5M). This mixture was heated at 95°C for 
10 minutes to denature, cooled quickly on ice, and then briefly spun. It was then 
placed in a hybridisation oven at 48°C for 2 minutes before being injected into the 
microarrays and hybridised overnight for 18 hours at 48°C. Loading the microarray 
was done by inserting a pipette tip into the upper septum of the microarray and 
injecting the hybridised DNA into the bottom septum of the microarray. We injected 
120µl of the hybridisation mix into the microarray, more than the 80µl recommended 
by Affymetrix, to prevent the formation of bubbles that interfere with the 
hybridisation process. The microarray septa were then sealed with tough-spots (Figure 
4.4). 
 




Step 10 Washing, Staining and Scanning Arrays 
Following 18 hours of hybridisation, the hybridisation mix was extracted from the 
microarray using a pipette. A stringent wash protocol was then performed to remove 
any remaining non-hybridised DNA fragments from the microarray that would 
otherwise cause background noise during scanning. The microarrays were washed and 
stained in a three-stage process consisting of two washes using a non-stringent wash 
A (6X SSPE, 0.01% Tween 20) and a stringent wash B (0.6X SSPE and 0.01% 
Tween-20), a streptavidin phycoerythin (SAPE) stain containing 450µl stain buffer 
(6X SSPE, 0.01% Tween-20, 1X Denhardt’s solution) and 5µl SAPE(1mg/ml),an 
antibody stain with biotinylated antibody containing 450µl stain buffer(6X SSPE, 
0.01% Tween-20, 1X Denhardt’s solution)and 5µl biotinylated antibody (0.5mg/ml) 
followed by a final stain with SAPE.  
Using Fluidics station_450 and Affymetrix GeneChip® Operating Software the arrays 
were washed and stained using the following protocol:  
Post hybridization wash 1: 6 cycles of 5 mixes/cycle with wash buffer A at 25oC 
Post hybridization wash2: 6 cycles of 5 mixes/cycle with wash buffer B at 45oC 
Stain 1: Stain the array for 10 minutes in SAPE solution at 25oC 
Post stain wash: 6 cycles of 5 mixes/cycle with wash buffer A at 25oC 
Stain 2: Stain the array for 10 minutes in antibody stain solution at 25oC 
Stain 3: Stain the array for 10 minutes in SAPE solution at 25oC 
Final Wash: 10 cycles of 6 mixes/cycle with wash buffer A at 30oC.  
Following the completion of the wash and stain cycles, the microarrays were filled 
with a 1X array holding buffer containing 8.3ml MES buffer (12X), 18.5ml NaCL 
(5M), 0.1ml Tween-20 and 73.1ml water) in preparation for the scanner. Any excess 
fluid was cleaned from around the septa, and tough spots were reapplied to each 
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septum. The arrays were placed in the GeneChip® Scanner 3000 7G and the GCOS 
software was used to the scan the arrays.  
Step 11: Data Generation and Genotype Calling 
The scanner automatically generated .CEL files, containing raw allele intensity 
scores, which were processed by the GeneChip® DNA Analysis Software (GDAS) to 
derive SNP genotypes. A Modified Partitioning Around Medoids (MPAM) mapping 
algorithm that assigns SNP genotypes on the basis of relative allele signal (RAS) 
intensities is used by the software (Liu et al., 2003). The SNP allele signals are scored 
relative to a centre point (medioid) given to each AA, AB, and BB genotype. The 
mediods are based on samples from multiple individuals from diverse populations and 
reflect the allele frequencies of the SNPs (Affymetrix manual).  To calculate the RAS 
score for each probe quartet, the average mismatch (MMAve) from the expected 
mediod intensity is first calculated using: 
MMAve = (MMA + MMB)/2 
Where MMA refers to the mismatch intensity value for allele A and MMB refers to 
allele B. MMAve is then subtracted from the perfect match intensity for allele A 
(PMA) and the perfect match intensity for allele B (PMB) to correct for background  
noise due to non-specific hybridisation, as follows: 
A = max (PMA – MMAve)  
B = max (PMB - MMAve) 
Finally the RAS score is calculated using 
RASquartet = A/A+B 
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These calculations are repeated for the sense and antisense strands for each quartet 
and a median RAS score for the sense strand (RAS1), a median RAS for the antisense 
strand (RAS2) is derived. RAS1 and RAS2 are plotted for each SNP using MPAM. If 
(RAS1,RAS2) cluster near (0,0) genotype BB is called, if they cluster near (1,1) 
genotype AA is called, and if they cluster near (0.5,0.5) genotype AB is called.  RAS 




Figure 4.5. A graphical representation of three SNPs. The blue ellipse represents the 
area of BB genotypes near (0,0), the green ellipse represents the area of AB genotypes 
near (0.5,0.5) and the purple ellipse represent the area of AA genotypes near (1,1). SNP 
with relative allele scores falling within those areas are assigned the appropriate 
genotypes. SNPs with relative allele scores falling outside those areas, represented here 
in red, are not assigned a genotype call. Each SNP has a different area for AA, AB, and 
BB genotypes reflective of different population allele frequencies. Figure adapted from 
(Huentelman et al., 2005). 
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4.4 Quality Control (QC) 
The quality of genotype data is a major source of bias and loss of power in linkage 
and association studies making stringent quality control (QC) an essential step prior to 
any analysis of genetic variation. It is standard in family based studies to conduct per-
individual QC and per-SNP QC, in that order, as well as Mendelian and non-
Mendelian error checks.   
4.4.1 Genotyping Quality Control 
A considerable number of genotyping errors occur in most large genotype datasets. 
This mistyping could be due to human oversight, to shortcomings in genotype scoring 
software, or simply to errors in the biochemical assays. Several authors have shown 
that genotyping errors mask linkage signals and distort the accuracy of the marker 
map by giving an inaccurate estimate of the disease location on the marker map. In 
two-point linkage analysis genotyping errors usually lead to inflated estimates of 
recombination fractions, whereas in multipoint linkage analysis they result in the false 
exclusion of true linkage to disease (Göring & Terwilliger, 2000). Even a small (1% 
to 2%) error rate can have an enormous impact on linkage results (Abecasis, Cherny, 
& Cardon, 2001; Buetow, 1991; Sobel, Papp, & Lange, 2002). It is therefore essential 
to obtain a data set as free of genotyping errors as possible before proceeding to 
linkage analysis.   
4.4.1.1 Per Individual Quality Control 
Data quality control was commenced by excluding individuals with more than 10% 
missing genotype rate. The lowest call rates (n=12) were obtained from individuals in 
Branches 2 and 3 of the family, where the quality of the DNA was not optimal and 
! "# 
several DNA cleaning steps were performed (section 4.3.1). These samples were 
collected and batch processed, so it is suspected that handling (repeat freeze thawing) 
as well as variation in laboratory techniques may have lead to impediments to optimal 
assay performance. In addition, in the first wave of ascertainment, when Branch 1 of 
the BBF was collected, psychiatrists visited Senhora de Oliveira or nearby cities for a 
maximum of two days before returning to São Paulo and processing the DNA samples 
with laboratory technicians. However, in the second wave of ascertainment, when 
Branches 2 and 3 were collected psychiatrists spent more days in the village and thus 
delayed processing the DNA samples by up to a week.  
After the exclusion of low quality individual data, the mean call rate in the 
BBF samples was 93%. Discussion with Affymetrix customer support revealed that 
this array has a lower average call rate than the Affymetrix 500k and 1M arrays, being 
one of the earlier designed arrays in the Affymetrix product range.  
Gender misspecification was then addressed by looking at the homozygosity 
of X-linked SNPs using PLINK v1.07 (Purcell et al., 2007) sex check, which 
calculates an inbreeding coefficient estimate (F Co-efficient), based on the observed 
versus expected number of homozygous X-chromosome SNPs. This highlights 
individuals for whom reported sex in the pedigree file does not match X-chromosome 
estimated sex. This test is conducted mainly to identify sample mix-ups and errors in 
pedigree data entry. Because males only have one copy of the X-chromosome they 
cannot be heterozygous for any marker outside the pseudo-autosomal region of the Y-
chromosome. As a result, one expects male samples to have a homozygosity rate of 1 
(PLINK makes a male call if F co-efficient is greater than 0.8 to account for 
genotyping error) and female samples to have a homozygosity rate of less than 0.2. 
Male samples that are mistakenly marked as female in the pedigree file will have a 
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higher than expected homozygosity rate and female samples marked as male will 
have a lower than expected heterozygosity rate (Anderson et al., 2010) (Table 4.1).  
ID Assigned Sex Genotyped Sex Status F Co-efficient 
54 2 2 Ok 0.11 
1 1 1 Ok 1 
682 2 1 Problem 1 
34 2 0 Ambiguous 0.27 
37 2 0 Ambiguous 0.34 
39 2 0 Ambiguous 0.27 
97 2 0 Ambiguous 0.55 
98 2 0 Ambiguous 0.35 
185 2 0 Ambiguous 0.48 
 
Table 4.1. PLINK sex check used as a quality control step mainly to identify sample mix. 
The F Co-efficient for individuals with the correct sex, problematic sex and ambiguous 
sex are presented. Males are expected to have an F Co-efficient greater than 0.8 and 
females are expected to have an F Co-efficient less than 0.2.   
 
Sample 682 had discordant sex information and was removed from the data set and 
further investigation revealed it must have been mislabelled as no record of it existed. 
There were a number of ambiguous sex estimations, which belonged to females from 
consanguineous marriages. These samples were not removed from the dataset as 
comparison with their autosome inbreeding statistics revealed these females to be of 
high inbreeding/homozygosity, thus artificially inflating the X chromosome F 
statistic. After per individual quality control a total of 309 family members were left 
in the pedigree dataset. 
4.4.1.2 Per SNP Quality Control 
Following per-individual quality control, we commenced per-SNP quality control by 
excluding SNPs with more than 10% missing genotype rate (n=1133) using PLINK. 
We then identified SNPs with a minor allele frequency less than 25% in unaffected 
BBF founders (n=54), i.e. unrelated individuals who marry into the family or families 
under study, and excluded them from BBF pedigree dataset. This was done to 
increase the heterozygosity of the data and therefore information content.  
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4.4.1.2.1 Hardy Weinberg Equilibrium 
In performing genetic studies it is normally assumed that unaffected individuals (or in 
the case of a population study the sample as a whole) are in Hardy-Weinberg 
Equilibrium (HWE). HWE states that under conditions of random mating, absence of 
migration, mutation, and selection at the gene in question, a biallelic marker with 
alleles A and a should have a stable frequency distribution of genotypes AA, Aa, and 
aa in the proportions p2,2pq, and q2 respectively where p is the frequency of allele A 
and q is the frequency of allele a. HWE may therefore be calculated for a biallelic 
marker using the following equation: 
 
The most common cause of significant deviations from HWE is genotyping errors in 
the laboratory or due to genotype calling algorithms that consistently mis-score 
certain heterozygotes as homozygotes or fail to score a specific allele. Testing for 
HWE is therefore part of quality control procedures in gene mapping studies and is 
typically performed using a standard chi-square test that compares the expected allele 
frequencies with those observed in the data (significant p-values would indicate 
deviation from HWE).  
HWE is only expected to occur in randomly mating populations as both 
inbreeding and assortative mating cause increases in homozygosity (in all genes and 
genes involved in the trait that is assortatively mated respectively) and therefore 
deviations from HWE. As both inbreeding and assortative mating are evident in the 
BBF only unaffected BBF founders were used to delineate SNPs that deviated from 
HWE, which were subsequently removed from the entire pedigree data. Both of these 
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procedures were conducted using PLINK. After per SNP quality control 5315 SNPs 
were available for analysis.  
Following the conclusion of standard per-individual and per-SNP QC checks 
for pedigree structure, Mendelian and non-Mendelian errors were conducted.  
4.4.2 Pedigree Structure Errors 
Pedigree structure errors occur due to a number of factors including unreported 
adoptions, non-paternity, errors in entry of pedigree information, and sample mix-ups. 
We used PLINK pair-wise Identical-By-Decent (IBD) estimation across all SNPs to 
detect misspecified family relationships. The expectation is that IBD = 1 is for 
duplicates or monozygotic twins, IBD = 0.50 for first-degree relatives, i.e. parents, 
children, siblings, IBD=0.25 for second-degree relatives, i.e. half-siblings, 
grandparents, uncles/aunts, cousins, and IBD=0.125 for third-degree relatives, i.e. 
second cousins, great uncles/aunts. Evaluation of pair-wise IBD estimates between 
BBF members revealed a number of misspecified family relationships, which were 
dealt with on an individual basis.  
 
 
Figure 4.6. Subfamily 3 with relationship misspecifications in the section highlighted in 
red, as determined by IBD estimates.   
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In subfamily 3 (Figure 4.6), non-paternity was established for individual 183 based on 
estimated allele sharing of zero between her and her alleged father (Table 4.2). As she 
had half siblings, a dummy paternal ID (1000) was created and her data was included 
in all subsequent analyses.   
 
ID 1 ID2 Relationship Pair-wise IBD Conclusion 
183 179 Father Zero Non-paternity 
183 180 Mother 0.5 Mother 
183 181 Sibling 0.28 Half-sibling 
183 182 Sibling 0.22 Half-sibling 
183 184 Sibling 0.23 Half-sibling 
 
Table 4.2. IBD estimates for a section of subfamily 3 showing family relationship 
misspecification  
 
Figure 4.7. Subfamily 2 with relationship misspecifications in the section highlighted in 
red, as determined by IBD estimates.   
 
A similar picture emerged from subfamily 2, where the section of the family, 
highlighted in red in Figure 4.7 was removed from the pedigree data due to non-
paternity. As the father in question was deceased, we evaluated the relationship of his 
daughter 159 with supposed uncles (Table 4.3), and found that the genetic data 
indicated no relationship to her. In fact individual 159 had no genetic relationship to 
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any BBF member. As a result, individuals 158, 159, 160, and 161, were removed 
from the data set.  
ID 1 ID2 Relationship Pair-wise IBD Conclusion 
159 158 Mother 0.5 Mother 
159 161 Son 0.5 Son 
159 43,38, 42,48,49,51 Uncles 0 No relationship 
 
Table 4.3. IBD estimates for a section of subfamily 2 showing family relationship 
misspecification determined by IBD estimates.  
 
 
Figure 4.8. Subfamily 17 with relationship misspecifications in the section highlighted in 
red, as determined by IBD estimates. Individuals 633 and 624 had low genotyping rates.  
 
Contrary to the first two discrepancies in family relationships, family relationships in 
subfamily 17 (Figure 4.8) were more difficult to decipher and the whole subfamily 
was dropped from all subsequent analyses. The decision to do so was backed by 
inconclusive relationships between the children of 603, who in the diagnostic 







ID 1 ID2 Relationship Pair-wise IBD Conclusion 
608 614 Siblings 0.5 Siblings 
608 618 Siblings 0.14 Ambiguous 
608 619 Siblings 0.124 Ambiguous 
614 618 Sibling 0.15 Ambiguous 
614 619 Sibling 0.25 Ambiguous 
618 619 Sibling Zero Ambiguous 
633 Low Genotyping Rate 
640 Low Genotyping Rate 
 
Table 4.4. IBD estimates for a section of subfamily 17 showing family relationship 
misspecification  
 
4.4.3 Mendelian Inconsistent Error 
When dealing with family data an important part of the genotyping quality control is 
testing for Mendelian inconsistencies, or genotype patterns that do not follow 
Mendel’s law of inheritance, which states that every individual inherits one paternal 
allele and one maternal allele. Mendelian inconsistencies help identify genotyping 
errors or pedigree structure errors. After the correction of pedigree structure errors 
informed by PLINK pair-wise IBD estimates, the program PEDSTATS (Wigginton & 
Abecasis, 2005) was used to identify genotypes that did not conform to Mendelian 
inheritance in the pedigree, which were set to zero in the analyses.  
4.4.4 Non-Mendelian Errors 
Not all genotyping errors cause Mendelian inconsistencies. A non-Mendelian error is 
a genotyping error that is consistent with Mendelian inheritance. Simulation studies 
have shown the percentage of genotyping errors consistent with Mendelian 
inheritance could be up to approximately 40% for multiallelic markers and as high as 
87% for biallelic markers (Douglas, Skol, & Boehnke, 2002). As a result a check for 
Mendelian inconsistencies alone is unlikely to identify all problematic genotypes. 
Non-Mendelian errors are much harder to determine than Mendelian errors, however, 
they still have a profound effect on the validity of linkage analyses.  
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Non-Mendelian genotyping errors are detected when there is excessive number of 
recombination events occurring in a particular chromosomal location. Two or more 
close recombination events on the same chromosome are uncommon, due to 
interference, where the occurrence of a crossover event alters the probability of 
another crossover event occurring at a nearby location. This probability could be 
increased or decreased but the latter is more usual as studies have suggested the 
probability of double recombinants within a 20 centiMorgan (cM) interval in humans 
is only 2 in 1000 (Broman & Weber, 2000). Therefore, the occurrence of a double 
recombinant more likely reflects genotyping error in one of the markers used to infer 
the location of the recombination event. 
The error detection procedure in the program MERLIN (Abecasis, Cherny, 
Cookson, & Cardon, 2002) was used to search for non-Mendelian errors or unlikely 
recombinants in the dataset. MERLIN considers all pedigree data simultaneously, i.e. 
not only pairs of individuals, so its error detection procedure has improved accuracy 
in larger pedigrees. Unlikely genotypes were flagged and MERLIN “pedwipe” was 
used to set them to zero in the pedigree dataset. McLinkage (Thomas, Camp, 
Farnham, Allen!Brady, & Cannon!Albright, 2008) “CheckErrors” procedure was 
also used to calculate the posterior probability of genotype mistyping at each 
observed genotype in the data, which were incorporated into subsequent McLinkage 
analyses to account for genotyping errors.  
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4.5 Data Analysis and Statistical Methods 
4.5.1 Splitting the BBF Sub-families for Analysis 
Algorithms for exact LOD score calculations (e.g. Elston-Steward, Lander-Green) 
consider each inheritance configuration consistent with the available genotype data to 
calculate LOD scores. These algorithms are limited by the complexity and size of the 
pedigrees they could handle because the total number of underlying inheritance 
configurations becomes too large to compute. A solution is to split large pedigrees 
into computable subfamilies that meet the complexity constraints of exact linkage 
analyses. Linkage programs, such as MERLIN, GENEHUNTER (Daly et al., 1998), 
or Mendel (Lange et al., 2001) that use the Lander-Green exact LOD score algorithm 
require large pedigrees to be split into subfamilies of no larger than 30 bits, where a 
bit is defined as two times the number of individuals with parents presented in the 
pedigree minus the number of pedigree founders. As the computational complexity of 
the Lander-Green algorithm increases linearly with the number of markers, but 
exponentially with the bit-size of the pedigree, it can analyse a large number of 
markers if the pedigree bit size is small. While splitting large pedigrees apart can 
reduce inheritance information by removing transmission links among pedigree 
branches, it is the only way to perform exact multipoint analysis in large complex 
pedigrees such as the BBF.  
To accommodate the requirements of MERLIN, our linkage software of 
choice for exact LOD score calculations, the BBF was split into 19 appropriately 
sized (30 bits or less) subfamilies. When splitting the BBF important aspects of 
family relatedness, such as first cousin marriages and complex marriage loops were 
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preserved where possible and the number of duplicate individuals in the subfamilies 
was kept to a minimum (See Chapter 2 section 2.17). 
4.5.2 Pedigree Datasets 
Whole genome linkage analyses were separately conducted on two sets of data: 
Branch 1 and the BBF, which included Branches 1, 2, and 3. The decision to analyse 
Branch 1 separately and as part of the BBF was based on the fact that Branch 1 
appeared to be a distinct group that manifested a higher density of psychiatric 
disorders. Both clinically and genotypically Branch 1 seemed to be more 
homogeneous than the other two branches of the BBF. Branches 2 and 3 were more 
outbreed than Branch 1 and segregated milder forms of BPD and mood disorders in 
general. However, analysing the BBF, it was thought would offer more power to 
detect linkage, as more recombination would be available for the analyses.  
Following the completion of the described QC procedures, 309 individuals with 
5315 genotyped SNPs were available for the linkage analyses. Four clean pedigree 
files were generated in standard linkage format:  
1. Branch 1 subfamilies including 208 genotyped individuals and 61 un-
genotyped individuals split into 12 subfamilies (n=269).    
2. Branch 1, Branch 2, and Branch 3 subfamilies including 309 genotyped 
individuals and 91 un-genotyped individuals split into 19 subfamilies (n=400), 
referred to hereinafter as the BBF subfamilies.  
3. Branch 1 with structure in tact including 208 genotyped individuals and 34 un-
genotyped individuals (n=242) 
4. BBF with structure in tact including 309 genotyped individuals and 52 un-
genotyped individuals (n=361).  
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Parametric and non-parametric linkage analyses were performed on the four pedigree 
files using four phenotype models:  
1. Narrow - included family members diagnosed with BPI, BPII, or SAD. 
2. Broad – included family members in the narrow model plus those diagnosed 
with BP NOS and cyclothymia. 
3. Super - included family members in the broad model plus those diagnosed 
with one episode of major depressive disorder, recurrent episodes of major 
depressive disorder, and cyclothymia. 
4. Depression – included family members diagnosed with unipolar depression 
and cyclothymia only. 
Details of the parametric and nonparametric methods will be presented next.  
 
4.5.3 Linkage Information content 
Information content mapping measures the total inheritance information extracted by 
the map of markers used in a study. It is a function of marker heterozygosity and the 
number of detectible meioses (which allow identification of whether a gamete is 
recombinant or non-recombinant) in the pedigree(s) under study. For multipoint 
linkage analysis, information content is also a function of marker density and spacing 
(Kruglyak, 1997). The information content is essentially how much power you have 
to assess any evidence for linkage. High information content is essential for genome 
wide searches for disease susceptibility loci or other traits so that regions of no 
linkage can be excluded, regions of significant linkage can be detected, and the 
linkage interval can be accurately defined (Kruglyak, 1997). 
MERLIN was used to calculate the inheritance information captured by the 
SNP data set in Branch 1 and the BBF using an entropy based measure (Kruglayk, 
1996). According to this measure information content of one indicates the availability 
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of full information on the inheritance pattern in a pedigree(s), where as information 
content of zero indicates total uncertainty about the inheritance pattern.  
4.5.4 Parametric Linkage Analysis 
The LOD score is a standard statistic used for linkage analysis. It compares the 
likelihood of the data under linkage (! <0.5) with the likelihood of the data under no 
linkage (! =0.5)(see chapter 3 section 3.2). To analyse the data under the LOD score 
method an inheritance model for BPD representative of the population under study 
was specified, SNP marker allele frequencies were estimated and recombination 
fractions between SNP markers were adjusted as will be discussed in this section.   
4.5.4.1 The BPD Inheritance Model 
In parametric linkage analysis of complex diseases, such as BPD, where the mode of 
inheritance is unknown, it is common practice to analyse the data under multiple 
inheritance models, most typically dominant, recessive, or intermediate models with 
incomplete penetrance. Taking as a precedent the large family studies from the 
Central Valley of Costa Rica and Colombia (Herzberg et al., 2006; McInnes et al., 
1996; Service et al., 2006), the BBF data was analysed under a recessive and a 
dominant inheritance model with incomplete penetrance. We assumed 1% penetrance 
for zero copies of the disease allele (i.e. phenocopy rate), 81% penetrance for one 
copy of the disease allele, and 90% penetrance for two copies of the disease allele, 
thus giving a penetrance vector of (0.01, 0.81, 0.90) for the dominant model and 
(0.01, 0.01, 0.90) for the recessive model.   
To calculate the frequency of the disease allele, we used BPD population 
prevalence rates of 1.5%, 5%, and 20% for the narrow, broad, and super phenotype 
models respectively. These population prevalence rates are consistent with 
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epidemiological surveys from European populations (Kessler, Chiu, Demler, & 
Walters, 2005; Judd & Akiskal, 2003). To calculate the disease allele frequencies for 
the various phenotype models, we used the general two allele single major locus 
formula  
 
Where Kp is the population prevalence of the disorder, p is the frequency of the 
common “normal” allele, q is the frequency of the disease allele, p + q =1, and f1, f2, 
and f3 are the penetrances for zero, one, and two disease alleles. Under a dominant 
mode of transmission, the parameters we specified resulted in a disease allele 
frequency (q) of 0.003, 0.03, and 0.13 for the narrow, broad, and super phenotype 
models respectively. Under a recessive mode of transmission, the values of q were 
0.07, 0.03, and 0.46 for the narrow, broad, and super phenotype models respectively. 
4.5.4.2 The Depression Inheritance Model 
Analyses on a depression only model were performed. The following parameters 
corresponding to a population prevalence for depression of 5%, and penetrance 
estimates of 50% for one or two copies of the disease allele, we specified disease 
allele frequency of 0.005 and parameters (0.05, 0.50, 0.50) for a dominant disease 
model and disease allele frequency of 0.033 and parameters (0.05, 0.05, 0.5) for a 
recessive disease model. These disease models have been previously used for the 
analysis of depression in multiple nuclear pedigrees from the UK (McGuffin et al., 
2005).  
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4.5.4.3 The Marker Allele Frequencies 
Accurate marker allele frequency estimation is necessary for the elimination of both 
false-positive evidence for linkage and biases in recombination fraction estimates. 
This is of particular importance when the number of marker alleles is large (Freimer, 
Sandkuijl, & Blower, 1993). Erroneous estimations are particularly problematic when 
genotypes for unavailable family members, particularly founders, are reconstructed in 
a dataset: a very common step in most linkage analyses. When affected offspring 
share a particular marker allele, the assumption is they either inherited it from a 
common ancestor, so it is identical-by-descent, or inherit it from multiple ancestors, 
and it is identical-by-state. Only the true population frequency of the shared marker 
allele could portray the true inheritance. When the frequency of the marker allele is 
underestimated, the probability of identity-by-descent, under linkage, will be 
overestimated (Ott, 1999). To estimate marker allele frequencies for the BBF study, 
we had three options:  
1. To genotype a number of unrelated individuals from the population under 
study and to use their marker allele frequencies, an option that usually 
involves additional genotyping costs, and is therefore unsatisfactory.  
2. To use the genotypes from the whole family, which typically leads to 
inaccurate estimation of population marker allele frequencies given that the 
genotypes in a family are not independent from each other. 
3. To use the genotypes of BBF founders to estimate marker allele frequencies.  
 
We opted for the third option. For analyses conducted using MERLIN estimates were 
derived by the program by counting marker allele frequencies among the BBF 
founders only using the --ff flag. For analyses conducted using McLinkage, 
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GeneCountAlleles, a program available as part of the McLinkage package was used. 
It is based on the C A B Smith’s gene counting method, and works by iteratively 
inferring the genotypes of the founders in a pedigree given the current allele 
frequency estimates, the pedigree structure, and any genotypes observed in the 
pedigree and uses the posterior distribution of the founder allele frequencies to derive 
new maximum likelihood estimates for the marker alleles (Thomas & Camp, 2006).  
4.5.4.4 The Recombination Fractions between Markers 
The Affymetrix 10K annotation file contains the genetic positions, also known as cM 
positions of the 10K markers. These positions required adjustment for the following 
reasons. The genetic map measures the distance between genes for which one meiosis 
in 100 is recombinant. The basic assumption behind this measure is not entirely 
correct given that the probability of recombination is not uniform along the entire 
length of the chromosome. Recombination is inhibited in some regions, e.g. near the 
centromere, and increased in other regions, referred to as recombination ‘hot spots.’ 
In addition, positive interference, which we previously described, whereby the 
occurrence of a crossover reduces the likelihood of another crossover in its vicinity is 
a well documented phenomena that changes the proportion of crossovers in a 
chromosome (negative interference, whereby the occurrence of a crossover enhances 
the occurrence of other crossovers in the same region of the chromosome, e.g. double 
crossover, occurs with less likelihood than positive interference and also has an 
effect). Moreover, the number of chiasma in a bivalent segment, or two homologous 
chromosomes paired during the prophase of the first meiotic division, could interfere 
with the recombination frequency (Cavalli-Sforza, 2001). As such, the Kosambi 
mapping function which adjusts the genetic map distance based on interference, was 
used to re-calculate marker cM position, as follows: 
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M = 1/2 tanh (2r) 
Where r is the recombination fraction and M is the distance between markers in 
Morgans, which can be converted into cM by multiplying with 100. This step was 
conducted to ensure the use of a genetic map with relatively accurate inter-marker 
distances. 
The 10K microarray SNP annotation were based on build 18 of the human 
genome adjustments to SNP physical positions using build 19 of the human genome 
were made and SNPs that did not map to the newer build were removed.  
 
4.5.4.5 Analyses using MERLIN 
Multipoint linkage analysis was conducted on 18 subfamilies from the BBF and 12 
subfamilies from Branch 1 of the family under a recessive and dominant mode of 
disease transmission using the narrow, broad, super, and depression phenotype 
models. Heterogeneity LOD (HLOD) scores as well as LOD scores were calculated. 
As previously mentioned, linkage is affected by locus heterogeneity so the presence 
of more than one susceptibility locus in different families under study affects the 
power to detect linkage and HLOD scores allow for the detection of linkage even 
when a subset of the data shows no linkage between the disorder and marker(s) in 
question. MERLIN parametric linkage analyses report LOD scores, and HLOD scores 
with associated alpha (!) parameters, where an alpha of one indicates that all family 
members show evidence for linkage at a particular locus and an alpha of zero 
indicates that no family members show evidence for linkage. The per family option 
(using the –perFamily flag) was used to get LOD scores for each subfamily as well as 
total LOD scores for all subfamilies. This option was used to give a detailed account 
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of each subfamily’s contribution to the overall LOD score and to evaluate if one or 
more subfamilies were driving the majority of the linkage signals detected.  
4.5.4.6 Analyses using McLinkage  
Multipoint linkage analyses of Branch 1 and the BBF were conducted using 
McLinkage. The program is based on the Markov Chain Monte Carlo (MCMC) 
algorithm capable of estimating LOD scores in large pedigrees. It does so by 
considering the underlying inheritance configurations (based on the observed 
genotypes) in proportion to their likelihood. Thus configurations that are theoretically 
possible but highly unlikely (probably due to the large number of recombinations they 
would require) will often not be considered. In the MCMC sampling from inheritance 
configurations begins randomly at any ‘legal’ or probable configuration and continues 
in a sequence of random sampling until a desired inheritance distribution that 
approximates the actual distribution is reached. The main difficulty with linkage 
programs based on the MCMC is deciding the number of samples needed to converge 
to a stationary distribution (Lange & Sobel, 1991). 
By utilising the MCMC algorithm, McLinkage calculates multipoint LOD 
scores (MLOD) and Theta LOD (TLOD) scores between the specified disease 
phenotype and genetic markers in the pedigree. In a TLOD score, the inheritance 
configurations in the pedigree are determined based on all the genetic markers but the 
LOD score is estimated at each marker position at recombination fraction (!) values 
of 0.0, 0.01, 0.1, 0.2, 0.3, 0.4, and 0.5 thus emulating a two-point linkage approach 
(that allows maximising the LOD score over the recombination fractions)(Abkevich 
et al., 2001).  
! ""# 
The McLinkage analyses were conducted per chromosome using an error rate 
of 3%, which was determined using CheckErrors, a program available as part of the 
McLinkage package that calculates the posterior probability of errors in the data 
based on the observed genotypes. A 1000 random samples and 100 burn-ins 
(iterations at the beginning of the MCMC run that are discarded from the analysis 
with the aim of achieving a more stationary distribution) were initially employed. 
However, the reported LOD scores were inconsistent, indicating that the sampling 
distribution did not converge. In fact each analysis was conducted three times and 
yielded different LOD scores each time. Subsequent analyses were therefore run 
using 10,000 random samples.  
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4.5.5 Non-Parametric Linkage (NPL) Analysis using MERLIN  
Multipoint NPL was performed using MERLIN, which uses the NPLpairs and NPLall 
statistics to score IBD allele sharing among pairs and groups of affected family 
members respectively (Whittemore & Halpern, 1994). To evaluate the evidence for 
linkage the (Kong & Cox, 1997) exponential model available in MERLIN was used. 
This model is offered as an alternative to the standard linear model, which is indicated 
for studies aiming to identify small increases in allele sharing among a large number 
of nuclear families. The exponential model is offered as a better option for studies 
aiming to identify large increases in allele sharing among a small number of families, 
and was therefore used in the BBF analyses. An allele sharing statistic (Delta) that 
measures IBD allele sharing between pairs and groups of affected family members in 
the NPLpairs and NPLall tests is reported in NPL tests.  
In all of the MERLIN analyses non-informative family members were 
dropped from the analysis using the --trim option. This was done to avoid ‘dragging 
down’ the linkage test statistic that occurs when relative pairs whose IBD allele 
sharing is uncertain or incomplete are kept in the analysis. IBD sharing scores are 
calculated under the null hypothesis of no linkage and inclusion of uninformative 
relative pairs that contribute to the test statistic biases the results by diluting the data 
set and therefore affecting the evidence of linkage it provides (Schork & Greenwood, 
2004). Simulation studies have revealed that even a small percentage of 
uninformative pairs cause the NPL statistic in MERLIN (as well as Genehunter and 
Allegro) to be considerably reduced (Cordell, 2004).  
NPLpairs and NPLall analyses were performed separately on 18 subfamilies 
from the BBF branches, and 12 subfamilies from Branch 1 using the narrow, broad, 
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super, and depression phenotype models. The per family option (using the –per 
Family flag) was used to get LOD scores for each subfamily as well as total LOD 
scores for all subfamilies.  
 
4.56 X-Chromosome Analyses 
MERLIN in X (MINX) was used to test for linkage in the X-chromosome. There are 
no manuscripts or published works describing MINX performance and algorithms, so 
little information is provided about it here. X-linked traits are often recessive with full 
penetrance in hemizygous males. In recessive X-linked diseases, the only affected 
people are females who are homozygous for the disease allele and males who are 
hemizygous with the disease allele. The only way a female can be homozygous, 
however, is if she receives a disease alleles from her affected father. In MINX males 
are scored as homozygous in the pedigree input file when perfuming linkage testing 
on the X-chromosome. NPL MINX analyses were conducted on Branch 1 and the 
BBF using 230 SNPs available on the X-chromosome after data cleaning under the 
narrow, broad, super, and depression phenotype models. 
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4.5.7 Multiple Testing 
In linkage studies multiple tests are usually performed in an attempt to find linkage 
between a marker(s) and a disease susceptibility locus. In the BBF four different 
phenotype models defining who is affected and who is unaffected were used and 
several different analysis methods and inheritance models were applied to the data. 
With the large number of tests performed the probability of false positives, i.e. 
significant results without there being linkage occurring increases. Therefore, to 
correct for multiple testing the formula below for a corrected LOD score (ZC) was 
used 
 
Where Z is the LOD score threshold if a single tests were used and m is the total 
number of independent tests performed (Ott, 1999). To apply this formula for 
multiple testing corrections, the number of independent tests needed to be determined 
given that the statistical tests and phenotype models used in the linkage analyses were 
nested. The Matrix Spectral Decomposition method implemented in the matSpD 
software (Li & Ji, 2005) was used to estimate the equivalent number of independent 
tests performed under the parametric and non-parametric linkage analyses separately. 
This was done with the view that the two tests represent alternative hypotheses as to 
the properties of the underlying genetic mutations in the family.  
Testing for linkage between disease and multiple markers also represents a 
case of multiple testing. However, correction for the number of SNPs tested was not 
performed because the false positive rate due to the large number of SNPs is 
counterbalanced by the increase in the prior probability of linkage, as more and more 
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of the genome is excluded with the testing of multiple markers (Terwilliger & Ott, 
1994).  
4.5.7.1 Data Simulations 
Data simulation is an alternative approach used to estimate empirical genome wide 
suggestive and significant levels. An average of 500 to 1000 simulations is usually 
generated under the assumption of no linkage. Random datasets that look like the 
original data in terms of marker informativeness, spacing and missing data patterns 
are generated while the pedigree structure and phenotypic information is preserved. 
The pedigree files generated are then analysed using the same linkage statistics, 
phenotype and disease inheritance models utilised in the original data. LOD scores 
exceeding a pre-set threshold for suggestive and significant linkage are recorded for 
each simulated dataset and counted. These LOD scores represent the number of false 
positives. A suggestive threshold reflecting LOD scores occurring by chance once in a 
genome scan and a significant threshold reflecting LOD sores occurring once in 20 
genome scans is set. Using this method to estimate significance levels was the first 
choice of this study. However, due to delays in the computing cluster and the long 
time the simulations were taking to finish, this method was abandoned.  
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Chapter 5 Whole Genome Linkage Results 
After data cleaning (chapter 4 section 4.4) whole genome linkage analyses were 
separately conducted on two sets of data: Branch 1 of the Brazilian Bipolar Family 
(Branch 1) and Branches 1, 2, and 3 of the Brazilian Bipolar Family (BBF), using 
5315 autosomal SNPs genotyped using the Affymetrix 10K array and four phenotype 
models; narrow, broad, super, and depression. Multipoint parametric and non-
parametric linkage (NPL) analyses were performed using the linkage software 
MERLIN (Abecasis, Cherny, Cookson, & Cardon, 2002) on 12 subfamilies from 
Branch 1 (n=269) and 18 subfamilies from the BBF (n=400). In addition, multipoint 
parametric linkage analyses were performed using the linkage software McLinkage 
Thomas, Camp, Farnham, Allen!Brady, & Cannon!Albright, 2008) where Branch 1 
(n=242) and the BBF (n=361) were separately analysed with their structures intact. 
Parametric Linkage analyses were conducted under dominant and recessive modes of 
disease transmission and NPL analyses were performed using NPLall and NPLpairs 






Figure 5.1. Flow chart detailing the whole genome parametric and non-parametric linkage analyses performed on Branch 1 and the BBF using four 
phenotype models; narrow including bipolar I, bipolar II, schizoaffective disorder/bipolar type; broad including all narrow phenotypes plus bipolar 
not otherwise specified and cyclothymia; super including all broad phenotypes plus one episode of major depressive disorder, recurrent episodes of 
major depressive disorder, and dysthymia and; depression including one episode of major depressive disorder, recurrent episodes of major 
depressive disorder, and dysthymia. The parametric linkage analyses were conducted under dominant (Dom) and recessive (Rec) modes of disease 
transmission. Non-parametric linkage was conducted using NPLall and NPLpairs.  
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5.1 Defining the Linkage Loci 
5.1.1 Whole genome Linkage Thresholds 
Following the recommendation of Morton (1955), a LOD score greater or equal to 3.0 
and a LOD score greater or equal to 2.0 were used in the analyses to indicate genome 
wide significant and suggestive evidence for linkage respectively. Correction for 
multiple testing was applied using the formula by (OTT, 1999) 
 
Where Z is the LOD score threshold if a single test was performed and m is the total 
number of independent tests performed. As the statistical tests and phenotype models 
used in the linkage analyses were nested, the matrix spectral decomposition method 
implemented in the matSpD software (Li & Ji, 2005) was used to estimate the 
equivalent number of independent tests performed under the parametric and NPL 
analyses separately. For the parametric linkage analyses, a spearman correlation 
matrix of sixteen variables including LOD scores achieved from the analyses 
performed on Branch 1 and the BBF using the four phenotype models under both the 
recessive and dominant modes of disease transmission (n=85040) was created in R, 
the statistical computing software (Team, 2010). The correlation matrix of the sixteen 
variables was entered into the matSpD program, which estimated the number of 
independent tests performed to be equivalent to eight (Appendix I). Likewise, for the 
NPL analyses, a spearman correlation matrix of sixteen variables including LOD 
scores achieved from the NPLall and NPLpairs analyses performed on Branch 1 and the 
BBF under the four phenotype models (n=85040) was created in R. The correlation 
matrix of the sixteen variables was entered into the matSpD program, which estimated 
the number of independent tests performed to be equivalent to five (Appendix II). 
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According to the number of independent tests estimated for the parametric and 
NPL analyses and using the formula by Ott (1999) to correct for multiple testing, a 
LOD score greater or equal to 3.9 and a LOD score greater or equal to 2.9 were used 
in the parametric linkage analyses to indicate whole genome significant and 
suggestive linkage respectively. A LOD score greater or equal to 3.7 and a LOD score 
greater or equal to 2.7 were used in the NPL analyses to indicate whole genome 
significant and suggestive linkage respectively.  
5.1.2 Core and Maximum Linkage Regions 
Linkage regions may be difficult to define, particularly in complex disease where 
broad flat peaks, or multiple peaks without clearly defined apexes are common. As 
such, chromosomal regions that achieved whole genome significant or suggestive 
linkage were defined in terms of a core and a maximum region. The core region was 
defined by markers with significant LOD scores (i.e. greater or equal to 3.9 or 3.7 for 
significance in parametric and NPL results respectively), or suggestive LOD scores 
(i.e. greater or equal to 2.9 and 2.7 for suggestive parametric and NPL results 
respectively), whereas the maximum region was defined by markers with a 1-LOD 
drop in threshold from the maximum LOD score achieved in the core region (Barnes, 
2003).  
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5.2 Information Content  
Information content mapping measures the total inheritance information extracted by 
the map of markers used in a study. Based on the marker density of the SNP set used 
in the analyses, Branch 1 subfamilies were estimated by MERLIN to have on average 
inheritance information of 81% with chromosome 22 having the least amount of 
information (76.7%). The information content across the BBF subfamilies was 
significantly lower than Branch 1 with an average of 65% across all chromosomes, 
with the lowest being chromosome 22, which captured the least amount of inheritance 
information (58.9%) (Figure 5.2). The reported sub-optimal coverage of the genome 
in Branch 1 and the BBF could result in false position linkage findings, significant 
linkage being missed, or inaccurately positioned on the genetic map. The information 
content of Branch 1 and the BBF with their structures in tact was not measured due to 
software limitations. However, one could assume that the information content of a 






Figure 5.2. Information content of Branch 1 subfamilies (B1) and BBF subfamilies per chromosome as estimated by MERLIN entropy 
measure. The information content of Branch 1 subfamilies is significantly higher than that of the BBF subfamilies. 
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5.3 Summary of Whole-Genome Linkage Results 
Using the corrected whole genome significant and suggestive thresholds, four 
chromosomal regions resulted in whole genome significant LOD scores: 2p23.1-
p22.3, 3p24.3-p24.1, 11p15.4, and 12q24.22-q24.32 and four chromosomal regions 
resulted in whole genome suggestive LOD scores: 1p22.2-p21.3, 1q21.1-q21.3, 
12p13.32-p13.31, and 22q11.21-q12.1 (Table 5.1). Graphs illustrating multipoint 
parametric and NPL peaks across the genome under the four phenotype models for 
Branch 1 and BBF subfamilies are presented in Figures 5.3 through 5.10. These 
graphs correspond to the MERLIN results only1. As seen in these graphs, MERLIN 
multipoint parametric and NPL analyses generally did not yield similar results, 
although some support across linkage methodologies was observed for the regions on 
chromosome 11p15.4 and 22q11.21-q12.1 with LOD scores greater or equal to 1.0. In 
addition, most of the linkage results were derived from Branch 1 subfamilies as 
linkage peaks either remained the same or decreased in size with the inclusion of 
subfamilies from Branches 2 or 3 in the BBF analyses. The exception is chromosome 
1q21.1-q21.3, where a suggestive linkage peak (maximum LOD=2.83) was only 
achieved in analysis of the BBF subfamilies. 
                                                
1 Graphing the linkage results from McLinkage across the genome was unfeasible given that 




























Table 5.1 Regions included in this table are those with significant or suggestive genome wide linkage in any analytic configuration. 
Two asterisks denote SNPs with whole-genome significance and one asterisk denotes SNPs with whole-genome suggestive evidence 
for linkage. All of the maximum LOD scores presented in the table are from analyses conducted on Branch 1, except the 




































































































Figure 5.3. Parametric HLOD and non-parametric LOD scores for Branch 1 subfamilies under the narrow phenotype model. Chromosomes are 
separated by dotted lines. Of note the long regions of negative NPL LOD scores observed on chromosome 17 are due to a reason unknown to us and 






Figure 5.4. Parametric HLOD and non-parametric LOD scores for the BBF subfamilies under the narrow phenotype model. Chromosomes are 
separated by dotted lines. Of note the long regions of negative NPL LOD scores observed on chromosome 17 are due to an unknown reason to us and 






Figure 5.5. Parametric HLOD and non-parametric LOD scores for Branch 1 subfamilies under the broad phenotype model. Chromosomes are 





Figure 5.6. Parametric HLOD and non-parametric LOD scores for the BBF subfamilies under the broad phenotype model. Chromosomes are 





Figure 5.7. Parametric HLOD and non-parametric LOD scores for Branch 1 subfamilies under the super phenotype model. Chromosomes are 





Figure 5.8. Parametric HLOD and non-parametric LOD scores for the BBF subfamilies under the super phenotype model. Chromosomes are 





Figure 5.9. Parametric HLOD and non-parametric LOD scores for Branch 1 subfamilies under the depression phenotype model. Chromosomes are 






Figure 5.10. Parametric HLOD and non-parametric LOD scores for the BBF subfamilies under the depression phenotype model. Chromosomes are 





5.4 Parametric Linkage Results 
This section will commence with a brief summary of the statistics employed by 
MERLIN and McLinkage in the analyses with the aim of clarifying their use in the 
study. Chromosomal regions achieving the corrected LOD scores for significant 
(LOD scores greater or equal to 3.9) and suggestive (LOD scores greater or equal to 
2.9) linkage will then be presented per chromosome.  
5.4.1 Parametric Linkage Statistics 
Parametric linkage using MERLIN performs a LOD score test as well as 
heterogeneity LOD (HLOD) score test that accounts for the possibility of a mixture of 
linked and unlinked families to the marker(s) under investigation. An admixture 
parameter alpha (!) is incorporated into the HLOD score test, and represents the 
proportion of families with evidence for linkage. Of note is that ! does not translate 
into the fraction of families with positive and negative LOD scores (Abecasis 2011, 
personal communication, 2011, see Appendix III). I interpreted this to be because the 
exclusion of linkage only occurs at a LOD score smaller or equal to -2, so families 
with LOD scores ranging from zero to -1.99 are considered not to have significant 
evidence against linkage to the marker(s) under investigation.  
In the presence of locus heterogeneity, the reported HLOD scores are usually 
higher than the reported LOD scores. In our analyses, the HLOD scores were in all 
cases higher than the LOD scores in significant or suggestive regions indicating locus 
heterogeneity (Badner, Gershon, & Goldin, 1998; Morissette et al., 1999). In fact 
none of the LOD scores reported from the MERLIN analyses were greater than 1.0 (A 
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LOD score of 1 is arbitrary and corresponds to a p-value of 0.022, however, it is often 
reported in the literature to signify regions that warrant further investigation). As 
such, only the HLOD scores and associated ! parameters are reported in this section.  
Parametric linkage analysis using McLinkage performs a TLOD score test, 
which uses a multipoint approach to evaluate evidence for linkage over multiple 
markers and then uses a two point approach to calculate the LOD score at each 
marker by allowing values of the recombination fraction theta (") to vary (Abkevich, 
et al., 2001) (see Chapter 4 section 4.5.4.6). Values of theta vary from zero, which 
indicates tight linkage, to 0.5, which is equivalent to independent assortment, or the 
null hypothesis of no linkage. In terms of distance between the marker and the 
putative disease locus, a theta of zero estimates that no genetic distance separates the 
two loci, a theta of 0.01 estimates the distance between the disease and the marker 
locus to be approximately 1 cM, and a theta of 0.02 estimates a distance of 2 cM. 
When theta is small, the genetic distance and theta are approximately equal. In 
practice geneticists treat them as equal for theta values of 0.1 or less. To achieve 
accurate genetic distances for theta values greater than 0.1 the Kosambi function (see 
Chapter 4section 4.5.4.4) was used. We will now explore significant and suggestive 
parametric linkage results per chromosome.  
                                                
2 The LOD score was converted to a p-value by multiplying by 4.6 for a chi-square 
and then taking the value at 1 degree of freedom and dividing it by 2 (OTT, 1999) 
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5.4.2 Chromosome 3p 
5.4.2.1 The Narrow Phenotype Model: McLinkage Results 
Branch 1 yielded a maximum TLOD score of 4.18 supportive of whole genome 
significant linkage on chromosome 3p24.3 in a core region of 518 kb using the 
narrow phenotype model under a dominant mode of disease transmission. This 
occurred at a recombination fraction of 0.2, which is indicative of “loose” linkage, as 
it estimates the disease and marker locus to be approximately 19 cM* away (Figure 
5.11). A maximum region defined by a 1-TLOD drop in threshold from 4.18 
identified an 8.4 Mb susceptibility region on chromosome 3p24.3-p24.1 (Table 5.2). 
Using the same phenotype model and mode of disease transmission, analysis of the 
BBF yielded a maximum TLOD score of 3.46 supportive of whole genome suggestive 
linkage in a core region spanning 3.3 Mb on chromosome 3p24.3-p24.2 at a 
recombination fraction of 0.2, indicating the disease and marker may be 
approximately 19 cM apart (Figure 5.11). Including markers with a 1-TLOD drop in 
threshold from 3.46 expanded the region to a maximum of 4.5 Mb. This region is 3.9 
Mb smaller than the maximum region identified in Branch 1. A shift in linkage peaks 
is observed between the findings from Branch 1 and the BBF as the marker achieving 
the maximum TLOD score in the BBF (rs2045300) is approximately 3.2 Mb away 
from the closest marker (rs904827) achieving the maximum TLOD score in Branch 1. 
Further, it is questionable that markers that achieved TLOD scores greater than 3.0 in 
Branch 1 yielded negative TLOD scores in the BBF (e.g. rs2370990). Of note, 
however, is that the region identified in the BBF is only suggestive of linkage and 
therefore more prone to being a false positive.  
                                                
* As theta is greater than 0.1 the Kosambi function M=1/2 tanh (2r) where M is the 
distance in Morgans and r is the recombination fraction or theta. 
! "#$ 
Using the narrow phenotype model, this region did not report any suggestive 




Figure 5.11. McLinkage TLOD scores for Branch 1 (B1) and the BBF at recombination fractions (Theta) ranging from 0.1 through to 0.3 on 
chromosome 3 versus centiMorgan position using the narrow phenotype model under the dominant mode of disease transmission. The TLOD scores 
in Branch 1 and the BBF were maximised at Theta=0.2. The maximum linkage peaks occur at different locations in Branch 1 and the BBF. TLOD 
scores smaller or equal to -2 were truncated in the graph for ease of presentation. 
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rs1392573 20695652 41.56  4.18** 2.60 
rs904827 20696379 41.56  4.18** 2.61 
rs725542 21213394 42.22  4.02** 3.04* 
rs721623 21650537 42.77 3.70* 2.90* 
rs2358693 22574169 43.58 3.50* 2.99* 
rs1074612 22579568 43.59 3.49* 3.00* 
rs778480 23498492 44.75 3.45* 3.26* 
rs2045300 23871402 45.34 3.52* 3.46* 
rs951015 24053792 45.63 3.43* 3.41* 
rs1112195 24085166 45.68 3.40* 3.42* 
rs1394764 24405050 46.18 2.97* 3.05* 
rs2196427 24533278 46.39 2.96* 3.03* 
rs720822 25232155 47.77 3.02* 2.37* 
rs1348979 27027497 49.44 3.43* 0.68 
rs2037472 27070331 49.49 3.43* 0.64 
rs724244 27242153 49.69 3.42* 0.22 
rs2370990 27690531 50.22 3.25* -1.32 
rs2371121 27850725 50.40 3.23* -1.61 
rs1609729 28303111 51.13 3.22* -0.15 
rs1979113 29057186 52.44 3.23* 0.17 
 
Table 5.2. McLinkage TLOD scores at a recombination fraction of 0.2 on chromosome 
3p24.3-p24.1 under the narrow phenotype model and dominant mode of disease 
transmission. Two asterisks denote SNPs with whole genome significance defined as 
LOD scores greater or equal to 3.90 and one asterisk denotes SNPs with whole genome 
suggestive evidence for linkage defined as LOD scores greater or equal to 2.90. 
 
5.4.2.2 The Narrow Phenotype Model: MERLIN Results 
MERLIN analysis identified a maximum region that spans 18.3 Mb on chromosome 
3p25.3-p24.1 with near suggestive evidence for linkage (maximum HLOD score of 
2.79 in Branch 1 and 2.68 in the BBF) that encompasses the susceptibility locus 
identified by McLinkage under the same phenotype model and mode of disease 
transmission (Table 5.3). However, the linkage peaks identified by the two programs 
are approximately 7.4 Mb apart (Figure 5.12). This region is only presented here as a 
point of comparison between the two programs. 
! "#" 
  
Branch 1 BBF SNP Physical Position cM Position 
HLOD !  HLOD !  
rs59585 13501254 31.98 2.79 0.58 2.68 0.53 
rs1368575 13831304 32.43 2.79 0.57 2.64 0.53 
rs934448 13831352 32.44 2.79 0.57 2.64 0.50 
rs1392573 20695652 41.56 2.38 0.47 2.23 0.42 
rs904827 20696379 41.57 2.38 0.47 2.23 0.40 
rs725542 21213394 42.22 2.33 0.45 2.18 0.40 
rs721623 21650537 42.77 2.30 0.44 2.16 0.39 
rs2358693 22574169 43.58 2.12 0.43 1.98 0.39 
rs1074612 22579568 43.59 2.12 0.43 1.98 0.49 
rs778480 23498492 44.75 1.67 0.41 1.54 0.37 
rs2045300 23871402 45.34 1.70 0.43 1.56 0.38 
rs951015 24053792 45.63 1.72 0.43 1.58 0.38 
rs1112195 24085166 45.68 1.72 0.43 1.58 0.38 
rs1394764 24405050 46.18 1.74 0.44 1.59 0.39 
rs2196427 24533278 46.39 1.74 0.44 1.59 0.39 
rs720822 25232155 47.77 1.94 0.47 1.77 0.42 
rs1348979 27027497 49.44 2.12 0.49 1.94 0.44 
rs2037472 27070331 49.49 2.12 0.49 1.95 0.44 
rs724244 27242153 49.69 2.14 0.49 1.96 0.44 
rs2370990 27690531 50.22 2.18 0.49 2.01 0.44 
rs2371121 27850725 50.40 2.20 0.49 2.02 0.44 
rs1609729 28303111 51.13 2.25 0.49 2.07 0.44 
rs1979113 29057186 52.44 2.25 0.49 2.08 0.44 
 
Table 5.3. MERLIN near suggestive HLOD scores on chromosome 3p25.3-p24.1 under 
the narrow phenotype model and dominant mode of disease transmission. Only SNPs 
with the maximum HLOD scores and those that overlap the McLinkage region are 




Figure 5.12. MERLIN HLOD and McLinkage TLOD scores (at recombination fraction of 0.2) for Branch 1 and the BBF on chromosome 3 versus 
centiMorgan position under the narrow phenotype model and dominant mode of disease transmission. McLinkage TLOD scores smaller or equal to 
-2 were truncated in the graph for ease of presentation. a) The MERLIN and McLinkage linkage regions overlap, however, the peaks occur 7.4 Mb 
apart. A clear shift in the linkage peaks defined by McLinkage in Branch 1 and the BBF is observed. b) Linkage graphs are presented separately for 




5.4.2.2.1 Subfamily Contribution to the Heterogeneity LOD Score 
The region on chromosome 3p24.3-p24.1 influences susceptibility to disorders 
defined under the narrow phenotype model (BPI, BPII, and SAD) in a proportion of 
subfamilies in Branch 1 and the BBF. Evaluation of subfamily contribution to the 
overall HLOD score in Branch 1 indicated that only six subfamilies contributed 
positively to the overall HLOD score. Subfamilies 2, 3, and 9 seemed to be driving 
the linkage signal in this region by contributing with nominally significant (p-values 
greater or equal to 0.05) HLOD scores of 1.48, 1.37, and 1.173. Further, expanding 
the analysis to the BBF showed that in addition to the contributions of subfamilies 
from Branch 1 only subfamily 14 from Branch 2 contributed positively to the linkage 
signal in this region (Figure 5.13). These findings may be suggestive of heterogeneity 
at this locus.  
 
Figure 5.13. Subfamily contribution to the HLOD scores on chromosome 3p24.3-p24.1 using the 
narrow phenotype model under a dominant mode of disease transmission. SNPs in this region 
nearly achieved significance using MERLIN and were reported as significant using McLinkage 
(For family contribution to the HLOD score in the larger region, which showed a similar 
pattern, see Appendix V). Subfamilies 1 through to 12 constitute Branch 1, subfamilies 13 and 14 
constitute Branch 2 and subfamilies 15 through to 19 constitute Branch 3. Subfamily 17 was 
dropped from the analyses.  
                                                
3 A LOD score of 0.59 is equivalent to a p-value of 0.05, which is nominally 
significant.  
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 5.4.2.3 The Broad, Super and Depression Phenotype Models 
The region identified on chromosome 3p24.3-p24.1 (and 3p25.3-p24.1) using the 
narrow phenotype model yielded no suggestive or significant evidence for linkage 
using the broad, super or depression phenotype models in MERLIN or McLinkage 
analyses under the dominant or recessive modes of disease transmission in Branch 1 
or the BBF. These results implicate chromosome 3p24.3-p24.1, possibly 3p25.3-
p24.1, as a susceptibility locus for phenotypes identified under the narrow model 
(BPI, BPII, and SAD) only.  
5.4.3 Chromosome 12p 
5.4.3.1 The Depression Phenotype Model: McLinkage Results  
Assuming a dominant mode of disease transmission and using the depression 
phenotype model, Branch 1 yielded a maximum TLOD score of 3.09 supportive of 
whole genome suggestive linkage on chromosome 12p13.31 in a core region spanning 
18.2 kb. This occurred at a recombination fraction of 0.1, which indicates that the 
disease and marker locus are approximately 10 cM apart. A maximum region defined 
by a 1-TLOD drop in threshold from 3.09 identified a 1.6 Mb disease susceptibility 
region on chromosome 12p13.32-p13.31 (Figure 5.14 in section 5.4.4). The TLOD 
score was reduced to a non-significant score of 2.02 occurring at a recombination 
fraction of 0.1 when the BBF was analysed (Table 5.4).  
Using the depression phenotype model, this region did not report any 


















Table 5.4. McLinkage TLOD scores at a recombination fraction of 0.1 on chromosome 
12p13.32-p13.31 under the depression phenotype model and a dominant mode of disease 
transmission. One asterisk denotes SNPs with whole genome suggestive evidence for 
linkage defined as LOD scores greater or equal to 2.90.  
 
5.4.3.2 The Depression Phenotype Model: MERLIN Results  
Using MERLIN, the region on chromosome 12p13.32-p13.31 reported no suggestive 
or significant linkage signals in either Branch 1 or the BBF using the depression 
phenotype model under a dominant or recessive mode of disease transmission.  
5.4.3.3 The Narrow, Broad, and Super Phenotype Models 
The linkage region identified on chromosome 12p13.32-p13.31 using the depression 
phenotype model yielded no suggestive or significant linkage signals using the 
narrow, broad or super phenotype models under the dominant or recessive modes of 
disease transmission in Branch 1 or the BBF. These results implicate chromosome 
12p13.32-p13.31 as a susceptibility locus for phenotypes identified under the 
depression model (MDD and dysthymia) only. 
SNP Physical Position cM Position Branch 1 BBF 
Rs720334 4493794 13.22 2.31 0.95 
Rs501004 5238215 14.79 2.35 1.08 
Rs2041428 5375028 15.03 2.36 1.10 
Rs1005221 5493117 15.14 2.36 1.10 
Rs764220 5711247 15.63 2.33 1.11 
Rs2192190 5741549 15.72 2.74 1.37 
Rs723188 6063905 16.19 3.07* 2.02 
Rs917858 6081938 16.207 3.09* 2.03 
Rs917859 6082113 16.208 3.09* 2.03 
Rs717180 9395807 24.008 -0.52 0.25 
Rs252027 9412418 24.013 -0.52 0.25 
Rs252028 9412883 24.014 -0.52 0.25 
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5.4.4 Chromosome 12q 
5.4.4.1 The Depression Phenotype Model: McLinkage Results 
The highest linkage signal achieved in the whole genome linkage scan occurred on 
chromosome 12q24.31-q24.32 under a depression only phenotype model assuming a 
dominant mode of disease transmission. McLinkage identified a linkage peak in 
Branch 1 with a maximum TLOD score of 4.74 in a region spanning 120 kb at a 
recombination fraction of 0.01, which estimates the disease and marker locus are 
approximately 1 cM away. Surprisingly, the linkage peak is followed by a sharp drop 
in TLOD scores and a maximum region is therefore not defined. Analysis of the BBF 
reduced the linkage signal to a maximum TLOD score of 3.16 at recombination 
fraction 0.01, which only meets study criteria for whole genome suggestive linkage. A 
smoother decline in LOD scores is observed in the BBF analysis and a maximum 
region defined by a 1-TLOD drop in threshold from this maximum identified a 2.5 
Mb susceptibility region on chromosome 12q24.31-q24.32. (Table 5.5, Figure 5.14).  
Using the depression phenotype model, this region did not report any 














Table 5.5. McLinkage TLOD scores at a recombination fraction of 0.01 on chromosome 
12q24.22-q24.32 under the depression phenotype model and a dominant mode of disease 
transmission. Two asterisks denote SNPs with whole genome significance defined as 
LOD scores greater or equal to 3.90 and one asterisk denotes SNPs with whole-genome 
suggestive evidence for linkage defined as LOD scores greater or equal to 2.90. 
SNP Physical Position cM Position Branch 1 BBF 
rs325095 125885304 145.80 4.04** 3.06* 
rs849346 126005019 146.256 4.74** 3.16* 
rs861070 126005488 146.258 4.74** 3.16* 
rs722704 126921171 149.21 2.28 3.51* 
rs950591 127672428 151.60 0.92 2.71 
rs3851661 127724123 151.77 0.13 2.67 
rs721605 127980028 152.70 2.92* 2.69 





Figure 5.14. McLinkage TLOD scores for Branch 1 (B1) and the BBF at recombination fractions (Theta) ranging from 0.0 through to 0.1 on 
chromosome 12 versus centiMorgan position under the depression phenotype model. Two linkage peaks are observed on the two arms of 
chromosome 12, a suggestive linkage peak on chromosome 12p13.32-p13.31 maximising the TLOD scores at recombination fraction of 0.1, and a 
significant peak on chromosome 12q24.31-q24.32 maximising the TLOD scores at recombination fraction of 0.01. TLOD scores smaller or equal to   
-2 were truncated in the graph for ease of presentation.  
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5.4.4.2 The Depression Phenotype Model: MERLIN Results 
MERLIN analyses using the depression phenotype model found no suggestive or 
significant linkage signals on chromosome 12q24.22-q24.32 under a dominant or 
recessive mode of disease transmission in either Branch 1 or the BBF, reporting LOD 
scores approaching zero.  
5.4.4.3 The Narrow, Broad, and Super Phenotype Models 
The linkage region identified on chromosome 12q24.22-q24.32 using the depression 
phenotype model revealed no suggestive or significant evidence for linkage using the 
narrow, broad, or super phenotype models in MERLIN or McLinkage analyses under 
the dominant or recessive modes of disease transmission in Branch 1 or the BBF. 
However, McLinkage TLOD scores greater than 1.0 were found at a recombination 
fraction of 0.2 under the super phenotype model (BPI, BPII, SAD, BPNOS, 
cyclothymia, MDD, and dysthymia) using the dominant mode of disease transmission 
in Branch 1 and the BBF. All of the other phenotype models had LOD scores of 
approximately zero. These results implicate chromosome 12q24.22-q24.32 as a 
susceptibility locus for phenotypes identified under the depression model (MDD and 
dysthymia) only.  
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5.4.5Chromosome 22q 
5.4.5.1 The Broad Phenotype Model: McLinkage Results 
McLinkage analysis of Branch 1 yielded a maximum TLOD score of 3.53 supportive 
of whole genome suggestive linkage on chromosome 22q11.21-q11.22 in a core 
region of 720 kb using the broad phenotype model under a recessive mode of disease 
transmission. This occurred at a recombination fraction of zero, which is indicative of 
tight linkage (no recombination). A maximum region defined by a 1-TLOD drop in 
threshold from 3.53 identified a 9.3 Mb susceptibility region on chromosome 
22q11.21-q12.1. Using the same phenotype model and mode disease transmission, 
analysis of the BBF yielded a maximum TLOD score of 3.34 also supportive of 
whole genome suggestive linkage in a core region spanning 4.5 Mb on chromosome 
22q11.21-q11.22. This evidence for linkage occurs at a recombination fraction of 0.1 
estimating the disease and marker locus to be approximately 10 cM away, as opposed 
to the tight linkage identified in Branch 1 at a recombination fraction of zero. The 
maximum region defined in the BBF analysis by including markers with a 1-TLOD 
drop in threshold from 3.34 expanded this region to a maximum region of 9.7 Mb that 
encompasses the region identified in Branch 1 (Figure 5.15, Table 5.6).  
Using the broad phenotype model, this region did not report any suggestive or 





Figure 5.15. McLinkage TLOD scores for Branch 1 (B1) and the BBF at recombination 
fractions (Theta) ranging from 0.0 through to 0.1 on chromosome 22 versus 
centiMorgan position. TLOD scores are maximised at recombination fraction of 0.0 in 
Branch 1 and at 0.1 in the BBF.  
 
 
5.4.5.2 The Broad Phenotype Model: MERLIN Results 
Using the same broad phenotype model and recessive mode of disease transmission, 
MERLIN analysis of Branch 1 and the BBF identified the same maximum region 
reported by McLinkage on chromosome 22q11.21-q12.1, where a maximum HLOD 
score of 3.76 (!=0.76) and 3.37 (!=0.67) was reported for Branch 1 and the BBF 
respectively, indicating suggestive evidence for linkage. The core region implicated 
by MERLIN does however differ from that identified by McLinkage, with the former 
implicating a region spanning 95.4 kb on chromosome 22q12.1 for both Branch 1 and 
the BBF, approximately 3.8 Mb away from the closest marker in the Mclinkage core 
region (Figure 5.16, Table 5.6).  
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Using the broad phenotype model, this region did not report any suggestive or 





Figure 5.16. MERLIN HLOD scores and McLinkage TLOD scores, at recombination 
fractions (Theta) of 0.0 for Branch 1 (B1) and 0.1 for the BBF, on chromosome 22 
versus centiMorgan position using the broad phenotype model under the recessive mode 
of disease transmission. The linkage regions identified by the two programs overlap, 



























Table 5.6. MERLIN HLOD and McLinkage TLOD scores at a recombination fraction of zero for Branch 1 and 0.1 for the BBF on 
chromosome 22q11.21-q12.1 under the broad phenotype model and a recessive mode of disease transmission. One asterisk denotes SNPs 
with whole genome suggestive evidence for linkage defined as LOD scores greater or equal to 2.90. 
MERLIN HLOD McLinkage TLOD SNP Physical Position 
Genetic 
Position Branch 1 !  BBF !  Branch 1 BBF 
rs181402 18229774 4.40 3.01* 0.86 2.64 0.74 2.25 3.00* 
rs2401505 18583574 5.77 3.07* 0.84 2.69 0.72 2.49 2.97* 
rs2871038 19634134 8.36 2.93* 0.80 2.57 0.69 2.75 3.23* 
rs431319 21449028 12.69 2.63 0.75 2.30 0.63 2.68 2.96* 
rs448041 21449411 12.70 2.63 0.75 2.30 0.63 2.68 2.96* 
rs878825 21982249 14.00 2.78 0.79 2.42 0.65 2.96* 3.17* 
rs2014298 22702291 15.10 2.98* 0.84 2.58 0.69 3.53* 3.34* 
rs134709 26503944 24.290 3.76* 0.76 3.37* 0.67 2.61 2.52 
rs134711 26504037 24.292 3.76* 0.76 3.37* 0.67 2.61 2.52 
rs79360 26599293 24.36 3.75* 0.76 3.36* 0.67 2.60 2.54 
rs720914 27219881 27.20 3.49* 0.73 3.14* 0.63 2.71 1.44 
rs2157465 27381346 27.97 3.51* 0.73 3.16* 0.63 2.70 1.80 
rs743958 27388405 28.01 3.51* 0.73 3.16* 0.63 2.70 1.80 
rs760531 27493361 28.51 3.51* 0.72 3.16* 0.63 2.70 2.38 
rs471216 27610637 29.07 3.49* 0.72 3.16* 0.63 2.71 2.51 
rs1401527 27610680 29.07 3.49* 0.72 3.16* 0.63 2.71 2.51 
rs2342939 27761128 29.78 3.45* 0.72 3.13* 0.64 2.58 2.69 
rs734088 27889627 30.40 3.45* 0.72 3.15* 0.65 2.48 2.56 
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5.4.5.2.1 Subfamily Contribution to the Heterogeneity LOD Score 
The putative linkage region on chromosome 22q11.21-q12.1 confers susceptibility to 
disorders defined under the broad phenotype model (BPI, BPII, SAD, BPNOS, 
cyclothymia) in a proportion of subfamilies from Branch 1 only. Evaluation of 
subfamily contribution to the overall HLOD score in Branch 1 indicated that only six 
subfamilies contributed positively to the overall HLOD score. Subfamilies 1, 5, and 7 
seemed to be driving the linkage signal in this region by contributing HLOD scores 
greater than one (nominally significant). Expanding the analysis to the BBF showed 
that in addition to the contributions of subfamilies from Branch 1, none of the 
subfamilies in Branches 2 or 3 contributed positively to the linkage signal in this 
region. These findings are suggestive of heterogeneity at this locus (Figure 5.17) and 
contrast with the results of the 3p24.3-p24.1 region with subfamilies 1, 5 and 7 having 
positive HLOD scores for 22q11.21-q12.1 and negative for 3p25.1-p23.2 whereas 
subfamilies 2 and 3 show the opposite pattern.  
 
 
Figure 5.17. Subfamily contribution to the HLOD scores on chromosome 22q11.21-q12.1 
under the broad phenotype model. Subfamilies 1 through to 12 constitute Branch 1, 
subfamilies 13 and 14 constitute Branch 2 and subfamilies 15 through to 19 constitute 
Branch 3. Subfamily 17 was dropped from the analyses 
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5.4.5.3 The Broad Phenotype Model: Non-parametric Results  
The region on chromosome 22q11.21-q12.1 is the only parametric linkage region 
supported with some linkage evidence from NPL methods using the same phenotype 
model. It achieved NPLall and NPLpairs LOD scores greater than one in Branch 1 and 
the BBF, with a maximum NPLall LOD score of 1.26 (Delta=0.61) and NPLpairs LOD 
score of 1.0 (Delta=0.95) in Branch 1 and a maximum NPLall LOD score of 1.23 
(Delta=0.60) and NPLpairs LOD score of 1.01 (Delta=0.94) in the BBF.  
5.4.5.4 The Narrow, Super, and Depression Phenotype Models 
The region identified on chromosome 22q11.21-q12.1 using the broad phenotype 
model yielded no suggestive or significant evidence for linkage using the narrow, 
super, or depression phenotype models under the dominant or recessive modes of 
disease transmission in Branch 1 or the BBF.  
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5.5 Non-Parametric Linkage Analyses 
This section will commence with a brief summary of the statistics employed by 
MERLIN in the analyses with the aim of clarifying their use in the study. 
Chromosomal regions achieving the corrected LOD scores for significant (LOD 
scores greater or equal to 3.7) and suggestive (LOD scores greater or equal to 2.7) 
linkage will then be presented per chromosome.  
5.5.1 Non-parametric Linkage Statistics Linkage Statistics 
Nonparametric linkage using MERLIN performs an NPLall and an NPLpairs test. 
NPLall estimates Identity-by-Decent (IBD) allele sharing across groups of affected 
family members and therefore only attributes significance to regions where a single 
variant confers susceptibility. Conversely NPLpairs estimates IBD between pairs of 
affected family members and therefore attributes significance to regions where 
multiple variants infer susceptibility in different pairs of affected family members. In 
other words, NPLpairs allows for allelic heterogeneity within family members in each 
subfamily, while NPLall does not. LOD scores from both statistics will be presented in 
this section. The allele sharing parameter Delta (Kong & Cox, 1997), which measures 
excess IBD allele sharing between pairs and groups of affected family members under 
NPLpairs and NPLall respectively will also be reported here. As a rule, Delta scores 
above zero indicate excess in IBD sharing. We will now explore significant and 
suggestive non-parametric linkage results per chromosome. 
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5.5.2 Chromosome 1p 
5.5.2.1 The Narrow Phenotype Model  
NPL analysis undertaken on Branch 1 yielded a maximum NPLall LOD score of 2.96 
supportive of whole genome suggestive linkage in a core region of 9.4 Mb on 
chromosome 1p22.2-p21.3 using the narrow phenotype model (Figure 5.18). This was 
reported using the NPLall statistic only, indicating excess IBD allele sharing between 
affected groups in Branch 1 (Delta=2.12). Expanding the region to include markers 
with a 1-LOD drop in threshold from 2.96 identified a maximum putative 
susceptibility locus of 10.7 Mb on chromosome 1p22.2-p21.2. The linkage signal was 
specific to Branch 1 as analysis of the BBF substantially decreased the NPLall LOD 
score to a maximum of 2.12 (Delta=0.98), which does not meet criteria for suggestive 
linkage (Table 5.7).  
 
 
Figure 5.18. NPLall and NPLpairs exponential LOD scores for Branch 1 (B1) and the 


























Table 5.7. NPLall and NPLpairs exponential LOD scores and allele sharing score (Delta) reported for Branch 1 and the BBF on 
chromosome 1p22.2-p21.2 using the narrow phenotype model. One asterisk denotes SNPs with whole-genome suggestive evidence for 
linkage defined as LOD scores greater or equal to 2.7. 
Branch 1 BBF 
SNP Physical Position 
Genetic 
Position NPLall Delta NPLpairs Delta NPLall Delta NPLpairs Delta 
rs1074541 89509499 113.46 2.64 1.47 1.78 1.47 1.87 0.95 0.97 1.03 
rs1380416 89949213 113.88 2.75* 1.49 1.89 1.49 1.97 0.95 1.06 1.06 
rs2390795 90139260 114.06 2.80 * 1.52 1.99 1.53 2.01 0.96 1.13 1.09 
rs519989 90223400 114.14 2.82* 1.53 2.02 1.54 2.02 0.96 1.15 1.09 
rs716988 91543728 115.42 2.89* 1.59 2.18 1.60 2.07 0.97 1.27 1.14 
rs1926261 92162920 116.09 2.92* 1.61 2.24 1.62 2.09 0.98 1.31 1.15 
rs546550 94550555 117.62 2.96* 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs545542 94550696 117.62 2.96* 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs952499 94558425 117.62 2.96* 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs951534 94625274 117.68 2.96* 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs1411698 94686110 117.73 2.96* 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs1073364 94828209 117.84 2.96 * 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs696619 95005220 117.98 2.96 * 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs2040074 95158357 118.11 2.96 * 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs1414904 95633977 118.50 2.96 * 1.64 2.31 1.63 2.12 0.98 1.37 1.16 
rs1113271 96168570 118.88 2.96 * 1.64 2.31 1.63 2.11 0.98 1.37 1.16 
rs953401 96186671 118.89 2.96 * 1.64 2.31 1.63 2.11 0.98 1.37 1.16 
rs1935571 96414335 118.98 2.96 * 1.64 2.31 1.63 2.11 0.98 1.37 1.16 
rs321241 96476493 119.01 2.96 * 1.64 2.31 1.63 2.11 0.98 1.37 1.16 
rs1144305 96506730 119.02 2.96 * 1.64 2.31 1.63 2.11 0.98 1.37 1.16 
rs54790 97265741 119.34 2.96 * 1.67 2.35 1.66 2.14 0.99 1.44 1.20 
rs728656 98855166 120.58 2.97 * 1.78 2.43 1.74 2.21 1.04 1.63 1.30 
rs764051 99356958 120.80 2.94 * 1.80 2.41 1.75 2.19 1.04 1.62 1.31 
rs951125 100198059 121.81 2.50 1.80 1.99 1.72 1.81 1.05 1.31 1.28 
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5.5.2.1.1 Subfamily Contribution to the LOD Score 
The putative linkage region on chromosome 1p22.2-p21.2 confers susceptibility to 
disorders defined under the narrow phenotype model (BPI, BPII, and SAD) in a 
proportion of subfamilies in Branch 1 only. Evaluation of subfamily contribution to 
the overall LOD score indicated that only seven subfamilies from Branch 1 
contributed positively to the overall LOD score, with only subfamily 1 achieving 
nominally significant scores (i.e. LOD scores greater or equal to 0.59 equivalent to p-
value of 0.05). Further, expanding the analysis to the BBF showed that in addition to 
the contributions of subfamilies from Branch 1 none of the subfamilies in Branches 2 
or 3 contributed positively to the linkage signal in this region (Figure 5.19). 
 
 
Figure 5.19. Subfamily contribution to the NPLall LOD score on chromosome 1p22.2-
p21.2 using the narrow phenotype model. Subfamilies 1 through to 12 constitute Branch 
1, subfamilies 13 and 14 constitute Branch 2 and subfamilies 15 through to 19 constitute 
Branch 3. Subfamily 17 was dropped from the analyses.  
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5.5.2.2 The Broad Phenotype Model  
A subset of SNPs in the core region identified using the narrow phenotype model 
showed suggestive evidence for linkage using the broad phenotype model in Branch 1 
(Figure 5.20). Using this phenotype model refined the core linkage peak to a narrower 
region of approximately 5.6 Mb on chromosome 1p22.2-p21.3 with a maximum 
NPLall LOD score of 2.93 and a maximum NPLpairs LOD score of 2.70, indicating 
excess allele sharing between groups (Delta=0.94) and pairs (Delta =1.49) of affected 
family members respectively. Expanding the region to include markers with a 1-LOD 
drop in threshold identified a maximum susceptibility locus of 9.8 Mb on 
chromosome 1p22.2-p21.3, 900 kb smaller than the maximum region defined under 
the narrow phenotype model (Tables 5.8).  
 
Figure 5.20. NPLall and NPLpairs exponential LOD scores for Branch 1 (B1) and the 





























Table 5.8. NPLall and NPLpairs exponential LOD scores and allele sharing scores (Delta) for chromosome 1p22.2-p21.3 using the broad phenotype 
model for Branch 1 and BBF. One asterisk denotes SNPs with whole-genome suggestive evidence for linkage defined as LOD scores greater or equal 
to 2.7.  
Branch 1 BBF 
SNP Physical Position 
cM 
Position NPLall Delta NPLpairs Delta NPLall Delta NPLpairs Delta 
rs1074541 89509499 113.46 2.75* 0.92 2.33 1.42 2.12 0.71 1.69 1.12 
rs1380416 89949213 113.88 2.75* 0.93 2.42 1.43 2.20 0.71 1.77 1.13 
rs2390795 90139260 114.06 2.86* 0.93 2.48 1.44 2.23 0.71 1.82 1.14 
rs519989 90223400 114.14 2.88* 0.93 2.50 1.44 2.24 0.71 1.83 1.14 
rs716988 91543728 115.42 2.90* 0.93 2.60 1.47 2.26 0.71 1.92 1.16 
rs1926261 92162920 116.09 2.91* 0.94 2.64 1.48 2.27 0.71 1.95 1.17 
rs546550 94550555 117.62 2.93* 0.94 2.70* 1.49 2.28 0.71 1.99 1.18 
rs545542 94550696 117.62 2.93* 0.94 2.70* 1.49 2.28 0.71 1.99 1.18 
rs952499 94558425 117.62 2.93* 0.94 2.70* 1.49 2.28 0.71 1.99 1.18 
rs951534 94625274 117.68 2.93* 0.94 2.70* 1.49 2.28 0.71 1.99 1.18 
rs1411698 94686110 117.73 2.93* 0.94 2.70* 1.49 2.28 0.71 1.99 1.18 
rs1073364 94828209 117.84 2.88* 0.93 2.63 1.49 2.23 0.71 1.93 1.17 
rs696619 95005220 117.98 2.80* 0.92 2.54 1.48 2.17 0.71 1.85 1.16 
rs2040074 95158357 118.11 2.72* 0.91 2.43 1.47 2.10 0.70 1.76 1.15 
rs1414904 95633977 118.50 2.30 0.81 1.71 1.19 1.80 0.66 1.23 0.95 
rs1113271 96168570 118.88 2.29 0.81 1.70 1.19 1.80 0.66 1.23 0.95 
rs953401 96186671 118.89 2.29 0.81 1.70 1.19 1.80 0.66 1.23 0.95 
rs1935571 96414335 118.98 2.29 0.81 1.70 1.19 1.79 0.66 1.22 0.95 
rs321241 96476493 119.01 2.29 0.81 1.70 1.19 1.79 0.66 1.22 0.95 
rs1144305 96506730 119.02 2.29 0.81 1.70 1.19 1.79 0.66 1.22 0.95 
rs54790 97265741 119.34 2.29 0.81 1.72 1.20 1.80 0.66 1.26 0.97 
rs728656 98855166 120.58 2.25 0.82 1.73 1.23 1.80 0.67 1.37 1.02 
rs764051 99356958 120.80 2.21 0.82 1.71 1.23 1.78 0.67 1.36 1.02 
rs951125 100198059 121.81 1.86 0.80 1.53 1.25 1.48 0.65 1.24 1.03 
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5.5.2.2.1 Subfamily Contribution to the LOD Score 
The putative region on chromosome 1p22.2-p21.3 confers susceptibility to disorders 
defined under the broad phenotype model (BPI, BPII, SAD, BPNOS, cyclothymia) in 
a proportion of subfamilies from Branch 1 only. Evaluation of subfamily contribution 
to the overall LOD score indicated that only eight subfamilies from Branch 1 
contributed positively to the overall LOD score. Similar to findings from the narrow 
phenotype model, only subfamily 1 achieved nominally significant scores (i.e. LOD 
scores greater or equal to 0.59 equivalent to p-value of 0.05) in this region. Expanding 
the analysis to the BBF showed that in addition to the contributions of subfamilies 
from Branch 1, none of the subfamilies from Branches 2 or 3 contributed positively to 
the LOD score (Figure 5.21). 
 
Figure 5.21. Subfamily contribution to the NPLall LOD score on chromosome 1p22.2-
p22.3 under the broad phenotype model. Subfamilies 1 through to 12 constitute Branch 
1, subfamilies 13 and 14 constitute Branch 2 and subfamilies 15 through to 19 constitute 
Branch 3. Subfamily 17 was dropped from the analyses. 
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5.5.2.3 The Super and Depression Phenotype Models 
The linkage region identified on chromosome 1p22.2-p21.3 using the narrow and 
broad phenotype models yielded no suggestive or significant evidence for linkage 
using the super or depression phenotype models in Branch 1 or the BBF. The only 
positive LOD scores greater or equal to 1 were achieved in analysis under the super 
phenotype model, which yielded a maximum NPLpairs LOD score of 1.19. These 
results implicate chromosome 1p22.2-p21.3 as a putative susceptibility locus for 
disorders defined under the broad phenotype model (BPI, BPI, SAD, BPNOS 
cyclothymia). 
5.5.3 Chromosome 1q 
5.5.3.1 The Super Phenotype Model 
A region on chromosome 1q21.1-q21.2, spanning 1.1 Mb, was identified with 
suggestive evidence for linkage in the BBF with a maximum NPLpairs LOD score of 
2.83 under the super phenotype model (Figure 5.22). These results were achieved 
using the NPLpairs statistic only, indicating increased allele sharing among pairs of 
affected family members only (Delta=0.95). A maximum region including SNPs with 
a 1-LOD drop in threshold from the maximum LOD of 2.83 was identified on 
chromosome 1q21.1-q21.3 and expanded the putative region to approximately 8 Mb. 
This region was not corroborated in Branch 1, yielding less than whole genome 
suggestive LOD scores (Table 5.9). These results implicate chromosome 1q21.1-
q21.3 as a putative susceptibility locus for mood disorders (BPI, BPII, SAD, BPNOS 
cyclothymia) in the BBF. 
! "#$ 
 
Figure 5.22. NPLall and NPLpairs exponential LOD scores for Branch 1 (B1) and the 





















Table 5.9. NPLall and NPLpairs exponential LOD scores and allele sharing scores (Delta) for chromosome 1q21.1-q21.3 under the super 
phenotype model for Branch 1 and the BBF. One asterisk denotes SNPs with whole-genome suggestive evidence for linkage defined as 
LOD scores greater or equal to 2.7.  





Position NPLall Delta NPLpairs Delta NPLall Delta NPLpairs Delta 
rs719969 146555660 140.78 0.36 0.18 1.43 0.76 0.51 0.19 2.13 0.85 
rs2077749 146652637 142.04 0.38 0.18 1.97 0.87 0.57 0.19 2.83* 0.95 
rs720609 146653028 142.05 0.38 0.18 1.97 0.87 0.57 0.19 2.83 * 0.95 
rs953087 146739540 142.05 0.38 0.18 1.97 0.87 0.57 0.19 2.83 * 0.95 
Rs1832116 147779090 142.09 0.38 0.18 1.97 0.87 0.56 0.19 2.82 * 0.95 
Rs1196462 151627604 145.24 0.27 0.17 1.70 0.82 0.46 0.18 2.56 0.91 
Rs2338019 151956814 145.53 0.25 0.17 1.62 0.80 0.44 0.18 2.48 0.90 
rs726865 152400055 145.94 0.21 0.16 1.43 0.74 0.38 0.17 2.23 0.84 
rs726863 152400361 145.94 0.21 0.16 1.43 0.74 0.38 0.17 2.23 0.84 
rs950338 152756806 146.26 0.21 0.16 1.43 0.74 0.38 0.17 2.23 0.84 
rs1560832 153335384 146.78 0.21 0.16 1.43 0.74 0.38 0.17 2.22 0.84 
rs724781 153336018 146.79 0.21 0.16 1.43 0.74 0.38 0.17 2.22 0.84 
Rs2335230 154589628 147.67 0.20 0.15 1.36 0.73 0.37 0.17 2.16 0.84 
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5.5.3.1.1 Subfamily Contribution to the LOD score 
The putative linkage region on chromosome 1q21.1-q21.3 confers susceptibility to 
disorders defined under the super phenotype model (BPI, BPII, SAD, BPNOS, 
cyclothymia, MDD, dysthymia) in a proportion of subfamilies from Branch 1 and the 
BBF. Evaluation of subfamily contribution to the overall LOD score indicated that ten 
subfamilies from Branch 1 contributed positively, albeit in different proportions, to 
the overall LOD score in the analyses conducted in Branch 1. Further, expanding the 
analysis to the BBF showed that, in addition to the contributions of subfamilies from 
Branch 1, two subfamilies from Branches 2 (subfamily 14) and 3 (subfamily16) 
contributed positively to the overall LOD score. However, none of the subfamilies 
reported nominally significant LOD scores in the region (Figure 5.23). 
 
Figure 5.23. Subfamily contribution to the NPLpairs LOD score on chromosome 1q21.1-
q21.3. Subfamilies 1 through to 12 constitute Branch 1, subfamilies 13 and 14 constitute 
Branch 2 and subfamilies 15 through to 19 constitute Branch 3. Subfamily 17 was 
dropped from the analyses. 
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5.5.3.2 The Narrow, Broad, and Depression Phenotype Models 
The linkage region identified on chromosome 1q21.1-q21.3 using the super 
phenotype model yielded LOD scores that did not meet criteria for suggestive or 
significant linkage using the narrow, broad, or depression phenotype models.  
5.5.4 Chromosome 2p 
5.5.4.1 The Super Phenotype Model 
A region spanning 3 Mb on chromosome 2p23.1-p22.3 achieved whole genome 
significant linkage under the super phenotype model (Figure 5.24). NPLpairs produced 
a maximum LOD score of 3.83 in Branch 1, while NPLall yielded non-significant 
LOD scores at this locus, indicating that increased allele sharing was only present 
between pairs of affected family members (Delta=1.10). A maximum region defined 
by a 1-LOD drop in threshold from the maximum LOD of 3.83 identified a larger 
region on chromosome 2p23.1-p22.3 spanning 5.4 Mb. Analysis of the BBF 
decreased the LOD scores to levels indicative of suggestive linkage only, with a 
maximum NPLpairs score of 3.46 (Table 5.10). These results implicate chromosome 
2p23.1-p22.3 as a putative susceptibility locus for mood disorders identified under the 






Figure 5.24. NPLall and NPLpairs exponential LOD scores on chromosome 2 versus 





























Table 5.10. NPLall and NPLpairs exponential LOD scores and allele sharing scores (Delta) on chromosome 2p23.1-p22.3 under the super phenotype 
model. Two asterisks denote SNPs with whole-genome significance defined with LOD scores greater or equal to 3.7 and one asterisk denotes SNPs 
with whole-genome suggestive defined with LOD scores greater or equal to 2.7. 
Branch1 BBF 
SNP Physical Position 
cM 
Position NPLall Delta NPLpairs Delta NPLall Delta NPLpairs Delta 
rs1509577 30410818 53.30 0.63 0.20 2.85 0.99 0.61 0.61 2.55 0.90 
rs829669 30720752 53.82 0.63 0.20 2.89 0.99 0.61 0.61 2.58 0.90 
rs499476 30985774 54.26 0.64 0.20 2.92* 0.99 0.62 0.62 2.60 0.91 
rs2364445 31176516 54.58 0.70 0.20 3.43*  1.08 0.68 0.68 3.06 0.98 
rs1862975 31326432 54.84 0.74 0.20 3.67*  1.11 0.72 0.72 3.27 1.00 
rs2365842 31588288 55.34 0.80 0.20 3.80** 1.10 0.78 0.78 3.40*  1.00 
rs206847 31611367 55.37 0.80 0.20 3.81**  1.10 0.78 0.78 3.41*  1.00 
rs2208532 31788989 55.44 0.80 0.20 3.83**  1.10 0.78 0.78 3.43*  1.00 
rs564310 31892342 55.48 0.80 0.20 3.83**  1.10 0.78 0.78 3.43*  1.00 
rs219085 33292452 56.02 0.80 0.20 3.82** 1.10 0.78 0.78 3.42*  1.00 
rs723042 33541702 56.34 0.80 0.20 3.82** 1.10 0.78 0.78 3.42*  1.00 
rs723043 33541787 56.34 0.80 0.20 3.82**  1.10 0.78 0.78 3.42*  1.00 
rs602622 33658226 56.54 0.80 0.20 3.82**  1.10 0.78 0.78 3.42* 1.00 
rs2197804 33916066 56.98 0.80 0.20 3.81** 1.10 0.78 0.78 3.44*  1.01 
rs1961268 34249225 57.56 0.80 0.20 3.80**  1.10 0.78 0.78 3.46*  1.01 
rs722289 34265233 57.59 0.80 0.20 3.80**  1.10 0.78 0.78 3.46*  1.01 
rs2371923 34474473 57.93 0.80 0.20 3.79**  1.10 0.78 0.78 3.45*  1.01 
rs3845765 34531775 58.00 0.80 0.20 3.78**  1.10 0.78 0.78 3.45*  1.01 
rs3910275 34541186 58.01 0.80 0.20 3.78** 1.10 0.78 0.78 3.44*  1.01 
rs3845767 34543150 58.01 0.80 0.20 3.78**  1.10 0.78 0.78 3.44*  1.01 
rs1583366 34601927 58.08 0.80 0.20 3.74** 1.10 0.78 0.78 3.40*  1.00 
rs892457 34667721 58.15 0.79 0.20 3.43* 1.06 0.78 0.78 3.12* 0.97 
rs1371422 35772759 59.44 0.63 0.19 3.00* 1.02 0.61 0.61 2.72* 0.93 
rs1371427 35779358 59.45 0.63 0.19 3.00* 1.02 0.61 0.61 2.71* 0.93 
rs1371426 35779431 59.46 0.63 0.19 3.00* 1.02 0.61 0.61 2.71* 0.93 
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5.5.4.1.1 Subfamily Contribution to the LOD Score 
The significant linkage region identified on chromosome 2p23.1-p22.3 confers 
susceptibility to disorders defined under the super phenotype model (BPI, BPII, SAD, 
BPNOS, cyclothymia, MDD, dysthymia) in a proportion of subfamilies from Branch 
1 and the BBF. Evaluation of subfamily contribution to the overall LOD score 
indicated that ten subfamilies from Branch 1 contributed positively, albeit in different 
proportions, to the overall LOD score signal in analyses conducted in Branch 1. 
Expanding the analysis to the BBF showed that in addition to the contributions of 
subfamilies from Branch 1 only subfamily 14 from Branch 2 contributed positively to 
the overall LOD score (Figure 5.25). However, none of the subfamilies reported 




Figure 5.25. Subfamily contribution to the NPLpairs LOD scores on chromosome 
2p23.1-p22. Subfamilies 1 through to 12 constitute Branch 1, subfamilies 13 and 14 
constitute Branch 2 and subfamilies 15 through to 19 constitute Branch 3. Subfamily 17 
was dropped from the analyses. 
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5.5.4.2 The Narrow, Broad, and Depression Phenotype Models 
The region identified on chromosome 2p23.1-p22 using the super phenotype model 
yielded no suggestive or significant evidence for linkage using the narrow, broad, or 
depression phenotype models. Analysis under the depression phenotype model, 
however, yielded a maximum NPLpairs LOD score of 1.18, which only achieves 
nominal significance.  
5.5.5 Chromosome 11p 
5.5.5.1 The Depression Phenotype Model 
The second highest LOD scores achieved in the entire linkage study occurred in a 
telomeric region spanning 73.8 kb on chromosome 11p15.4 using the depression 
phenotype model. NPL analysis revealed whole genome significant linkage using 
both NPLall and NPLpairs test statistics, indicating excess IBD allele sharing among 
groups and pairs of affected family members in Branch 1 and the BBF. A maximum 
LOD score of 4.49 (Delta=1.28) in Branch 1 and 4.70 (Delta=1.33) in the BBF was 
achieved using the NPLall test. This region was expanded to a maximum region of 2.4 
















Table 5.11. NPLall and NPLpairs exponential LOD scores and allele sharing scores (Delta) on chromosome 11p15.4. Two asterisks denote SNPs 
reaching whole-genome significance defined with LOD scores greater or equal to 3.7 and one asterisk denotes SNPs with whole-genome suggestive 
defined with LOD scores greater or equal to 2.7. 





Position NPLall Delta NPLpairs Delta NPLall Delta NPLpairs Delta 
rs1822285 4232627 6.18 3.08* 1.41 2.87* 2.28 3.30* 1.48 3.11* 2.31 
rs968856 5260576 7.98 1.17 0.53 1.85 1.13 1.32 0.54 2.07 1.15 
rs956471 5470716 8.40 4.39** 1.29 4.03** 2.00 4.61** 1.33 4.27** 2.02 
rs979752 5539139 8.54 4.49** 1.28 4.13** 1.98 4.70** 1.33 4.36** 2.00 
rs1433567 5544512 8.55 4.49** 1.28 4.12** 1.98 4.70** 1.33 4.36** 2.00 
rs2345344 6582512 10.46 3.41* 1.02 2.53 1.38 3.60* 1.05 2.74* 1.39 






Figure 5.26. NPLall and  NPLpairs exponential LOD scores for Branch 1 (B1) and the 




5.5.5.1.1 Subfamily Contribution to the LOD Score 
The significant linkage region on chromosome 11p15.4 confers susceptibility to 
disorders defined under the depression phenotype model mainly in subfamilies from 
Branch 1, as examining subfamily contribution to the overall LOD score revealed that 
eight subfamilies contributed positively to the overall LOD score, with subfamily 7 
achieving nominal significance (LOD greater or equal to 0.59) in the region. 
Expanding the analysis to the BBF showed that in addition to the contributions of 
subfamilies from Branch 1 only subfamily 16 from Branch 3 contributed positively to 
the overall LOD score (Figure 5.27). These findings are suggestive of heterogeneity 
at this locus. 
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Figure 5.27. Subfamily contribution to the NPLall LOD scores on chromosome 
11p15.4.Subfamilies 1 through to 12 constitute Branch 1, subfamilies 13 and 14 
constitute Branch 2 and subfamilies 15 through to 19 constitute Branch 3. Subfamily 17 
was dropped from the analyses. 
 
5.5.5.2 The Depression Phenotype Model: Parametric Linkage 
The region on chromosome 11p15.4 is the only NPL region corroborated with some 
linkage evidence from parametric analyses using MERLIN. Under a dominant mode 
of disease transmission and using the depression phenotype model, this region 
achieved a maximum HLOD score of 1.72 (!=1) in Branch 1 and a maximum HLOD 
score of 1.78 (!=1) in the BBF. The region did not yield any LOD scores greater or 
equal to 1.0 under the recessive mode of transmission nor was it supported by any of 
the McLinkage analyses.  
5.5.5.3 The Narrow, Broad, and Super Phenotype Models 
The linkage region identified on chromosome 11p15.4 yielded LOD scores that did 
not meet criteria for suggestive or significant evidence for linkage using the narrow, 
broad, or super phenotype models in NPLall and NPLpairs tests. Therefore the results 
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implicate chromosome 11p15.4 as a susceptibility locus for phenotypes identified 
under the depression model (MDD and dysthymia) only.  
5.5.6 The X-Chromosome  
NPL multipoint MINX (MERLIN in X) linkage analysis was performed on 
subfamilies from Branch 1 (n=269) and the BBF (400) using 230 SNPs genotyped on 
the X chromosome using the Affymetrix 10K array. The information content, derived 
from the genotypes generated across the X chromosome ranged from 62 to 80%. 
Little evidence was observed for linkage on the X-chromosome by any phenotypic 
model (Figure 5.28).  
 
Figure 5.28. Graph showing NPLall and NPLpairs exponential LOD scores on the X-
chromosome versus centiMorgan position for Branch 1 (B1) and the BBF under the 
narrow, broad, super and depression phenotype models.  
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5.6 Interpretation of Results using the Allele Sharing Statistic Delta 
Delta is the allele sharing statistic reported by MERLIN as part of the NPL output. It 
measures excess IBD allele sharing between pairs and groups of affected family 
members in the NPLpairs and NPLall tests respectively (see section 4.55). Delta is 
difficult to interpret across studies, as it is not a normalised statistic. However, it has 
been used as a measure of effect size to compare phenotype models within studies 
(Breen et al., 2010). Under the null hypothesis of no linkage, excess IBD allele 
sharing, as measured by Delta, approaches zero. Deviation for the null indicates 
excess or negative allele sharing. 
A maximum allele sharing score conditional on family relatedness, genotype 
data, and the definition of affectedness is estimated by Delta under NPLpairs and 
NPLall. In Branch 1 and the BBF the maximum allele sharing score achievable in 
NPLpairs by all affected pairs investigated was estimated to be approximately 10 for 
the narrow, broad, super, and depression phenotype models. The maximum 
achievable allele sharing score between groups of affected family members was 
estimated to be approximately 10 for the narrow, 9.34 for the broad, 2.55 for the 
super, and 7.51 for the depression phenotype model. A region with allele sharing 
scores approaching the maximum possible estimated value of Delta is considered to 
have a major effect on disease susceptibility.  
Using hierarchal phenotype models poses a challenge to the interpretation of 
linkage results as increased evidence for linkage in larger groups of affecteds (due to 
broadening the phenotype definition) could be attributed to an increase in power as 
opposed to true genetic differences between the phenotype groups. The allele sharing 
statistic Delta offers an opportunity to further evaluate the linkage regions identified 
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in NPL analyses under different phenotype models. However, I emphasise that the 
interpretation of Delta presented in this thesis is only exploratory. Discussion of Delta 
for each MERLIN significant linkage region is presented below. 
5.6.1 Chromosome 1p 
In the disease susceptibility locus identified in Branch 1 on chromosome 1p22.2-
p21.2 under the narrow and broad phenotype models both of which meet criteria for 
genome wide suggestive evidence for linkage, a maximum Delta score of 1.8 
(LOD=2.94) was achieved under the narrow phenotype model, which was reduced to 
a maximum Delta score of 0.94 (LOD=2.93) under the broad phenotype model. The 
Delta scores under the narrow phenotype model indicated this region has a modest 
influence on susceptibility to narrowly defined BPD (BPI, BPII, and SAD) when 
compared to the maximum possible estimated value of 10. However, this influence is 
reduced further when considering individuals with broadly defined BPD (BI, BPII, 
SAD, BPNOS and cyclothymia) as affected. The maximum Delta scores for the super 
and depression phenotype models were estimated to be 0.27 (LOD=0.17) and 0.10 
(LOD=0.01) respectively, indicating a small increase in allele sharing from what 
would be expected under the null hypothesis of no excess sharing (i.e. Delta of zero).  
Even though there is equal evidence for suggestive linkage in the narrow and broad 
phenotype models, IBD allele sharing that is approximately halved when the 
definition of affectedness is broadened to include bipolar spectrum disorders, suggests 
the evidence for linkage in the region is probably driven by phenotypes under the 
narrow model.  
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5.6.2 Chromosome 1q 
In the disease susceptibility locus identified in the BBF on chromosome 1q21.1-q21.3 
under the super phenotype model, which only achieved genome wide suggestive 
evidence for linkage in the NPLpairs analysis, a maximum Delta score of 0.95 
(LOD=2.83) was achieved, indicating this region had a modest influence on 
susceptibility to mood disorders defined under the super phenotype model (BPI, BPII, 
SAD, BPNOS, cyclothymia, MDD, and dysthymia). A similar maximum Delta score 
of 0.94 was estimated for the narrow phenotype model, although it did not meet 
criteria for genome wide suggestive evidence for linkage (LOD=0.95). The maximum 
Delta scores for the broad and depression phenotype models were estimated to be 
0.68 (LOD=0.91) and 0.61 (maximum LOD=0.64) respectively, which is a small 
increase in allele sharing from the null of zero. A similar patter of Delta scores is 
observed in Branch 1, under which none of the phenotype models achieved 
suggestive significance. A maximum Delta score of 0.91 (LOD=0.81) was achieved 
under the narrow phenotype model, a maximum Delta score of 0.72 (LOD=0.72) 
under the broad phenotype model, a maximum Delta score of 0.87 (LOD=1.97) under 
the super phenotype model, and a maximum Delta score of 0.55 (LOD=0.45) under 
the depression phenotype model. 
The modest differences in IBD allele sharing reported by Delta between the 
super phenotype model in comparison with the other phenotype models suggest that 
linkage evidence was not achieved using the other phenotype models possibly due to 
a lack of power to detect linkage rather than do to underlying differences between the 
phenotype groups.  
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5.6.3 Chromosome 2p 
In the disease susceptibility locus identified on chromosome 2p23.1-p22.3 under the 
super phenotype model with genome-wide significant linkage using the NPLpairs 
analysis only, maximum Delta scores of 1.10 (LOD=3.83) and 1.01 (LOD=3.46) were 
reported in Branch 1 and the BBF respectively, indicating this region had a modest 
influence on susceptibility to mood disorders defined under the super phenotype 
model (BPI, BPII, SAD, BPNOS, cyclothymia, MDD, and dysthymia).  
The maximum Delta scores reported in Branch 1 for the narrow, broad, and 
depression phenotype models were 0.98 (LOD = 0.99), 0.76 (LOD=0.73), and 0.89 
(LOD=1.34) respectively. The Delta scores in the BBF indicated similar allele 
sharing patterns across the groups in this region, with maximum scores of 0.79 
(LOD=0.67), 0.58 (LOD=0.40), and 0.72 (LOD=0.47) in the narrow, broad, and 
depression phenotype models respectively. These Delta scores indicate the linkage 
evidence was not achieved using the narrow, broad, and depression phenotype models 
in this region possibly due to a lack of power to detect linkage rather than true 
differences between the phenotype groups.  
Of interest, evaluation of allele sharing under the NPLall analyses, under 
which the super phenotype group did not achieve significance, allele sharing 
estimated by Delta in Branch 1 was the lowest under the super phenotype model 
(maximum Delta=0.20, LOD= 0.80) in comparison with that reported under the 
narrow phenotype model (Delta=0.64, LOD=0.88), the broad phenotype model 
(maximum Delta = 0.43 LOD=0.42), and the depression phenotype model (maximum 
Delta=0.43, LOD=0.68). A similar pattern of results was reported in the BBF. 
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5.6.4 Chromosome 11p 
In the disease susceptibility locus identified on chromosome 11p15.4 under the 
depression phenotype model, which met criteria for genome wide significant linkage 
in Branch 1 and the BBF, a maximum NPLall Delta score of 1.41 (LOD=3.08) and 
1.48 (LOD=3.30) were achieved in Branch 1 and the BBF respectively, indicating 
this region has a modest influence on susceptibility to unipolar depression. A small 
increase in allele sharing is reported in the narrow and super phenotype models with 
maximum Delta scores of 0.21 (LOD=0.04) and 0.28 (LOD=0.11) reported under the 
narrow phenotype model in Branch 1 and the BBF respectively and maximum Delta 
scores of 0.13 (LOD= 0.09) and 0.11 (LOD= 0.05) reported under the super 
phenotype model in Branch 1 and the BBF respectively. Further, Delta scores in the 
broad phenotype group were indicative of no excess sharing with zero IBD allele 
sharing reported in Branch 1 (LOD= -0.29) and the BBF (LOD=-0.35). A similar 
pattern is observed across the phenotype group in NPLpairs Delta scores (data not 
presented here). These Delta scores suggest the region on chromosome 11p15.4 may 
be specific to depression only.  
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Chapter 6 Case Control Exploration of Linkage Regions 
6.1 Introduction 
Genome wide significant and suggestive linkage signals were reported in eight chromosomal 
regions in the BBF linkage study (see Chapter 5 section 5.3). To explore the generalisability 
of the linkage findings, two case-control association analyses of bipolar and depression case-
control cohorts were performed. The aim was to clarify the role of the identified linkage 
regions in the general aetiology of sporadic cases of BPD and unipolar depression and in 
particular to explore whether there are association signals in the linkage regions that might 
help explain and refine the source of the linkage signals.!
6.1.1 Linkage disequilibrium and Association Mapping   
As described in chapter 1 (section 1.42) linkage disequilibrium (LD) is based on the non-
random assortment between alleles in the population. Allelic association is the result of a 
mutation that occurred on an ancestral haplotype that was passed down from generation to 
generation along with the disease mutation. A number of processes contribute to the presence 
of LD and influence the level of LD across the genome, including rate of mutation, 
recombination and genetic drift (Ardlie, Kruglyak, & Seielstad, 2002). The most important of 
these is recombination. Over many generations, ancestral chromosomes have become mixed 
together, with small sections of DNA from each chromosome interspersed. As the sections of 
the ancestral chromosomes become smaller, the chance of a recombination event occurring to 
break up the section also becomes smaller. Markers in these sections are in high LD with 
each other and are always inherited together. LD based association mapping between cases 
and controls allows high resolution mapping because for many inherited diseases 
recombination events over the numerous generations between the mutated ancestor and 
current population have narrowed the DNA markers that remain part of the disease associated 
!
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haplotype to 50 kb or less (Ennis, Maniatis, & Collins, 2001), which allows for the 
identification of susceptibility genes with small effect sizes.  
Association mapping studies are conducted to investigate polymorphisms suspected 
of being implicated in a disease, positional candidate genes from prior linkage studies, 
functional candidate genes, as well as to perform fine mapping in regions of 1 to 20 Mb 
identified by linkage studies, and; more recently to perform genome wide association 
mapping aimed at identifying common causal variants across the genome. All of these 
methods investigate common genetic variants, i.e. polymorphisms that occur in more than 1 
percent of the population in cases versus controls, and are all sensitive to population 
stratification. !
6.1.2 Methods of Association Mapping 
Single SNP analyses in cases and controls test the null hypothesis of no association between 
the disease and genotypes under investigation. A number of options are available for SNP 
association tests. In the first, the genotype counts of AA, AB, and BB are tested in cases and 
controls using an observed versus expected test statistic without providing any order across 
the genotypes AA, AB, and BB, a so called general genetic model that typically tests the 
observed number of AA genotypes in cases and controls. The data may be also analysed 
assuming a specified genetic model. For example, for a single SNP with alleles A and B and 
the hypothesis that carrying allele B increased risk of disease, the data may be analysed 
assuming a dominant model in which carrying alleles AB and BB confer similar risk to 
disease or assuming a recessive model in which only carrying minor alleles BB confers risk 
to disease. Alternatively the data may be analysed assuming an additive genetic model in 
which heterozygote risk AB is intermediate between the two homozygote risks (BB > AB > 
AA) (Lewis, 2002). For complex diseases, risk from individuals SNPs is often considered to 
be additive and most association studies perform additive genetic tests unless the data 
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suggests the presence of dominant or recessive genetic effects. Generally, however, there is 
no accepted answer as to which single SNP test to perform. Adopting an additive model 
sacrifices power to detect association if the genetic risk is far from additive but gives greater 
power for near additive risk (Balding, 2006). An alternative approach is to analyse case 
control data by alleles, as opposed to genotypes. Allelic association tests break down the 
genotypes to compare the total number of A and B alleles in cases and controls regardless of 
genotype. This method has more power than the additive genetic model, however, it is not 




 In addition to analysing single markers for association with a trait, a number of markers in 
combination can be studied. This is known as haplotype analysis. A haplotype is made up of 
a specific combination of alleles at adjacent SNPs (Figure 6.1). In the example shown, the 
alleles at three SNPs in three individuals can be seen. When the identical sequence 
surrounding the alleles is removed, the alleles can be combined to form a haplotype. 
 
Figure 6.1. A haplotype is made up of particular combination of alleles at nearby SNPs. In the 
above example, there are three biallelic SNPs, highlighted by the red rectangles. The alleles of 
these SNPs are shown in three different individuals, surrounded by sequence , which is identical 
across all. The haplotype is made up by combining the alleles across each sequence, and 
removing the identical sequence. Adapted from www.hapmap.org. 
 
Markers genotyped in an association study are not necessarily directly contributing to 
disease, but may be in LD with markers that are. For example, in Figure 6.1, assume that only 
SNP1 and SNP3 have been genotyped. If the A allele at SNP2 is the risk allele, this can be 
detected using haplotype analysis. The A allele at SNP2 is only present with a C allele at 
SNP1 and an A allele at SNP3. Therefore, the CA haplotype of SNP1 and SNP3 ‘tags’ the A 
allele at SNP2. In this way un-genotyped susceptibility alleles for complex diseases can be 
mapped through their LD with genotyped marker alleles. The pattern of LD in the human 
genome has been extensively studied and is a great tool for haplotype analysis. 
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Recombination happens at different rates across the genome, regions with low recombination 
and high LD (haploblocks) are interspersed with regions of high recombination and low LD, 
so called recombination hot spots (Figure 6.2). Where blocks of LD encompassing a number 
of SNPs are present over a gene, the number of SNPs to be genotyped can be reduced. SNPs 
are chosen which predict the genotypes of a number of other SNPs in the block.  
 
Figure 6.2 Pattern of LD across a genomic region in a specific population. Red colour represents 
a high level of LD between the markers, which are represented in chromosomal order at the top 
of the diagram. Regions of high LD are known as haploblocks. Haploblocks are split up by 
regions of low LD and a high degree of recombination, known as recombination hotspots. The 
top track represents a measure of recombination, with peaks indicating recombination hotspots. !
6.1.3 Population Stratification  
Association between a disease and a genetic marker can arise as an artefact of population 
stratification rather than genuine association to disease. Population stratification may either 
be caused by historically distinct subgroups (each with its own different set of allele 
frequencies) or intra-population heterogeneity in allele frequency due to recent admixture of 
historically distinct subpopulations. The problem arises when cases and controls are sampled 
from genetic subgroup with alleles frequencies that substantially differ irrespective of disease 
status resulting in spurious associations between genotype and phenotype at markers that are 
! "#$!
completely unlinked to the disease. For example, in a population that is a mixture of African 
and Caucasians cases of hypertension will occur disproportionately among African 
Americans who have a higher prevalence of the disease. If we conduct an association study 
using cases of African American ancestry and Caucasians any alleles that occur more 
commonly in African Americans will tend to be associated with disease, even if they are 
completely unlinked to disease causing genes (Reich & Goldstein, 2001). In addition to 
confounding from false positive associations, population stratification my lead to reduced 
statistical power resulting in fewer true positive findings. Population stratification could be 
dealt with by matching cases and controls for genetic ancestry, which has become a common 




6.2.1 Bipolar Case Control Analysis 
Nine hundred and thirteen individuals with BPD, recruited from London and Toronto were 
used for the case-control association analysis. Details of the sample have been previously 
published (Gaysina et al., 2009). The mean age for Canadian subjects was 45.99 years 
(SD±12.54 years; n=383 total, 143 men and 240 women), and for UK subjects 48.02 years 
(SD±11.40;n=514 total, 176 men and 338 women). Subjects were recruited following 
identical protocols and were identified from psychiatric clinics, hospitals, primary care 
physicians, patient support groups, and from respondents to media advertisements. Subjects 
were included if they were over the age of 18 and had been diagnosed with BPI or BPII 
disorder as defined by the DSM-IV (American Psychiatric Association, 1994) or the 
International Classification of Disease 10th edition operational criteria (ICD-10) (World 
Health Organization, 1993). All subjects were interviewed using the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN) (Wing et al., 1990). The age of onset of disease was 
21.28 ± 10.48 years. To minimize population stratification all subjects were white and of 
European parentage. Exclusion criteria were:  
1. First degree relative having fulfilled criteria for schizophrenia.  
2. Being related to an individual already included in the study.  
3. Psychotic symptoms that were mood incongruent or present when there was no 
evidence for mood disorders.  
4. Intravenous drug use with a lifetime diagnosis of drug dependence. 
5. Mania or depression occurred solely as a consequence of alcohol or substance 
abuse/dependence and or medical illness or in response to medication. 
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A total of 1687 control individuals (721 men and 966 women; mean age ± SD: 42.07±13.17) 
were recruited from two sites; London, UK and Toronto, Canada. The mean age of the 
Canadian control group was 43.66 years (SD±13.12 years; n=311 total, 142 men and 169 
women), and for the UK control group 41.70 (SD±13.16 years; n=1376 total, 579 men and 
797 women). Control subjects from both centres were screened for lifetime absence of 
psychiatric disorder using a modified version of the Past History Schedule (McGuffin, Katz, 
& Aldrich, 1986). They were either interviewed by telephone or in person. All control 
subjects were white and of European parentage. Exclusion criteria were: 
1. If they scored 10 or more on the Beck Depression Inventory (Beck & Steer, 1984) 
2. Did not consent to give blood or check swab samples 
All subjects gave written informed consent and the local ethical committees of all centres 
involved approved the study.  
6.2.2 Depression Case-Control Analysis 
A total of 2948 individuals (871 men, 2077 women; mean age ± SD: 45.25 ±12.15 years) 
sourced from three studies: the Depression Case-Control (DeCC) study (Gaysina et al., 
2008), Depression Network (DeNT) study (Farmer et al., 2004) and the Genome-Based 
Therapeutic Drugs for Depression (GENDEP) study were used in the depression case-control 
association analysis conducted (Uher et al., 2009). The DeCC sample comprises subjects with 
recurrent unipolar depression (minimum two episodes) of at least moderate severity as 
defined by the DSM IV or ICD10 criteria, recruited from three UK sites (London, Cardiff and 
Birmingham). The DeNT is an affected sibling pair linkage study consisting of cases with 
recurrent unipolar depression of at least moderate severity recruited form nine European sites 
and one US site. Probands only were used for the association analyses. The GENDEP study 
includes individuals with one episode of depression of at least moderate severity recruited 
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from nine European centres. The depression in the later study was not necessarily recurrent. 
As with the Bipolar Case Control subjects, all subjects were interviewed using the SCAN. To 
minimize population stratification all subjects were white and of European parentage. 
Exclusion criteria were:  
1. First degree relative having fulfilled criteria for mania, hypomanic, schizophrenia, or 
BP disorder.  
2. Depression occurred solely as a consequence of alcohol or substance 
abuse/dependence, a medical illness, or in response to medication. 
A total of 1288 control individuals contacted via the Medical Research Council general 
practice research framework were interviewed by telephone using the Past History Schedule 
(McGuffin et al., 1986). Of these subjects, 58.4% were women, with mean age of 47.24 years 
(range=20–69). A further 457 healthy volunteers (61.4% female) were staff or students of 
King’s College London, again screened for mental health using the Past History Schedule. To 
minimize population stratification all subjects were white and of European parentage. Details 
of the sample and the methods used to assess the subject have been previously published 
(Farmer et al., 2004; Lewis et al., 2010).— 
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6.3 Materials and Methods 
6.3.1 Case-Control Genotype Data 
Cases and controls from the bipolar and depression case control studies were genotyped using 
the Illumina HumanHap610-Quad BeadChips by the Centre National de Génotypage. The 
data underwent stringent quality control procedures by members of the SGDP research team 
for previous studies. Briefly, subjects were excluded if their genotypic data showed a missing 
rate greater than 1%, abnormal heterozygosity, or a sex assignment that conflicted with 
phenotypic data. SNPs with a missing rate greater than 1%, minor allele frequency less than 
1%, or showing departure from Hardy Weinberg equilibrium (p < 1!10–5) were also excluded 
(Lewis et al., 2010). In addition, subjects who failed PLINK pair-wise Identity-by-Descent 
(IBD) estimation test (--genome) (see Chapter 4 section 4.4.2) by having an IBD pair-wise 
estimate greater than 0.05, which indicates relatedness to a subject already included in the 
study were removed. After quality control there was a total of 502,877 SNPs in the bipolar 
case control study and 471,581 SNPs in the depression case control study.  
6.3.2 Statistical Methods 
6.3.2.1 Extraction of Linkage Regions Identified Under the BPD Phenotype  
SNPs identified with significant or suggestive evidence for linkage in the BBF linkage 
analysis using BBF members diagnosed with BPI, BPII, SAD, BPNOS, and cyclothymia as 
affected (i.e. under the narrow, broad, and super phenotype models) were extracted from the 
HumanHap610-Quad BeadChips SNP data using the PLINK --extract command for inclusion 
in the bipolar case-control analysis. In total 1723 SNPs were available for analysis on 
chromosome 1p22.2-p21.2, 1046 SNPs on chromosome 1q21.1-q21.3, 1133 SNPs on 
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chromosome 2p23.1-p22.3, 1814 SNPs on chromosome 3p24.3-p24.1, and 2175 SNPs on 
chromosome 22q11.21-q12.1.  
6.3.2.2 Extraction of Linkage regions Identified Under the Depression Phenotype  
The linkage regions identified with significant or suggestive evidence for linkage in the BBF 
linkage analyses using BBF members diagnosed with depression as affected (i.e. depression 
phenotype and super phenotype models) were included in the depression case-control 
analysis. In total 930 SNPs were available for analysis on chromosome 1q21.1-q21.3, 1002 
SNPs on chromosome 2p23.1-p22.3, 756 SNPs on chromosome 11p15.4, 2002 SNPs on 
chromosome 12p13.32-p13.31, and 1901 SNPs on chromosome 12q24.22-q24.32. 
6.3.2.3 Ancestry Principal Component Analysis 
As discussed, population stratification is problematic in case control association studies as 
ancestry differences between cases and controls can lead to false positive, or false negative 
association between phenotype and genotype (Marchini, Cardon, Phillips, & Donnelly, 
2004). To account for population stratification in the bipolar and depression case control 
cohorts, principal component analysis (PCA) was conducted.  
PCA is a multivariate technique in which a number of related variables are 
transformed into sets of uncorrelated variables (Jackson & Wiley, 1991). Multivariate 
analyses involve observation and analyses of more than one statistical variable at a time. 
Fundamentally, PCA aims to reduce the number of variables, revealing the underlying 
structure of the dataset explaining the majority of the variance of the data (Dunteman, 1989; 
Manly, 2005). PCA is non-parametric meaning no assumption about the data is made (Jolliffe 
& MyiLibrary, 2002). It is often used for exploratory data analysis where the underlying 
structure of a dataset is unknown. PCA seeks a linear combination of variables, such that the 
maximum variance is extracted. It then removes this variance and seeks a second linear 
! "#"!
combination, which explains the maximum proportion of the remaining variance, and so on. 
The maximum number of components that can be extracted from a PCA is equal to the 
number of variables in the data. However the aim is to extract a smaller number of 
components that explain nearly all of the variance present in all of the original data (Jolliffe 
& MyiLibrary, 2002). The first component explains the majority of variance observed in a 
dataset and each subsequent component explains a declining amount of the remaining 
variance. Usually, only the first few components account for a meaningful amounts of 
variance.  
 The scree plot is one way to determine the number of components that explain the 
majority of the variance. It plots the principal components as the X-axis and the 
corresponding eigenvalues (the amount of variance explained) as the Y-axis (Cattell, 1966). 
As one moves to the right, toward later components the eigenvalues drop. The place where 
the smooth decrease of eigenvalues levels off to a less steep decline (making an elbow) 
denotes the position where further components no longer contribute to the overall variance 
and should be dropped. This technique is problematic when there is no clear break or 
multiple break points exist in the scree plot. 
The program EIGENSOFT (Price et al., 2006) was used to derive ancestry principal 
components for incorporation into the association analyses. The program uses PCA to model 
ancestry differences between cases and controls using SNP information. To avoid 
confounding the PCA, the bipolar and depression datasets were pruned using PLINK linkage 
disequilibrium based SNP pruning. A window size of 1500 and a genotypic correlation (r2) of 
0.2 were specified. Using these parameters, the program calculated LD between each pair of 
SNPs within the specified window and removed one of the SNP pairs if the LD or genotypic 
correlation (r2) between them was greater than 0.2. EIGENSOFT PCA was conducted on the 
pruned datasets.  
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6.3.2.4 Correction for Multiple Testing 
Permutation tests are statistical randomisation tests that rearrange labels on the observed data 
many times under the assumption of no association, calculating the test statistic that each re-
arrangement yields. Labels of cases and controls are interchanged under the null hypothesis 
of no association so only the phenotype-genotype relationship is changed, while all aspects of 
the data (e.g. genotypes, LD structure) are maintained. This is repeated multiple times 
determined by the user and the empirical p-value is generated using the formula: 
  
Where P is the corrected p-value following the permutation procedure, r is the number of 
times the permuted tests exceeded the observed statistic obtained from the real dataset, and n 
is the total number of permutations (North, Curtis, & Sham, 2002). Permutation testing is a 
computationally demanding task. The p-value attained from the actual test statistic is what 
should determine the number of permutations required. Should a low p-value be attained by 
the actual data (e.g. p=10-6) then the number of permutation runs should reflect this (106 or 
10,000,000, permutations). However, generally, in genetic studies 10,000 permutations is 
considered acceptable as p-values are commonly more modest (equal to or less than 10-4) 
(Gao, Becker, Becker, Starmer, & Province, 2010).  
6.3.2.5 Bipolar Case Control Association Tests 
PLINK logistic regression tests for association with 913 bipolar cases and 1687 screened 
comparison controls at the four chromosomal regions identified by the BBF linkage study 
under the narrow, broad, and super phenotype models using ancestry principal components as 
covariates were conducted, assuming an additive genetic model for all the regions under 
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study. In addition, association tests under a dominant model of disease transmission in region 
3p25-24 and a recessive model of disease transmission in region 22q11.21-q12.1 were 
performed, as informed by findings from the BBF linkage study. Correction for multiple 
testing was applied using 10,000 multiple permutation (--mperm) of the dataset.  
6.3.2.6 Logistic Regression Depression Case Controsl Analysis 
PLINK logistic regression tests for association with 2948 depression cases and 1288 screened 
comparison controls at the three chromosomal regions identified by the BBF linkage study 
under the depression and super phenotype models using ancestry principal components as 
covariates. The association analyses were conducted assuming an additive genetic model for 
all chromosomal regions under study, as well as a dominant genetic model in regions 
11p15.4, 12p13.32-p13.31, and 12q24.22-q24.32 as informed by findings from the BBF 
linkage study. Correction for multiple testing was applied using 10,000 multiple permutation 




6.4.1 Bipolar Case Control Analyses 
6.4.1.1 Principal Component Analysis in the Bipolar Case Control Sample 
Pruning the bipolar case control dataset resulted in 101513 SNPs that were in approximate 
linkage equilibrium with each other. The pruned data set was used in the analysis. Twenty-
three individuals were outliers and were therefore removed from the dataset. Based on the 
scree plot (Figure 6.3), the first four principal components were used as covariates in the 
association analysis. The clustering of the bipolar cases and controls by ancestry, as indicated 
by the first four principal components, is shown in Figure 6.4. 
 
Figure 6.3. Scree plot for the bipolar case-control study showing the principal 
components (PC) across the x-axis and their respective eigenvalues on the y-axis. The 
scree plot shows that four components explain the majority of the variance in the data.
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Figure 6.4. The first four principal components (PC) for the bipolar case control data after the removal of outliers (23 individuals). The 
graph shows the pattern of clustering according to ancestry in the cases (black) and controls (red). These first four factors, which 
explain the majority of the variance in ancestry were included in the case-control association analysis to account for population 
stratification.  
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6.4.1.2 Logistic Regression Bipolar Case Control Analysis 
The results of the association analysis showed none of the SNPs in any of the interrogated 
regions achieved significance under the additive or other models indicated by significant or 
suggestive linkage signals in the BBF analysis. The top two SNPs from each region are 
presented in Table 6.1.  
Chromosomal 









rs2497750 99119372 1.295 T 0.4265 1p22.2-p21.2 
 
ADD 
 rs524322 94253345 1.232 C 0.9389 
rs12047833 150190059 0.6908 C 0.1922 1q21.1-q21.3 
 
ADD 
 rs3006423 150214737 0.6647 C 0.1953 
rs1366817 31504054 1.214 G 0.9413 2p23.1-p22.3 
 
ADD 
 rs13404913 33520608 0.7982 C 0.9511 
rs3860582 21616961 0.7618 T 0.1045 ADD 
 rs11708571 21566381 0.7505 G 0.1399 
rs1879167 21764574 0.6673 C 0.4965 
3p25.3-p24.1 
 DOM 
 rs3860582 21616961 0.7317 T 0.7283 
rs5761045 24078813 0.7081 A 0.31 ADD 
 rs5996921 24078331 0.7145 G 0.3584 
rs131677 21957219 1.899 C 0.5894 
22q11.21-q12.1 
 REC 
 rs1297593 26494075 2.335 C 0.3308 
 
Table 6.1. Results from the bipolar case-control association analysis in regions 
indentified in the BBF linkage study under the narrow (1p22.2-p21.2, 3p25-24), broad 
(22q11.21-q12.1) and super (1q21.1-q21.3, 2p23.1-p22.3) phenotype models. Association 
tests were performed under the additive (ADD) genetic model in all of the regions, in 
addition to dominant (DOM) in the chromosome 3p25.3-p24.1 region and recessive 




6.4.2 Depression Case Control Analyses 
6.4.2.1 Principal Component Analysis in the Depression Case Control Sample 
Pruning the depression case control dataset resulted in 99240 SNPs that were in approximate 
linkage equilibrium with each other. The pruned data set was used in the EIGENSOFT 
analysis. Twenty-eight individuals were outliers and were therefore removed from the 
dataset. Based on the scree plot (Figure 6.5) the first four principal components were used as 
covariates in the association analysis. The clustering of the depression cases and controls by 
ancestry, as indicated by the first four principal components, is shown in Figure 6.6.   
 
 
Figure 6.5. Scree plot for the depression case-control study showing the principal 
components (PC) across the x-axis and their respective eigenvalues on the y-axis.  The 




Figure 6.6. The first four principal components (PC) for the depression case control data after the removal of outliers (28 individuals). 
The graph shows the pattern of clustering according to ancestry in cases (black) and controls (red). These first four factors, which 
explain the majority of the variance in ancestry were included in the case-control association analysis to account for population 
stratification. 
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6.4.2.2 Logistic Regression Depression Case Control Analysis 
The results of the association analysis showed none of the SNPs in any of the interrogated 
regions achieved significance under the additive or dominant models indicated by significant 
or suggestive linkage signals in the BBF analysis. The top two SNPs from each region are 












































rs7934676 4355857 1.162 G 0.52 ADD rs4910623 4346215 0.8852 A 0.91 
rs12293167 4344336 0.7832 T 0.34 11p15.4 DOM 
 rs4910623 4346215 0.7843 A 0.37 
rs887357 3344906 1.258 C 0.23 ADD 
 rs11046589 8699273 1.193 C 0.23 
rs12818044 493187 1.303 A 0.37 
12p13-12 
 
 DOM  rs2238023 2072798 0.6123 C 0.37 
rs830123 120910600 1.251 A 0.54 ADD 
 rs7964822 118839946 0.8259 C 0.83 
rs7964822 118839946 0.7844 C 0.41 
12q24.22-q24.32 
 DOM 
 rs830123 120910600 1.289 A 0.43 
 
Table 6.2. Results from the depression case-control association analysis in regions 
identified in BBF linkage study under the depression (11p15.4, 12p13-12, and 12q24.22-
q24.32 ) and super (1q21.1-q21.3, 2p23.1-p22.3) phenotype models. None of the SNPs 
showed association with depression. Association tests were performed under the 
additive (ADD) genetic model in all of the regions, in addition to dominant (DOM) 
genetic model in the chromosome 11p15.4, 12p13-12, and 12q24.22-q24.32 regions. None 




None of the SNPs identified in the BBF linkage regions showed an association with disease 
in the case-control cohorts. The results suggest that the linkage regions identified in the BBF 
do not play a general role in the aetiology of common forms of BPD or unipolar depression in 
the population. It is plausible that the linkage regions identified in the BBF are rare and 
family specific. However, a limitation of this study is the sample size of the case-control 
cohort, which may have reduced power to detect risk variants with low odds ratios. The 
findings of the case-control cohort will be discussed in reference to the BBF linkage findings 
in more detail in the general discussion of this thesis (Chapter 7).  
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Chapter 7 Discussion 
The overarching aim of this thesis was to localise and identify genetic variants that 
underlie the aetiology of BPD. However, the picture emerging from the BBF linkage 
study is one of a general liability to mood disorders, both with linkage hits specific to 
either BPD or depression and hits that go across the mood disorder spectrum. When 
we initially collected this family it was hypothesised that this was primarily a 
‘bipolar’ family with depression cases reflecting bipolar cases early in the 
development of their disorder or “milder” bipolar cases. However, the linkage results 
make it clear that while there are genetic risk loci segregating in the family, these act 
across the mood spectrum and are not preferentially transmitted to clear bipolar cases 
only. Given this, the family is best interpreted in genetic terms as a family with mood 
spectrum disorders, in which a set of loci of larger (if not large) effect segregate. This 
may be alongside a higher polygenic loading for these disorders. 
This chapter will commence with a discussion of the results of the whole 
genome linkage analyses presented in chapter 5. The strengths and the limitations of 
the linkage method will be discussed in light of the study findings. Secondly, the 
results form the case-control replication study presented in chapter 6 will be discussed 
in terms of the generalisability of linkage findings, and the common disease/common 
variant and common disease/rare variant hypotheses. Finally the future directions of 
the BBF study will be presented 
! "#"!
7.1 Whole Genome Linkage Regions 
I successfully performed a whole genome linkage analysis on a large 
multigenerational family segregating severe BPD and mood disorders. After 
correcting for multiple testing, and from across the phenotypes tested, four regions on 
chromosomes 2p23.1-p22.3, 3p24.3-p24.1, 11p15.4, and 12q24.22-q24.32 achieved 
genome wide significance while four regions on chromosomes 1p22.2-p21.2, 1q21.1-
q21.3, 12p13.32-p13.31, and 22q11.21-q12.1 achieved genome wide suggestive 
linkage (Figure 7.1). Many of these regions overlap with and provide further support 
for previous linkage findings. It is important to note that concordant linkage findings 
between BPD studies, as well as between BPD and other psychiatric disorder studies, 
do not necessarily mean that the underlying genetic susceptibility found is the same. 
Different genes under the same linkage peaks could be driving the linkage signals. 
Concordant linkage regions might also occur by chance, given the large number of 
chromosomal regions that are potentially involved in BPD aetiology and other 
psychiatric disorders (Kendler, 2006). Drawing comparisons between linkage studies 
should therefore be regarded as descriptive until fine mapping studies are conducted 





Figure 7.1. Flow chart detailing the results of the parametric and non-parametric 
linkage analyses performed using MERLIN and McLinkage. The four regions 
highlighted in red achieved genome wide significance and the four regions in black 
achieved genome wide suggestive linkage. Chromosomal regions were identified under 
all four phenotype models. Only one region on chromosome 22q11.21-q12.1 was 
identified using both MERLIN and McLinkage. None of the same regions reached 
suggestive or significant thresholds using both parametric and non-parametric linkage. 
In parametric linkage three regions were identified under a dominant (Dom) mode of 
disease transmission (3p24.3-p24.1, 12p13.32-p13.31, and 12q24.22-q24.32) and one 
region under a recessive (Rec) mode of disease transmission (22q11.21-q12.1). 
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7.1.1 Chromosome 1p 
A suggestive linkage region that confers susceptibility to BPD was identified in the 
BBF on chromosome 1p22.2-p21.2 under the narrow (maximum LOD=2.96) and 
broad phenotype models (maximum LOD=2.93). This region has been implicated in 
previous linkage studies of BPD. It was first reported as a susceptibility locus 
(maximum LOD=3.4) in sibling pairs affected with BPI and BPII disorder in families 
from Sardinia (Del Zompo et al., 2010). An earlier genome scan in two 
multigenerational families from Denmark reported 1p22-21 as a suggestive linkage 
region for BPI, BPII, and SAD using marker D1S216 (Ewald, Flint, Kruse, & Mors, 
2002). However, this marker is positioned at the 1p31.1 region according to the new 
build of the human genome (hg19, UCSC browser) and is approximately 11.8 Mb 
telomeric to the linkage peak identified in the BBF. Further, this region overlaps with 
a larger suggestive linkage region identified on 1p31.1-p21.2 (maximum LOD=1.32) 
using fifteen pedigrees from Antioquia, a population isolate in Colombia (Kremeyer 
et al., 2010). Their finding was, however, consistent with a general mood disorder 
liability including BPD and unipolar depression, as opposed to the current study that 




Figure 7.2. Graphical display of genes located on chromosome 1p22.2-p21.2 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases 
(Mb). The p-value for each SNP is plotted with the recombination rate between SNPs. P-
values from the NPLall analysis of Branch 1 under the narrow phenotype are presented 
in the graph. The purple diamond depicts the most significant SNP. Plotted with 
LocusZoom (Pruim et al., 2010) 
  
Figure 7.2 shows, amongst the many genes in the 1-LOD region is the GCLM gene, 
which codes glutamate cysteine ligase modifier, one of three enzymes responsible for 
Glutathione synthesis. Glutathione is involved in the detoxification of reactive oxygen 
and other radical species. Its role has been investigated in BPD. Studies have shown 
that the mood stabilising drugs lithium and valproate increase expression of the 
glutathione s-transferase (GST) gene, that encodes enzymes known to detoxify 
endogenous and exogenous agents and participate in the activation and inactivation of 
oxidative metabolites. Fullerton et al., (2010) investigated several genes in the 
oxidative stress pathway, including GCLM, in 325 BPD patients and 392 controls and 
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found nominal association between BPD and genes in this metabolic pathway. The 
region also harbours MIR137 (MicroRNA 137). A recent genome wide association 
study found a strong association (P = 1.6 ! 10"11) between schizophrenia and 
rs1625579 located within an intron of a putative primary transcript for MIR137 
(Ripke et al., 2011). The role of MIR137 in regulating neuronal maturation and adult 
neurogenesis has been recently reported. Its over-expression has been shown to 
inhibit dendritic morphogenesis, phenotypic maturation, and spine development both 
in brain and cultured primary neurons (Smrt et al., 2010). These finding suggests that 
a pathological pathway involving the dysregulation or dysfunction of MIR137 may 
underlie the aetiology of schizophrenia and possibly BPD, particularly as a recent 
study by (Kwon, Wang, & Tsai, 2011) showed that CACNA1C, a confirmed BPD 
gene (Sklar et al., 2011) is a MIR137 target. This further supports the involvement of 
MIR137 in the aetiology of both BPD and schizophrenia. There are many additional 
genes with roles in the brain in this region. Nevertheless, the identification of a 
suggestive and replicated linkage peak harbouring MIR137 in the BBF suggests the 
microRNA is possibly involved in BPD susceptibility. However, fine mapping is 
required to confirm its role.  
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7.1.2 Chromosome 1q 
A suggestive linkage region was identified in the BBF genome scan on chromosome 
1q21.1-q21.3 (maximum LOD=2.83). No BPD study has reported linkage in this 
region although one study found suggestive evidence for linkage at region 1q23.3 
(approximately 6 Mb centromeric to the putative BBF region) for narrowly defined 
BPI and BPII disorder in 41 Ashkenazi Jewish families (Fallin et al., 2004) with a 
maximum LOD score of 2.46. This locus overlaps with a highly significant 
(HLOD=6.50) schizophrenia locus identified in 22 Celtic Canadian families at 1q21-
q23 (Brzustowicz, Hodgkinson, Chow, Honer, & Bassett, 2000) with the BBF linkage 
peak occurring approximately 7.7 Mb more centromeric to their linkage peak.  
 
Figure 7.3. Graphical display of genes located on chromosome 1q21.1-q21.3 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases 
(Mb). The p-values for each SNP is plotted with the recombination rate between SNPs. 
P-values from the NPLpairs analysis of the BBF under the super phenotype model are 
presented in the graph. The purple diamond depicts the most significant SNP. Plotted 
with LocusZoom (Pruim et al., 2010). 
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As indicated by Figure 7.3, this region has a number of genes of interest including 
PRKAB2, which is a candidate gene for diabetes mellitus (Jablonski et al., 2010; 
Prochazka, Farook, Ossowski, Wolford, & Bogardus, 2002). The co-morbidity 
between BPD and diabetes (Mcintyre, Konarski, Misener, & Kennedy, 2005), along 
with the prevalence of type I diabetes in the BBF, could potentially explain the 
suggestive linkage observed in this region. It is possible that the linkage signal is in 
fact due to diabetes as opposed to BPD. However, chromosome 1q21.1-q21.3 remains 
an interesting locus for BPD in its own right, as a family of genes encoding calcium-
binding proteins, S100A1, S100A5, S100A6, and S100A7 is located in this region. The 
S100 protein family is essential in the regulation of serotonin signalling in the brain 
via interactions with serotonin receptors and are implicated in depression 
(Svenningsson et al., 2006). Expression of the S100 gene family has also been shown 
to be upregulated in the frontal cortex of rats chronically treated with olanzapine, a 
drug typically used to treat schizophrenia, BPD, and some forms of depression, 
suggesting their involvement in the pathobiology of psychiatric disorders (Fatemi et 
al., 2006).  
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7.1.3 Chromosome 2p 
The region on chromosome 2p23.1-p22.3 presents evidence for genome wide 
significant linkage in the BBF (maximum LOD=3.83), under the super phenotype 
model that includes both BPD and unipolar depression. It partially overlaps with a 
region of possible linkage implicated with nominally significant evidence by (Pato et 
al., 2004) in 102 Portuguese Island families with multiple patients suffering from 
BPD and SAD (LOD=1.131) and is approximately 401 kb from another reported 
suggestive linkage peak on 2p23.1 (LOD=1.98) reported in 75 BPD families of 
German, Israeli, and Italian origin with BPI disorder only (Cichon et al., 2001). These 
are the only two linkage scans that support this region as a susceptibility region for 
BPD, however they do implicate it as a specific susceptibility locus for BPI disorder 
and SAD, whereas in the BBF it confers liability to mood disorders in general.  
 The limited support for this region in the literature could be because the finding 
regarding its role in general mood liability is a false positive, or alternatively it could 
be because the region has no significant impact on other families, but is of specific 
relevance to mood disorder susceptibility in the BBF.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 This region was reported by Pato et al. (2004) as an NPL score of 2.28 that was 
converted to a LOD score using LOD=NPL2/4.62 (Ott, 1999). 
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Figure 7.4. Graphical display of genes located on chromosome 2p23.1-p22.3 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases 
(Mb). The p-value for each SNP is plotted with the recombination rate between SNPs. P-
values from the NPLpairs analysis of Branch 1 under the super phenotype are presented 
in the graph. The purple diamond depicts the most significant SNP. Plotted with 
LocusZoom (Pruim et al., 2010). 
 
As shown in Figure 7.4, the region on chromosome 2p23.1-p22.3 contains a number 
of interesting genes, including the EH domain-containing 3 gene (EHD3), involved in 
endocytic trafficking. This was recently implicated with nominal significance (10 x 
10-5) in a whole-genome association study of 1022 cases with recurrent major 
depression and 1000 controls (Muglia et al., 2010). The identification of this gene in 
depression case-control cohorts further supports the potential relevance of this region 
in unipolar depression as well as BPD, as indicated by the findings from the BBF 
study. The region also includes the ALK gene, which encodes tyrosine kinase, a 
member of the insulin receptor super family that plays an important role in 
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neurodevelopment (Entrez Gene). Genetic variations of the ALK have been associated 
with schizophrenia in the Japanese population (Kunugi et al., 2006).  
7.1.4 Chromosome 3p 
The region on chromosome 3p24.3-p24.1 surpasses genome wide significant linkage 
in the BBF study (maximum LOD=4.18) under the narrow phenotype model with a 
dominant mode of disease transmission. With the exception of modest support to a 
marker on 3p24.3 (maximum LOD=1.19) reported in a study of 97 sibling pairs 
affected with BPI, BPII, SAD, and unipolar depression (Edenberg et al., 1997), this is 
not a previously implicated region in linkage studies of BPD, although there is 
evidence in both schizophrenia and depression if we consider the larger region on 
chromosome 3p25.1-p24.1 reported by MERLIN with near suggestive evidence for 
linkage. 
A region on chromosome 3p26.2-p25.3, approximately 16.4 Mb more 
telomeric to the BBF near suggestive linkage peak, has been identified in a genome 
wide scan of 124 Indonesian sibling pair families with schizophrenia (LOD=3.76) 
(Schwab et al., 2008) and a region on chromosome 3p26-25, partially overlapping 
with the BBF linkage region, was reported with genome wide significant linkage 
(maximum LOD=4.0), in families with severe depression (Breen et al., 2010; 
Pergadia et al., 2011). These findings suggest that one region or multiple unrelated 
regions on chromosome 3p26-p24 confer susceptibility to BPD, severe depression 




Figure 7.5. Graphical display of genes located on chromosome 3p25.3-p24.1 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases 
(Mb). The p-value for each SNP is plotted with the recombination rate between SNPs. P-
values from the MERLIN analysis of Branch 1 under the narrow phenotype model are 
presented in the graph. The HLOD scores were converted to p-values by multiplying by 
4.6 for a chi-square and then taking the value at 1 degree of freedom and dividing it by 2 
(OTT,1999). The purple diamond depicts the most significant SNP. Plotted with 
LocusZoom (Pruim et al., 2010).  
 
Of interest, in this region is the NR1D2 gene (which is in the significant region 
implicated with significant linkage) involved in the regulation of circadian rhythms, 
although the extent of its involvement is yet to be determined (GeneCard). None of 
the other genes in the region have any relevance to BPD or mood disorders in general 
(Figure 7.5)  
! "#$!
7.1.5 Chromosome 11p 
The region on chromosome 11p15.4 achieved the second strongest genome wide 
significant linkage (maximum LOD=4.49) in the BBF under the depression phenotype 
model. Approximately 3.9 Mb telomeric to the BBF linkage peak, (Zubenko et al., 2003) 
reported a depression susceptibility locus on 11p15.5 with significant evidence for linkage 
(maximum LOD=4.20) using 81 families ascertained through probands with recurrent 
MDD. The findings from (Zubenko et al., 2003) are, however, difficult to interpret given 
that thirteen chromosomal regions revealed evidence of significant linkage in their study 
(Craddock & Forty, 2006). This region has also been implicated as a susceptibility locus 
for BPD (BPI, BPII and SAD) (maximum LOD=1.902) in 153 multiplex bipolar families 
ascertained as part of the NIMH Genetic Initiative Bipolar Group on 11p15.5-p15.4 (Zandi 
et al., 2003). Their finding partially overlaps the BBF linkage region, however, it does not 
generalise to unipolar depression, which does differentiate it from the current study. This 
could be explained by the presence of genes that predispose to BPD in the region as well as 
genes that predispose to unipolar depression. Alternatively, this region could pleitropoic in 
that it confers risk to BPD in some families and to unipolar depression in others.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 This region was reported by Zandi et al. (2003) as an NPL score of 2.97 that was converted to a 




Figure 7.6. Graphical display of genes located on chromosome 11p15.4 according to the 
human genome build 19. The graph depicts chromosomal positions in mega bases (Mb). The 
p-value for each SNP is plotted with the recombination rate between SNPs. P-values from the 
NPLall analysis of Branch 1 under the super phenotype are presented in the graph. The 
purple diamond depicts the most significant SNP. Plotted with LocusZoom (Pruim et al., 
2010). 
 
There are multiple genes of relevance in the region (Figure 7.6) including the CCKBR gene, 
also known as CCK2, which encodes the cholecystokinin B receptor protein (CCKB) and 
has a modulating effect on anxiety, analgesia, arousal, and neuroleptic activity 
(UniProtKB). CCKB activation appears to possess a general inhibitory action on dopamine 
activity in the brain, opposing the dopamine enhancing effects of CCKA (or CCK1). 
Several authors demonstrated CCKB receptor antagonists attenuate rodent anxiety (Griebel, 
Perrault, & Sanger, 1997), stop panic attacks in patients with a history of panic disorder 
(Bradwejn et al., 1994), and reverse pentagastrin-induced symptoms of anxiety in healthy 
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volunteers (Lines, Challenor, & Traub, 1995). More recently, the CCK neurotransmitter 
system has been implicated in the pathogenesis of panic disorder (Koefoed et al., 2010).  
7.1.6 Chromosome 12p 
Chromosome 12p13.32-p13.31 achieved genome wide suggestive evidence for linkage in 
the BBF (LOD=3.09) under the dominant mode of disease transmission. It has been 
previously implicated in a study of Columbian bipolar families, identifying a larger region 
that encompasses the linkage peak identified in this study on 12p11.21-q14.1 with 
suggestive evidence for linkage (maximum LOD=1.203) (Kremeyer et al., 2010). Their 
finding was obtained using a broad phenotype model including BPI, BPII, and major 
depression, suggesting it as a mood disorder liability region. In contrast, the findings from 
the current study reported the effects of the region to be specific to depression. With the 
exception of the study by (Kremeyer et al., 2010) no linkage studies in mood disorders 





!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!%!This region was reported by Kryemer et al. (2010) as an NPL score of 2.35 that was 
converted to a LOD score using LOD=NPL2/4.62 (Ott, 1999).!
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Figure 7.7. Graphical display of genes located on chromosome 12p13.32-p13.31according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases (Mb). 
The p-value for each SNP is plotted with the recombination rate between SNPs. P-values from 
the McLinkage analysis of Branch 1 under the depression phenotype model are presented in 
the graph. The TLOD scores were converted to p-values by multiplying by 4.6 for a chi-
square and then taking the value at 1 degree of freedom and dividing it by 2 (OTT,1999). The 
purple diamond depicts the most significant SNP. Plotted with LocusZoom (Pruim et al., 
2010). 
 
Despite not being identified as a susceptibility region for BPD, but depression specifically, 
it is still of interest that the BBF linkage peak lies approximately 3.7 Mb centromeric to a 
SNP (rs1006737) in CACNA1C, a confirmed gene in the aetiology BPD (Ferreira et al., 
2008; Sklar et al., 2011). As indicated by Figure 7.7, the region on 12p13.32-p13.31 
harbours a number of genes that could potentially prove relevant to the aetiology of mood 
disorders, for example, NTF3, which encodes a protein that is a member of the 
neurotrophin family, that controls survival and differentiation of neurons and is closely 
related to both nerve growth factor and brain-derived neurotrophic factor (GeneCard) and a 
family of voltage-gated potassium channel genes (KCNA1, KCNA5, and KCNA6). 
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7.1.7 Chromosome 12q 
The highest LOD score reported in the BBF was on chromosome 12q24.22-q24.32 
(maximum LOD=4.74) under the depression phenotype model. This region is supported by 
multiple genome wide significant signals in BPD and unipolar depression (Baron, 2002). 
Interest in the region on chromosome 12q23-24 (approximately 21 Mb centromeric to the 
BBF signal) started when it was described by a British pedigree co-segregating mood 
disorders and Darier's disease (maximum LOD=2.1), an autosomal dominantly inherited 
skin disorder (Craddock et al., 1994). Investigations of this region followed and a number 
of researchers implicated it in mood disorders (Dawson et al., 1995). Subsequently, 
Darier’s disease was mapped to the ATP2A2 gene, which encodes SERCA, a 
sarcoplasmic/endoplasmic reticulum calcium pump that plays a role in intracellular calcium 
signalling (Sakuntabhai et al., 1999) and researchers found the Darier-causing mutation did 
not play a major role in mood disorders (Jones et al., 2002). However, the presence of one 
or more BPD susceptibility genes in the Darier region has received some support from 
linkage studies (Green et al., 2005).  
The BBF linkage region (12q24.22-q24.32) corresponds to a region implicated by a 
large pedigree from a homogeneous population in Québec (maximum LOD= 3.92) 
investigating individuals affected with BPD and unipolar depression (Morissette et al., 
1999). In addition, in a region on 12q24.31, approximately 1.2 Mb cetromeric to the BBF 
linkage region, Shink et al., (2005) reported a susceptibility locus for mood disorders with 
highly significant LOD scores of 5.05 in BPD families from the isolated Saguenay-Lac-St-
Jean population of Québec. The BBF region also overlaps with one identified by Ewald, 
Degn, Mors, & Kruse (1998) in two Danish families (maximum LOD= 3.37), however, 
unlike the findings of the current study, they reported evidence for linkage only when BPD 
patients were considered as affected. Further, approximately 27 Mb centromeric to the BBF 
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region Abkevich et al. (2003) identified a highly significant region on 12q22-12q23.2 
(maximum HLOD=6.1) in males from 110 Utah pedigrees with a strong family history of 
major depression. The report that most closely mirrors the BBF finding was reported by 
Curtis et al. (2003) who found suggestive linkage (maximum LOD=2.8) on chromosome 
12q24.31-q24.32 in seven families with multiple cases of BPD and unipolar depression. As 
with the BBF findings, they identified this region under a dominant mode of disease 
transmission and including unipolar cases as affected only.  
 Although, many of the regions discussed here do not match the specific one 
identified in the BBF, the localisation of susceptibility genes in complex diseases is 
difficult. Signals often are detected tens of centiMorgans away from the true locus 
(Roberts, MacLean, Neale, Eaves, & Kendler, 1999) with true linkage peaks usually being 
broader than false peaks (Terwilliger et al., 1997). Therefore, it is certainly plausible that 
the linkage peak identified in the BBF represents the same disease locus detected by the 
other studies described here. It is also plausible that the genes implicated in BPD and 
unipolar depression, in this region, are different or a collection of genes act in an additive 
or epistatic fashion to confer susceptibility to either BPD or depression. Further 
investigation of the region, possibly through sequencing may clarify its role in the different 
mood disorders.  
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Figure 7.8. Graphical display of genes located on chromosome 12q24.22-q24.32 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases (Mb). 
The p-value for each SNP is plotted with the recombination rate between SNPs. P-values from 
the McLinkage analysis of Branch 1 under the depression phenotype model are presented in 
the graph. The TLOD scores were converted to p-values by multiplying by 4.6 for a chi-
square and then taking the value at 1 degree of freedom and dividing it by 2 (OTT,1999). The 
purple diamond depicts the most significant SNP. Plotted with LocusZoom (Pruim et al., 
2010). 
 
Situated in this region are genes of interest (Figure 7.8) including P2RX7, previously 
associated with both BPD (Barden et al., 2006; McQuillin et al., 2009) and unipolar 
depression (Hejjas et al., 2009; Lucae et al., 2006). This association, however, was not 
replicated in two BPD studies (Green et al., 2009; Grigoroiu!Serbanescu et al., 2009). 
Another gene of interest in this region is the NOS1 gene that belongs to the family of nitric 
oxide syntheses, and in the brain displays many properties of a neurotransmitter (Enterz 
Gene). It has been associated with Schizophrenia (Fallin et al., 2005) but does not show 
evidence for association with BPD in two studies (Buttenschön et al., 2004; Silberberg, 
Ben!Shachar, & Navon, 2010).  
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7.1.8 Chromosome 22q 
Chromosome 22q11.21-q12.1 achieved genome wide suggestive evidence for linkage in 
the BBF (LOD=3.76) under a recessive mode of disease transmission and a broad 
phenotype model including BPI, BPII, SAD, BPNOS and cyclothymia. This region has 
been consistently implicated in psychiatric genetics in general. In BPD, Detera-Wadleigh et 
al. (1999) reported a suggestive linkage peaks that overlaps with the one identified in the 
BBF (LOD=2.1) in 22 U.S families affected with BPI, BPII, and SAD only. Edenberg et al. 
(1997) presented evidence for a linkage peak approximately 554 kb centromeric to the BBF 
peak in 540 individuals from 97 BPD families (NIMH bipolar initiative) with a maximum 
suggestive LOD score of 2.5 for affecteds with BPD and unipolar depression, thus 
implicating the region in general susceptibility to mood disorders. Kelsoe et al. (2001) 
reported a significant linkage peak 6.6 Mb telomeric to the BBF linkage peak in 20 U.S 
extended BPD families (maximum LOD=3.84) using a broad phenotype model that 
included BPI, BPII, SAD, and unipolar depression. The importance of this region in BPD 
and schizophrenia is further confirmed in a meta-analysis of eleven BPD linkage genome 
scans (P < 1x10-5) and a meta-analysis of eighteen schizophrenia genome scans  
(P < 9x10-5) (Badner & Gershon, 2002).  
Interest 22q11 was initially driven by a reported association between BPD (and 
other psychoses) and velocardio-facial syndrome, a genetic disorder with a known 
microdeletion in 22q11 (Murphy, Jones, & Owen, 1999). Today there is mounting evidence 
both from quantitative and molecular genetic studies (e.g. Potash et al., 2003; Berrettini, 
2003; Kohn & Lerer, 2005; Lewis et al., 2003) that suggest both BPD and schizophrenia 
share susceptibility genes in this region, offering support to the idea of a shared genetic 
aetiology for these disorders and suggesting that this region confers susceptibility to 
psychosis. 
! ""#!
Chromosome 22q11.21-q12.1 was identified in the BBF under the broad phenotype model 
that included disorders that do not feature psychosis. Moreover, analysis under the narrow 
definition of affectedness, including the majority of cases with a history of psychosis 
showed no evidence for linkage. However, this might be accounted for by lack of power to 
detect linkage in the narrow group due to a smaller number of affected cases. Nonetheless 
the current study, in conjunction with the previous literature provides compelling evidence 
for the implication of this region in mood disorder as general liability. 
 
 
Figure 7.9. Graphical display of genes located on chromosome 22q11.21-q12.1 according to 
the human genome build 19. The graph depicts chromosomal positions in mega bases (Mb). 
The p-value for each SNP is plotted with the recombination rate between SNPs. P-values from 
the MERLIN analysis of Branch 1 under the broad phenotype model are presented in the 
graph. The HLOD scores were converted to p-values by multiplying by 4.6 for a chi-square 
and then taking the value at 1 degree of freedom and dividing it by 2 (OTT,1999). The purple 
diamond depicts the most significant SNP. Plotted with LocusZoom (Pruim et al., 2010). 
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There are multiple genes of interest within 22q11.21-q12.1 (Figure 7.9). These include 
some that are BPD candidate genes including ADRBK2, which encodes G-protein-coupled 
receptor kinase 3 (GRK3) involved in the phosphorylation of beta-adrenergic and related G 
protein-coupled receptors and has been associated with BPD (Barrett et al., 2003). Another 
gene of interest is the Catechol-o-methyl transferase (COMT) gene, which encodes 
enzymes involved in the degradation of monoamines. COMT contains the much studied 
Val108/158Met polymorphism which influences the enzyme’s rate of activity and has been 
reported to influence clinical features BPD such as rapid cycling (Farmer, Elkin, & 
McGuffin, 2007). Other SNPs in the gene have also been reported in some studies to be 
associated with both BPD (Jones & Craddock, 2001; Rotondo et al., 2002) and 
schizophrenia (Palmatier et al., 2004; Shifman et al., 2002). 
7.1.9 X-Chromosome 
The X chromosome perhaps deserves special mention for historical reasons. It has 
recurrently been implicated since the very first attempt to discover genetic linkage in BPD 
with the observation of co-segregation of the disorder with colour blindness in one large 
pedigree (Reich, Clayton, & Winokur, 1969) and subsequently was the subject of several 
high profile early linkage studies with ‘classical’ makers (Baron, 2002). More recently 
there have been findings suggesting chromosome Xp22 and Xq26-28 (Stine et al., 1997) 
and Xq24-27 (Pekkarinen, Terwilliger, Bredbacka, Lönnqvist, & Peltonen, 1995) as 
susceptibility loci for BPD. None of these were replicated in the BBF study and it seems 
quite unlikely that X chromosome susceptibility loci have any role in BPD in this large 
BBF. 
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7.2 Interpretation of the Linkage Results 
As discussed, the results of the whole genome linkage analysis conducted in this thesis 
support a number of regions previously identified in the literature. The question remains as 
to why identifying consistent and significant genetic susceptibility loci in linkage studies is 
difficult. A number of factors could be culpable including phenotypic heterogeneity, the 
oligogenic or polygenic nature of the disorder and the potential of genetic interactions 
between genes of small and large effect, individual genes having a small effect on the 
phenotype that are undetectable using linkage approaches, the influence of environmental 
factors, gene-environment interactions or correlations, and the influence of rare genetic 
variants. These factors will be discussed in the context of the findings linkage findings 
presented in this thesis.  
7.2.1 Phenotypic Heterogeneity 
The DSM-IV classifies psychiatric disorders into discrete entities with distinct boundaries. 
The adoption of this classification system into genetic studies was made under the 
assumption that the biological basis of these disorders was as distinct as the phenotypic 
manifestations. As previously discussed, BPD embodies a spectrum of symptoms and 
clinical characteristics that vary in kind and severity and whose underlying biological 
relationship is yet to be determined. Families with BPD segregate different subtypes of the 
disorder, e.g. BPI, and BPNOS, at different severity levels along with a variable number of 
co-morbid disorders such as anxiety disorders and alcohol related disorders. Further, the 
diagnostic boundaries differentiating BPD from depression are repeatedly challenged by 
family studies in which both BPD and unipolar depression co-segregate at higher rates than 
in the general population and from evidence that a large proportion of patients (40-60%) 
diagnosed with major depression either meet criteria for BPII disorder or subthreshold BPII 
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disorder characterised by hypomania that lasts for less than four days (Benazzi, 1999; 
Merikangas et al., 2007). These factors suggest that even though a growing literature 
supports the distinctness of BPD and unipolar depression at the genetic level (Breen et al., 
2010), a general mood disorder liability is still plausible.   
Identifying a genotype-phenotype relationship that describes the influence of a 
putative susceptibility locus on a disease is the essence of linkage mapping. The success of 
disease localisation depends to a large extent on how well the disease is defined, detected, 
or measured. The variability observed in linkage findings of BPD may, therefore, reflect 
the difficulty of defining the bipolar phenotype (MacQueen, Hajek, & Alda, 2005). To 
address the problem of phenotypic heterogeneity, using multiple phenotype models that 
vary the definition of affectedness under study is the standard in linkage studies of BPD. 
Most studies investigate a severe phenotype model including BPI and SAD, or BPI, BPII, 
and SAD, and a broad, less severe phenotype model that usually includes unipolar 
depression. This study included an additional model that included all of the subtypes of 
BPD to assess their genetic relatedness before considering unipolar depression. Four 
phenotype models; a narrow including BPI, BPII and SAD; a broad including narrow plus 
BPNOS and cyclothymia; a super including broad plus unipolar depression, and; a 
depression only phenotype model were analysed in the BBF linkage study.  
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7.2.2 Susceptibility to BPD, Unipolar Depression, and Mood Disorders in the BBF 
Using hierarchal phenotype models does pose a challenge for the interpretation of the 
results, as increased evidence for linkage with a larger group of affecteds due to broadening 
the phenotype definition, could be attributed to an increase in power rather than to true 
genetic differences between the groups. By evaluating allele sharing statistics (available 
only from NPL tests) the interpretation of the results was facilitated. The BBF study 
presents some evidence for linkage under all investigated phenotype models. With the 
exception of chromosome 1p22.2-p21.3 being implicated with suggestive evidence for 
linkage under the narrow and broad phenotype models, none of the other chromosomal 
regions were implicated by more than one phenotype model.  
7.2.2.1 Specific Liability to BPD in the BBF 
Under the narrow phenotype model (BPI, BPII, SAD), locus 3p25.3-p24.1 yielded genome 
wide significant evidence for linkage. Broader phenotype models gave substantially lower 
LOD scores at this locus, indicating that susceptibility in this region is primarily to the 
more severe forms of BPD. This specificity could reflect underlying biological differences 
between the more severe forms of BPD, BPI, BPII, and SAD included in the narrow 
phenotype model, and the lesser severe mood disorders included in the other phenotype 
models.  
Broadening the definition of affectedness to include BPNOS and cyclothymia 
implicated chromosome 22q11.21-q12.1 as a susceptibility locus for bipolar spectrum 
disorders. This implies that a disease causing mutation at this locus could result in variable 
symptoms, ranging from the more severe BPI disorder to the relatively mild cyclothymic 
disorder, in different affected individuals; it is pleiotropic. Why this region was not 
identified under the narrow phenotype model could be explained by lack of power to detect 
! ""#!
linkage in the smaller number of affecteds in the narrow phenotype group or that the 
linkage signal is mainly driven by individuals affected with BPNOS and cyclothymia, as 
opposed to affecteds with more severe forms of BPD. However, it is important to address 
the fact that individuals classified under the broad phenotype model in the BBF are mainly 
children and adults whose mania was triggered by anti-depressant use. It is possible that 
these individuals will develop more severe forms of BPD later on and are arguably 
indistinguishable from individuals with BPI or BPII at the biological level. Association 
with depression, and therefore, more general liability to affective disorders, is dismissed at 
this locus based on the substantial decline in LOD scores observed with the inclusion of 
depression as an affected status in the analyses.  
Interpreting the results from the region on chromosome 1p22.2-p21.3 was 
facilitated with the use of allele sharing statistics. Equal evidence for suggestive linkage in 
the narrow and broad phenotype models is contrasted by IBD allele sharing that is more 
than halved when the definition of affectedness is broadened to include BPNOS and 
cyclothymia. Ott (1999) explains this loss of linkage information could be attributed to 
misclassification of affecteds resulting in discordance between the phenotype and 
underlying genotype and therefore dilution of the linkage signals. Indeed this could be the 
case in the BBF study in which classification of individuals with BPNOS and cyclothymia 
as affected resulted in the observed reduction in allele sharing reported using the broad 
phenotype model. Accordingly, we could assume the linkage signal in 1p22.2-p21.3 is 
mainly driven by narrowly defined BPD.   
The effort of this study to differentiate or examine the genetic liability of classic 
forms of BPD (BPI and BPII) versus BPNOS and cyclothymia often described as ‘soft’ 
BPD, yielded inconclusive results, probably due to the small number of affecteds with 
BPNOS and cyclothymia (n=12). Nevertheless, understanding the genetic relationship 
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between different forms of BPD is necessary for better treatment options in the future and 
is an area of research that warrants further investigation.  
7.2.2.2 Specific Liability to Unipolar Depression 
Findings from the study on chromosomes 11p15, 12p13.32-p13.31 and 12q24.22-q24.32 
were specific to depression. The specificity of region 11p15 to depression is confirmed by 
extremely low LOD scores reported under the other phenotype models, as well as allele 
sharing scores that are approximately 10-fold lower in the narrow and broad phenotype 
models, whereas the super phenotype model, which includes depression, performs better 
than the two other groups in terms of LOD scores and allele sharing statistics. Similar 
patterns are observed in terms of LOD scores under the narrow, broad, and super phenotype 
models on the chromosome 12 regions. The argument concerning the dilution of the LOD 
score in the super phenotype model may apply here, where due to the misclassification of 
multiple non-affecteds (i.e. those with BPD diagnoses) as affected, the LOD score in the 
super phenotype model became non-significant. While unipolar depression and BPD may 
share susceptibility loci these three loci seem to only confer susceptibility to depression in 
the BBF.  
7.2.2.3 General Liability to Mood Disorders 
Susceptibility to mood disorders in general was implicated on chromosomes 1q21.1-q21.3 
and 2p23.1-p22.3 under the super phenotype model, providing evidence they contribute 
susceptibility to both unipolar and BPD. These two chromosomal regions gave low, non-
significant LOD scores when the narrow, broad, and, to a lesser extent, depression 
phenotype models were investigated. Evaluation of IBD sharing across phenotype models 
shows only a modest change in IBD sharing in the super model in comparison to the other 
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models, indicating linkage evidence was not realised in the other groups due to lack of 
power.  
The presence of specific liabilities to both BPD and depression as well as a general 
liability to mood disorders is in keeping with twin study findings from McGuffin et al. 
(2003) who estimated the shared genetic influence in liability to mania and depression at 
approximately 29%, using twins ascertained from the Maudsley hospital twin register, 
indicating most genetic liability to mania (approximately 71%) is specific to bipolarity. 
Further, in line with the findings of this study are reports that unipolar depression is more 
common in the relatives of probands with BPD, while the opposite is not true (Jones et al., 
2002; McGuffin and Katz, 1989; Weissman et al., 1984; Gershan et al., 1982), suggesting 
that families segregating BPD carry susceptibility loci for both BPD in particular and mood 
disorders in general, while families segregating unipolar depression are only enriched with 
genetic variants predisposing to depression or mood disorders in general but not BPD.  
7.2.2.4 Limitation of Categorical Phenotype Definitions 
A limitation of the linkage study concerns using categorical DSM criteria in defining 
disease phenotypes irrespective of clinical characteristics. Findings from linkage studies 
that use symptom dimensions and clinical characteristics have been more encouraging. For 
example, a linkage study on early onset BPD found a strong susceptibility locus on 
chromosome 9q34 for cases with mania onset before age 20 (Faraone, Lasky!Su, Glatt, 
Eerdewegh, & Tsuang, 2006).  Another study attempting to address co-morbidity with BPD 
reported linkage on chromosome 6q25 with co-morbid suicidal behaviour, on chromosome 
7q21 with co-morbid panic disorder, and on chromosome 16p12 for BPD with co-morbid 
psychosis (Cheng et al., 2006). Psychosis, as a measure of disease severity, was considered 
as a phenotype m9odel in the BBF linkage analyses, however, most of the individuals with 
psychosis were already considered under the narrow phenotype model and so conducting a 
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separate analysis with psychosis as a phenotype made little statistical sense.   
In summary the linkage findings in the BBF family implicated chromosomes 
1p22.2-p21.3, 3p25.3-p24.1, and 22q11.21-q12.1 in specific liability to BPD, chromosomes 
11p12, 12p13.32-p13.31 and 12q24.22-q24.31 in specific liability to unipolar depression, 
and chromosomes 1q21.1-q21.3 and 2p23.1-p22.3 in a general liability to mood disorders. 
! "#$!
 
7.3 The Mode of Bipolar Inheritance 
The pattern of disease inheritance in the BBF does not support the presence of a founder 
effect where one or more major disease genes are inherited from a common ancestor and 
shared by all affected individuals in a pedigree. The whole genome linkage scan implicated 
eight chromosomal regions in the aetiology of BPD and unipolar depression in the BBF. 
Locus heterogeneity caused by “extraneous genes” introduced by marrying-in spouses is 
evident. Different combinations of the identified susceptibility loci were found to segregate 




Susceptibility Loci Branch1 Subfamilies 
(n=12) 
Branches 2 and 3 
(n=6) 
1p22.2-p21.3 1,2,3,5,7,9 None Narrow 
 3p25.3-p24.1 2, 3, 8, 9, 10,12 14 
1p22.2-p21.2 1,2,3,5,7,9,10 None Broad 
 22q11.21-q12.1 1,5,7,8,9,10 None 
1q21.1-q21.3 1,2,3,4,6,7,8,9,10,12 14,16 Super 
 2p23.1-p22.3 1,2,3,4,6,8,9,10,12 14 
Depression 11p15.4 1,2,6,7,8,9,10,12 16 
 
Table 7.1. Table showing the number of subfamilies positively contributing to the LOD score 
in the susceptibility loci identified using MERLIN. No single genetic locus imparted major 
risk for BPD or depression in all subfamilies in Branch 1 or the BBF. Although a subfamily’s 
positive contribution to the LOD score does not necessarily mean that it is linked to the 
particular locus, this table gives an indication of the varied distribution of genetic 
susceptibility in the Brazilian subfamilies. Information on subfamily contribution to linkage 
regions 12p13.32-p13.31 and 12q24.22-q24.32 identified using McLinkage is not available.  
 
Many other reports of densely affected large families and isolated populations where the 
segregation of major genes is plausible indicate locus heterogeneity and support the 
involvement of multiple genes in the aetiology of BPD (Morissette et al., 1999; Shink, 
Morissette, & Barden, 2003; Venken et al., 2005). In fact, with the exception of two 
segregation analyses in BPD suggesting the role of a single major gene in disease 
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transmission (Spence et al., 1995), the general consensus in linkage studies is that multiple 
genes confer susceptibility to BPD in nuclear and large families. The absence of a major 
susceptibility gene in BPD is also supported by mathematical modelling of the genetic 
transmission of BPD (Craddock, Khodel, Van Eerdewegh, & Reich, 1995).  
 
The pattern of disease inheritance in the BBF is more appropriately explained in 
terms of a mixed model in which loci with medium to large effect sizes segregate in a 
dominant or recessive manner, against a background of polygenes with modest effect sizes 
that may modify or potentiate their effects. The effect sizes of the linkage regions were not 
tested, however, the assumption that they have medium to large effect sizes is supported by 
Risch & Merikangas, (1996) who estimated that loci conferring disease risk of two or less 
(i.e. small effects) are impossible to identify in linkage studies because more than 
approximately 2500 family members would be required to do so. A polygenic background 
of disease susceptibility is suggested by molecular genetic studies in sporadic cases of BPD 
that confirm the contribution of minor genes to BPD liability (Purcell et al., 2009; Sklar et 
al., 2011); however, their interactive effects remain unclear, both in association and linkage 
studies. It is possible that susceptibility to BPD and unipolar depression in the BBF is 
modulated by the interactive effects of different loci, including those identified in the study. 
To date, only two genome wide interaction linkage scans have been conducted to address 
epistasis in BPD. Both studies identified strong interactions between putative linkage loci 
suggesting epistatic effects contribute to the aetiology of BPD (Abou Jamra et al., 2007; 
Fullerton, Donald, Mitchell, & Schofield, 2010). 
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7.4 Environmental Factors 
The whole genome linkage analysis conducted in this thesis did not account for the effects 
of the environment. Linkage methods were originally developed for Mendelian diseases 
that assumed the action of a single gene mutation was sufficient to cause disease. As such, 
environmental factors were not taken into consideration. This presents a methodological 
limitation to all linkage studies of complex multifactorial diseases.  
We know that genes account for the majority of the risk to BPD, with heritability 
estimates in excess of 80%. However, this means that non-genetic factors account for 
approximately 20% of the variance to BPD in the population and are likely to have a role 
even in the special case of densely affected families. Twin studies show that it is non-
familial environmental factors such as negative life events that influence susceptibility to 
BPD (Kendler, Pedersen, Neale, & Mathé, 1995; Kieseppa, Partonen, Haukka, Kaprio, & 
Jouko, 2004; McGuffin et al., 2003). Gene-environment interactions, the combined action 
of multiple genes of small effect together with a variety of environmental factors, have 
been shown to influence susceptibility to psychiatric diseases. In affective disorders the 
effects of gene-environment interactions have been limited to candidate gene studies. For 
example, fifteen independent studies have found an interaction between a common 
functional polymorphism in the promoter region of the serotonin transporter gene, 5-HTT, 
and environmental adversity to be associated with the onset of depression (Uher & 
McGuffin, 2008). This has not been consistently supported in the literature, however 
studies that fail to present evidence for this particular interaction seem to test different 
environmental measures and use different methodologies (Karg, Burmeister, Shedden, & 
Sen, 2011; Uher et al., 2010). To date there is only one study investigating the impact of 
stressful life events on the propensity to develop depressive and manic episodes in BPD 
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patients; in this study depressive episodes were found to be moderated by a valine to 
methionine substitution polymorphism in the BDNF gene, but not manic episodes (Hosang 
et al., 2010). 
 
7.5 Parametric and Nonparametric Linkage Results 
7.5.1 Parametric Linkage Results 
Parametric linkage analysis identified susceptibility loci on chromosomes 3p24.3-p24.1 
(significant), 12p13.32-p13.31 (suggestive), 12q24.22-q24.32 (significant) and 22q11.21-
q12.1 (suggestive) using McLinkage analyses conducted on Branch 1 and the BBF as 
connected family unit under the assumption of genetic homogeneity. Evidence for linkage 
was only attained on chromosome 22q11.21-q12.1 (suggestive) using MERLIN analyses 
on subfamilies from Branch 1 and the BBF under a model of heterogeneity. The region on 
chromosome 22q11.21-q12.1 was the only region to receive support from both linkage 
programs and MERLIN achieved higher HLOD scores than McLinkage indicating a level 
of heterogeneity, with the subfamilies in Branch 1 yielding a maximum LOD score of 3.76 
and the unit of Branch 1 yielding a maximum LOD score of 3.53.  
Chromosome 3p24.3-p24.1 achieved genome wide significant linkage (maximum 
LOD=4.18) in Branch 1 and the BBF using McLinkage and a larger region on chromosome 
3p25.1-p24.1 achieved near suggestive evidence using MERLIN. One could deduce that 
this is a true linkage peak that failed to reach significance using MERLIN due to loss of 
power from splitting the pedigree into subfamilies. However, one needs to keep in mind 
that the region only achieved significance in McLinkage at a recombination fraction of 0.2 
indicating that the disease locus is approximately 2 cM away form the marker locus. Fine 
mapping studies will clarify the role of this region in BPD.  
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It is perplexing as to why the region achieving the highest LOD score in the study 
on chromosome 12q24.22-q24.32 using McLinkage was not detected using MERLIN. In 
fact HLOD scores reported in this region by MERLIN equalled or were slightly greater 
than zero. This region could be a false positive given the small size of the linkage region 
(120 kb) and the reported sharp decline in LOD scores. However this region is commonly 
associated with mood disorders in general, so it warrants some consideration. Having said 
that and as will be discussed in section 7.6 the McLinkage analyses were somewhat 
problematic and therefore the results need to be considered with some caution.  
7.5.2 Nonparametric Linkage Results 
Non-parametric linkage analysis identified susceptibility loci on chromosomes 1p22.2-
p21.3 (suggestive), 1q21.1-q21.3 (suggestive), 2p23.1-p22.3 (significant), and 11p15.4 
(significant) using MERLIN. It is important to interpret these results in light of the 
properties of the NPL statistics used to identify them. By estimating IBD between pairs of 
affected individuals, NPLpairs may attribute significance to regions where multiple variants 
confer susceptibility to disease in different pairs of affected family members. Conversely, 
due to estimating of IBD scores across groups of affecteds, NPLall may only attribute 
significance to regions where a single variant confers susceptibility to disease (Kong and 
Cox, 1997). Therefore, NPLpairs allows for allelic heterogeneity within family members in 
each subfamily, while NPLall does not. Interpreting the findings of the NPL with respect to 
this allows us to draw some conclusions. Significant NPL was achieved on chromosome 
11p15.4 using NPLall and on chromosome 2p23.1-p22.3 using NPLpairs only, while 
suggestive NPL was achieved on chromosome 1p22.2-p21.3 using NPLall and on 
chromosome 1q21.1-q21.3 using NPLpairs only. Given the properties of these test, we can 
deduce that the same genetic variants on chromosomes 11p15.4 and 1p22.2-p21.3 confer 
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susceptibility to disease within and perhaps between the sub-subfamilies, while different 
and perhaps multiple variants within chromosomes 1q21.1-q21.3 and 2p23.1-p22.3 confer 
susceptibility to disease in the subfamilies.  
7.5.3 Parametric Versus Nonparametric Linkage Results 
Parametric and NPL methods yielded different results in the linkage analyses. Only two 
regions were corroborated with LOD scores greater or equal to one across linkage 
methodologies, chromosome 11p15.4 and 22q11.21-q12.1. One could reason the 
susceptibility loci identified using parametric linkage had segregation patterns compatible, 
or near compatible, with the specified genetic models and were therefore identified using 
parametric linkage. They were potentially not identified by NPL due to lack of power. 
Equally, susceptibility loci identified using NPL possessed more complex patterns of 
inheritance than the models specified under parametric linkage and were therefore 
undetected. Furthermore, unaffected individuals many of whom presumably carry disease 
alleles without expression of disease are not considered in NPL methods. With parametric 
linkage one can weight evidence of linkage that some unaffected individuals harbour the 
disease allele, but not express illness by using penetrance functions. However, they are 
difficult to estimate and could account for discrepancies between the two linkage 
approaches.
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7.6 Large Family Studies 
It has often been proposed that large families are ideal samples for the molecular 
investigation of BPD susceptibility genes because they may segregate highly penetrant 
variants that predispose to disease, thus making them easier to detect. Highly penetrant 
variants also mean that affected family members are less likely to represent phenocopies. In 
addition, information on linkage phase, anticipation, and imprinting is more readily 
available in large families, which enables more accurate definitions of the mode of disease 
transmission and penetrance parameters necessary for parametric linkage (Blackwood et 
al., 2001). One large multigenerational family might also have the advantage of a more 
consistent environment over a collection of multiple nuclear families.  
The benefit of analysing a large family as a connected unit were somewhat realised 
in the analysis of the BBF with the identification of two depression susceptibility loci on 
chromosomes 12p13.32-p13.31, and 12q24.22-q24.32 that would have otherwise been 
missed had the analyses been limited to those conducted on the subfamilies. However, the 
consistency of the findings generated using McLinkage where difficult to determine. 
Initially the Marcov Chain Monte Carlo (MCMC) based method (see chapter 4 section 
4.5.4.6) was run using 1,000 iterations that yielded inconsistent LOD scores every time the 
analyses were run, indicating a lack of convergence. Subsequent analyses were performed 
using 10,000 iterations, which posed a number of computational difficulties and took 
approximately four months to complete. This long run time is partially due to the large 
number of closely spaced SNPs in the BBF genome scan, as opposed to the couple of 
hundred microsatellites usually employed in linkage scans of bipolar pedigrees, which 
exponentially increases the time required to achieve convergence. Consequently, the 
stability of the McLinkage results (all of which were the product of 10,000 iterations) 
presented in this thesis was not assessed. The differences in linkage findings between 
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Branch 1 and the BBF (which appear to follow a similar pattern in MERLIN with Branch 1 
yielding more linkage evidence) as well as the observed sharp oscillations in LOD scores 
could be due to the non-convergence of the program.  
The increased power to detect linkage in a large connected multigenerational 
pedigree was demonstrated in a microsatellite based study (459 microsatellite markers) that 
successfully analysed a thirteen-generation pedigree from the Central Valley of Costa Rica 
that was previously analysed as disconnected units. Using Simwalk2 (Sobel & Lange, 
1996), a linkage program based on the MCMC method used in McLinkage, estimation of 
allele sharing among affected relative pairs confirmed previously reported linkage to 
chromosome 18 and identified suggestive evidence for linkage on a new locus on 
chromosome 5q31.3-33.2 (Garner et al., 2001), which was subsequently confirmed by fine 
mapping studies (Herzberg et al. 2006; Jasinska et al. 2009).  
Nevertheless, analysing large pedigrees using dense SNP maps, from the experience 
of the BBF study, and as indicated by reports in the literature is fraught with limitations. 
Similar computational difficulties to those experienced in analysing the BBF were reported 
by Service et al. (2006) who attempted to analyse SNP data (n=4,690) in a bipolar pedigree 
from the Central Valley of Costa Rica comprised of 168 members, 82 of whom were 
genotyped, and found the pedigree in its entirety was too large and complex for multipoint 
analysis using any available software. Attempts to use Simwalk2 were unsuccessful due to 
the program’s inability to converge after weeks of running. A similar scenario was 
encountered by Marcheco!Teruel et al. (2006) who attempted to conduct a genome wide 
scan of a highly consanguineous six-generation pedigree from a relatively isolated region 
in eastern Cuba, with 73 family members genotyped using the Affymetrix 10K SNP marker 
set (n=10043). The large size and complexity of the pedigree entailed subdividing it into 
four branches for the analyses.  
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The difficulties of linkage conducted using MCMC based approaches could be 
avoided with the use of exact LOD score calculations. However, this method is unfeasible 
with large complex families unless they are split into smaller units, which results in loss of 
inheritance information. At this point in time, taking advantage of the genetic information 
in large pedigrees is hindered by inadequate analytic tools. 
7.6.1 Inbreeding Loops and Increased Homozygosity 
The presence of inbreeding loops in the BBF posed a second challenge to the linkage 
analyses. Most linkage programs rely on the process of clipping or peeling, in which small 
nuclear families within a large pedigree are analysed and all the information is collapsed 
onto one of the parents or relatives whose own sibship is analysed next. This continues 
until all the information is collapsed into one final person, the founder. If a loop exists in a 
pedigree, the process of collapsing circles around and around in an infinite loop 
(Terwilliger & Ott, 1994a). Inbreeding also increases the frequency of homozygosity, 
which decreases the informativeness of marker sets, subsequently reducing power to detect 
linkage. This is because marker heterozygosity is an important factor that helps determine 
whether a parental gamete is recombinant or non-recombinant, necessary for parametric 
LOD score calculations, and to differentiate between IBD and IBS necessary for NPL 
calculations (Ott & Rabinowitz, 1997). The Affymetrix 10K marker set used in the 
analyses captured 81% and 65% of the information content of Branch 1 and the BBF 
respectively. The suboptimal coverage of the genome, which may have lead to significant 
linkage being missed, is possibly a consequence of increased homozygosity in the family 
but is also likely to be a consequence of splitting the BBF into small subfamilies.  
Homozygosity mapping is based on the assumption that homozygous segments are 
inherited from an ancestor common to the maternal and paternal lineage without 
recombination and has been effective in detecting genetic mutations in rare recessive 
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diseases. Its applicability to complex disease has been limited to identifying modifier genes 
inherited in a recessive manner in conjunction with major disease loci (Ewald, Kruse, & 
Mors, 2003). The description of homozygosity mapping in the literature is confusing and 
warrants explanation. Some researchers refer to linkage analysis using a recessive mode of 
disease transmission as homozygosity mapping (Ewald et al., 2003; Ewald et al., 2005). 
This I have completed as part of the parametric linkage investigation conducted in this 
thesis with only a region on chromosome 22q11.21-q12.1 yielding suggestive evidence for 
linkage to disorders defined under the broad phenotype model (BPI, BPII, SAD, BPNOS, 
cyclothymia). However, more recent approaches to homozygosity mapping, e.g. PLINK 
Runs of Homozygosity and IBDFinder (Carr, Sheridan, Hayward, Markham, & Bonthron, 
2009) involve scanning the genome for homozygous segments and evaluating their 
association with diseases in a case-control comparison between affected and unaffected 
family members. These methods require high density SNP maps, and therefore were 
inapplicable to the BBF study.  
 
7.7 Anticipation 
Anticipation, characterised by earlier disease onset in successive generations was reported 
in the BBF (see chapter 2 section 2.1.5). In line with the findings in the BBF, McInnis et 
al., (1993) found members of the younger generations in 34 unilineal families with BPD 
manifested significantly more severe forms of disease on the basis of age of onset and 
episode frequency. Genetically, anticipation correlates with the expansion of trinucleotide 
repeat sequences. After reaching a critical size, they show a tendency to increase in size 
during both meiosis and mitosis. They are known to cause disease when located near or 
adjacent to specific genes. A method called repeat expansion detection (RED) was 
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developed to allow the detection of large trinucleotide repeats in human genomic DNA 
(Schalling, Hudson, Buetow, & Housman, 1993). To date, at least nine disorders including 
fragile X (Mahadevan et al., 1992), myotonic dystrophy (Fu et al., 1991), and Huntington’s 
disease (MacDonald et al., 1993) have been found to be associated with these dynamic 
mutations.  
There are suggestions that genes with expanding trinucleotide repeat sequences may 
have a role in the genetic aetiology of BPD (and schizophrenia). Three RED studies 
showed that the length of the most common pathogenic trinucleotide repeat, CAG/CTG, 
was greater in individuals with BPD and schizophrenia than in healthy controls. These 
findings were replicated in a large multicentre European consortium; however evidence 
that maximum repeat size was related to age of onset was not found (O’Donovan & Owen, 
1996). Some subsequent studies partially replicated the findings (Del-Favero et al., 2002; 
Lindblad et al., 1998), while others failed to do so (O’Donovan, Jones, & Craddock, 2003). 
Further, the evidence got less convincing when studies found that genes in the vicinity of 
the two loci where the majority of the trinucleotide repeat expansions involved in BPD and 
schizophrenia occurred (90% of repeat trinucleotides detected by RED in BPD and 
schizophrenia occurred on chromosomes 18q21.1 and 17q21.3) were not associated with 
either BPD or schizophrenia (Vincent, Paterson, Strong, Petronis, & Kennedy, 2000). The 
lack of association with adjacent genes does not, however, mean that this trinucleotide 
repeat is not important. The trinucleotide repeat might have an impact on the structural, 
epigenetic, and/or translational aspects of genes – independent of those neighbouring 
genotypes. Today, there is no consensus as to whether trinucleotide repeats contribute to 
the aetiology of BPD or schizophrenia. Caution in interpretation of the reported 
anticipation in the BBF is advisable until further investigation as the anticipation in the 
family could be explained by environmental factors and/or an ascertainment bias.
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7.8 Case Control Replication Study 
In chapter 6, the contribution of the gene or genes driving the linkage signals in the BBF to 
disease susceptibility in sporadic BPD and depression cases was tested for association with 
disease in two large bipolar and depression case control cohorts. No associations with BPD 
or depression were found. This could be explained by a number of factors. Firstly, the 
susceptibility loci identified in the BBF may be a result of multiple rare variants that do not 
play a role in the aetiology of most cases of BPD and unipolar depression. Secondly, the 
linkage signals in the BBF may reflect the effects of multiple rare variants that are 
impossible to tag with the available SNP genotyping technologies that are based on 
common polymorphisms. Finally, the susceptibility loci identified in the BBF could be a 
result of combinations of common genetic variants, however their effect sizes are small in 
the general population and can only be detected with sample sizes larger than the two case-
control cohorts used in this thesis. It is most likely that the linkage peaks identified in the 
BBF reflect a combination of rare and common genetic variants that contribute to disease 
susceptibility in the BBF and a combination of the mentioned factors prevented their 
identification in the case-control cohorts. The presence of common and rare disease causing 
variants in complex diseases is supported by findings from diabetes, autoimmune disorders, 
cardiovascular disease and Alzheimer’s Disease (Badner et al., 2011). 
7.8.1 The Generalisability of Findings from Large Family Studies 
The common belief that disease causing genes identified in large families are rare, and 
therefore account for a small proportion of liability to disease in the larger population, is 
not entirely justified. Linkage analyses of complex diseases have enhanced the 
understanding of the molecular pathophysiology of a number of diseases, and have helped 
identify common disease causing variants that confer susceptibility to non-familial forms of 
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diseases, as in Alzheimer’s disease (AD). The localisation and identification of the first AD 
locus, the gene that encodes the Amyloid Precursor Protein (APP) lead to the formulation 
of the Amyloid cascade hypothesis that explained the aetiology of AD (Hardy & Higgins, 
1992). This hypothesis has been since corroborated by the subsequent identification of 
additional loci PSEN1 (Sherrington et al., 1995), PSEN2 (Levy-Lahad et al., 1995; Rogaev 
et al., 1995), and APOE (Pericak-Vance et al., 1991); all thought to act together in one 
pathway. Although familial forms of AD constitute a minority of all cases, the APP, 
PSEN1 and PSEN2 gene were all identified through linkage analysis in extended pedigrees. 
Subsequent findings confirmed the role of APOE4 in late onset AD that is more common in 
the general population by association analysis (Payami, Kaye, Heston, Bird, & 
Schellenberg, 1993). While it is uncertain whether this example could be transferred to 
complex psychiatric diseases that do not appear to have Mendelian forms, it shows that the 
identification of loci that have a direct impact on a small subset of individuals might 
provide an essential step towards the understanding of the molecular mechanisms of 
disease. In psychiatry, Disrupted in Schizophrenia (DISC1) is an example, first found to be 
disrupted by a balanced 1 to 11 translocation segregating with severe psychopathology, 
including schizophrenia, BPD, and mental retardation, in one extended pedigree from 
Scotland (St Clair et al., 1990). The research group subsequently cloned the break point on 
chromosome 1q42 and identified two genes they called DISC1 and DISC2 (Millar et al., 
2000). Association with common SNPs within DISC1 have since been found in unrelated 
individuals with schizophrenia and BPD in the general population (Hennah et al., 2003; 
Hodgkinson et al., 2004; Schosser et al., 2010). However, the findings have been 
inconsistent and are likely due to discrepancies in samples sizes, clinical phenotypes, and 
study methodologies (Chubb, Bradshaw, Soares, Porteous, & Millar, 2007; Prata et al., 
2010).  
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7.8.2 Common Genetic Variants in Complex Disease 
Linkage studies lost some favour in human genetics following a host of inconsistent and 
un-replicable findings. The advent of high throughput genotyping and possibility of 
analysing case-control data using a hypothesis-free approach saw a surge in genome wide 
association studies (GWAS). Today, GWAS have been completed for most psychiatric 
diseases and have probably identified most of the common genetic variants (minor allele 
frequencies greater than 5%) involved. However, most of the associated SNPs have very 
small effect sizes and the proportion of heritability explained is at best modest for most 
psychiatric diseases. The term missing heritability refers to the discrepancy between total 
heritability as estimated by twin and family data, and the proportion of phenotypic 
variation explained by all detected SNPs from GWAS that are associated with the disease 
at genome wide significance levels (Visscher, Goddard, Derks, & Wray, 2011). A recent 
collaborative BPD GWAS including a total of 4,387 cases and 6,209 controls identified 
only two regions of genome wide significant association in ANK3 (9.1 X 10-9) and 
CACNA1C (P=7.0X10-8) each with an odds ratio below 1.45 despite a heritability of 
approximately 70%-90% for BPD (Sklar et al., 2011). Further, hits from GWAS, or SNPs 
in LD with hits from GWAS, have rarely been tracked to causal polymorphisms and give 
no insight into disease mechanisms, leading many to assume that the associated variants 
must have subtle regulatory effects (Cirulli & Goldstein, 2010) (i.e. control the expression 
of one or more other genes. A regulator gene may encode a protein, or it may work at the 
level of RNA, as in the case of genes encoding microRNAs.).  
These observations from GWAS lead to suggestions that rare genetic variants 
defined by allele frequencies of less than 1% may contribute to common diseases (Bodmer 
& Bonilla, 2008). An increasing body of evidence from cardiovascular research and other 
complex diseases, indicates rare genetic variants explain a significant amount of disease 
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heritability. A series of studies that have re-sequenced genes of known function in 
individuals with cardiovascular disease have identified rare coding variants with substantial 
effects on levels of cholesterol, triglycerides, etc (Romeo et al., 2009). In addition, re-
sequencing of genes identified in GWAS for hypertriglyceridemia has concluded that there 
is an excess of rare variants from these genes in cases compared to controls (Johansen et 
al., 2010). The current suggestion is that GWAS signals may reflect the effect of multiple 
rare variants that have been credited to common variants, so called synthetic associations 
and sequencing or even targeted re-sequencing of candidate genes highlighted from GWAS 
data may reveal enrichment of rare variants in cases versus controls (Dickson, Wang, 
Krantz, Hakonarson, & Goldstein, 2010).  
Reassessment of the contribution of rare genetic variants to disease susceptibility 
renewed interest in linkage studies particularly those conducted in large families and 
isolated populations. Large families facilitate the detection of rare disease causing variants 
because they are present at much higher frequency in affected family members. Families 
with multiple early-onset cases are likely to be enriched with variants of large effect as well 
as variants of small effect. Isolated populations, such as the Icelandic population, are used 
to localise disease predisposing genes by tracing unexpectedly long runs of identity-by-
descent sharing among affected relatives (Kong et al., 2008). In retrospect, inconsistent 
linkage findings attributed to locus heterogeneity, reduced penetrance and phenocopy rates, 
terms that pertain to Mendelian diseases, could be explained in terms of multiple 
undetectable rare genetic variants (in linkage due to small effect sizes) in the aetiology of 
the disease (Cirulli & Goldstein, 2010).  
7.8.3 Whole Genome Sequencing  
Whole genome sequencing offers a comprehensive collection of rare variants and structural 
variation (deletions, duplications, copy-number variants, insertions, inversions and 
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translocations) for study. DNA sequencing technology has been available for many years; 
however recent advances in DNA sequencing technology have vastly increased the volume 
of sequence that can be obtained in a short period of time. New sequencing machines can 
currently sequence 25 billion base pairs of sequence a day (HiSeq 2000 from Illumina), 
although this rate has been increasing with remarkable rapidity. Large amounts of data 
provide sufficient coverage to identify most variants present in the genome. 
Large scale whole genome sequencing projects are currently under way. The 1000 
Genomes Project is an international research collaboration established to undertake 
sequencing of the complete genome of approximately 2500 individuals. The first part of the 
study sequenced two mother-father-adult-child trios from the HapMap project at high 
coverage, with each single base sequenced 20 to 60 times, and 179 individuals at low 
coverage, with each single base sequenced 2 to 4 times. They also sequenced 1,000 genes 
in 900 individuals at high coverage (50X). In the project’s second phase, the genomes of 
2,500 people will be sequenced at a rate of more than two genomes every 24 hours. The 
project aims to be able to identify very rare variants with a MAF of 0.5% and greater. 
Sequencing families with multiple affected members has been recommended 
(Manolio et al., 2009). Sequencing nuclear families enables the detection of approximately 
70% of sequencing errors and permits the identification of precise locations of 
recombination events. This results in turn to near complete knowledge of inheritance states 
by precisely determining the parental chromosomal origins of sequence blocks in offspring 
(Roach et al., 2010). Alternatively, sequencing family members with available linkage data 
is useful in prioritising variants identified in whole genome sequencing. It is a very 
efficient approach to sequencing that takes advantage of existing family data that is 
difficult to collect. Families driving the linkage evidence are re-contacted (granted consent 
is available) and enrolled in follow-up sequencing projects (Bowden et al., 2010).   
! "#$!
7.9 Future Directions 
7.9.1 Sequencing the BBF 
It is the objective of the BBF study to identify functional or causal mutations within the 
identified linkage regions that may contribute to the development of BPD and depression 
using next generation sequencing approaches. The first stage of the sequencing analysis of 
six BBF members has already begun. The following methodologies were used. To qualify 
for this sequencing study family members needed to have a BPI disorder diagnosis with 
psychotic features, and to belong to a subfamily showing evidence of linkage to one or 
more of the regions identified with whole genome significance in the BBF linkage 
analyses. Family members were then selected if they had PLINK Identity-by-Descent 
(IBD) pair-wise estimates (--genome) (see Chapter 4 section 4.4.2) greater than 0.25 (i.e. 
second degree relatives), as the more distantly related the affected individuals the fewer 
genetic variants they will share. Whole genome sequencing was outsourced to Beijing 
Genomics Institute (BGI). Following receipt of the sequence data from BGI, data cleaning 
and alignments to the reference genome were conducted. Variant calling will be completed 
in the near future. 
For a genetic variant (e.g. SNPs, CNVs) to truly have an effect on disease aetiology, 
it should somehow perturb either the protein itself or gene expression. Sequence analysis of 
the BBF will focus on variants with functional consequence for protein-coding genes in the 
linkage regions. For example variants that delete some or all of a gene, introduce a 
premature stop site into a protein or result in a non-conservative amino acid substitution. 
The aim is to identify genetic variants with functional effects and elucidate their biological 
mechanism in BPD.  
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7.9.2 Collaborative Studies 
The complex nature of BPD genetics has meant that the identification of susceptibility loci 
has remained difficult. To this end, the future of mood disorders and psychiatric genetics in 
general may be in large international collaborations, involving thousands or even tens of 
thousands of samples. For example, collaborations in GWAS offer increased sample size, 
thereby also increasing the power to detect associations of small effect. The psychiatric 
GWAS consortium (PGC) is one such mega collaboration that has recently reported on a 
combined GWAS of 7481 individuals with BPD and 9250 controls (Sklar et al. 2011).  
Common variants, however, are not solely responsible for the genetic aetiology of 
mood disorders. The percentage of individuals with mood disorders who may harbour rare 
genetic variants responsible for the manifestation of the disorder is currently unknown, but 
future re-sequencing projects will provide answers. In order to reduce type I error, re-
sequencing projects will have be performed in large cohorts of cases and controls as well as 
families to accurately define private (i.e. occurring in a single family) versus rare 
mutations. The future of BPD genetics is in large scale collaborative projects which are 
necessary for the sufficient sample sizes to be able to detect genetic variation of both small 
and large effect. However, the necessity for large sample sizes in BPD should not 
overshadow the need for stringent inclusion criteria that clearly define the disorder in terms 
of severity as well as explore its relatedness to unipolar depression and schizophrenia.  
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 7.10 Conclusion 
This thesis investigated the aetiology of BPD in a complex, multigenerational family from 
Brazil, with the aim of contributing to the current understanding of the genetic 
determinants of BPD. The BBF study found four genome wide significant regions that 
conferred susceptibility to BPD, unipolar depression, and mood disorders in general 
confirming the presence of a specific and a shared liability to BPD and unipolar depression. 
The significant linkage findings of the BBF study are promising given that they either 
replicate confirmed linkage regions, e.g. 12q24.22-q24.32 or provide further support for 
linkage regions previously identified with suggestive evidence for linkage e.g. 2p23.1-
p22.3. While the role of genetic variants driving the linkage signals in the BBF was not 
clarified in two case-control cohorts with BPD and unipolar depression, whole genome 
sequencing of the BBF is underway and will clarify the source of the linkage signals (if 
any), identify the genetic variants conferring susceptibility to BPD in the BBF, and 
elucidate their biological function. The hope for BPD and mood disorder genetic research 
is to one day translate clinical and genetic research into better diagnosis, prognosis and 
treatment with the ultimate aim being the alleviation of mood symptoms.  
There is potential to bridge the gap between research and patients through drug 
development and gene therapy. Uncovering novel pathways involved in the aetiology of 
psychiatric diseases (e.g. for depression outside the monoaminergic pathway which is 
currently targeted by all known classes of antidepressants) (Skolnick, Popik, & Trullas, 
2009) and better understanding already established pathways that could be targeted by new 
and possibly more effective therapeutic drugs is possible with the new wave of sequencing 
studies particularly those based on families segregating severe forms of psychiatric diseases 
and the collaborative atmosphere recently adopted in psychiatric genetics.  
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Appendix I 
The spearman correlation matrix for the parametric linkage tests performed where 1=recessive, narrow, Branch 1, 2=recessive, narrow, BBF, 3=recessive, 
super, Branch 1, 4= recessive, super, BBF, 5=recessive, broad, Branch 1, 6=recessive, broad, BBF, 7= recessive, depression, Branch 1, 8=recessive, 
depression, BBF, 9=dominant, narrow, Branch 1, 10= dominant, narrow, BBF, 11= dominant, super, Branch 1, 12= dominant, super, BBF, 13= dominant, 
broad, Branch 1, 14= dominant, broad, BBF, 15= dominant, depression, Branch 1, 16= dominant, depression, BBF and the number of estimated independent 





The spearman correlation matrix for the non-parametric linkage tests performed where 1=narrow, NPLpairs, Branch 1, 2= super, NPLpairs, Branch1, 3=broad, 
NPLpairs, Branch 1, 4= depression, NPLpairs, Branch 1, 5=narrow, NPLall, Branch 1, 6=super, NPLall, Branch1, 7= broad, NPLall, Branch 1, 8=depression, 
NPLall, Branch 1, 9=narrow, NPLpairs, BBF, 10= super, NPLpairs, BBF, 11=broad, NPLpairs, BBF, 12= depression, NPLpairs, BBF, 13=narrow, NPLall, BBF, 







When you do parametric linkage analysis, it is possible to estimate a 
parameter alpha that estimate the fraction of all families with evidence for 
linkage. This doesn't actually translate in any simple way into the fraction 
of families with positive and negative LOD scores (technically, there is a 
distribution of per family likelihoods expected under the null and under the 
alternative and - in you data - Merlin estimated that the distribution seen 
across your sample is compatible to what would be expected under your linked 
model). 
 
The delta parameter from the Kong and Cox LOD scores is not really 
interpretable - but if you want to know more, you should read the original 









Full table for MERLIN near suggestive HLOD scores on maximum region (1-highest LOD of 
2.47 region) on chromosome 3p25.1-p23.2 under the narrow phenotype model and the 
dominant mode of disease inheritance 





Position HLOD ! HLOD ! 
rs171239 10780817 28.48 2.47 0.49 2.48 0.49 
rs2017892 10825748 28.55 2.47 0.49 2.48 0.49 
rs2017903 10825837 28.55 2.47 0.49 2.48 0.49 
rs720352 11056831 28.90 2.48 0.49 2.48 0.49 
rs2616552 11666798 29.75 2.48 0.49 2.49 0.49 
rs2030151 12749130 30.70 2.49 0.49 2.50 0.49 
rs1828165 12895749 30.82 2.49 0.49 2.48 0.48 
rs11080 13169322 31.27 2.49 0.50 2.45 0.54 
rs59585 13501254 31.98 2.79 0.58 2.68 0.53 
rs1368575 13831304 32.43 2.79 0.57 2.64 0.53 
rs934448 13831352 32.43 2.79 0.57 2.64 0.50 
rs3846122 14680270 33.75 2.65 0.55 2.49 0.49 
rs1826215 14887182 34.11 2.60 0.54 2.44 0.47 
rs1947147 15903002 35.84 2.60 0.54 2.40 0.47 
rs723247 15997849 35.94 2.60 0.54 2.40 0.47 
rs953245 16199191 36.16 2.59 0.54 2.39 0.47 
rs1546377 16256377 36.24 2.58 0.54 2.38 0.45 
rs723813 17240402 37.70 2.49 0.51 2.31 0.45 
rs728022 17305303 37.74 2.48 0.50 2.30 0.43 
rs958542 18247966 38.46 2.43 0.48 2.26 0.43 
rs717793 18602534 38.91 2.42 0.48 2.26 0.43 
rs717939 18626742 38.94 2.42 0.48 2.26 0.43 
rs1398922 18670160 39.00 2.42 0.48 2.26 0.43 
rs1372555 19371580 39.89 2.41 0.48 2.25 0.42 
rs949665 19613756 40.19 2.41 0.47 2.25 0.42 
rs1506101 19761201 40.38 2.40 0.47 2.24 0.42 
rs1392573 20695652 41.56 2.38 0.47 2.23 0.42 
rs904827 20696379 41.56 2.38 0.47 2.23 0.40 
rs725542 21213394 42.22 2.33 0.45 2.18 0.40 
rs721623 21650537 42.77 2.30 0.44 2.16 0.39 
rs2358693 22574169 43.582 2.12 0.43 1.98 0.39 
rs1074612 22579568 43.586 2.12 0.43 1.98 0.49 
rs778480 23498492 44.75 1.67 0.41 1.54 0.37 
rs2045300 23871402 45.34 1.70 0.43 1.56 0.38 
rs951015 24053792 45.63 1.72 0.43 1.58 0.38 
rs1112195 24085166 45.68 1.72 0.43 1.58 0.38 
rs1394764 24405050 46.18 1.74 0.44 1.59 0.39 
rs2196427 24533278 46.39 1.74 0.44 1.59 0.39 
rs720822 25232155 47.77 1.94 0.47 1.77 0.42 
rs1348979 27027497 49.44 2.12 0.49 1.94 0.44 
rs2037472 27070331 49.49 2.12 0.49 1.95 0.44 
rs724244 27242153 49.69 2.14 0.49 1.96 0.44 
rs2370990 27690531 50.22 2.18 0.49 2.01 0.44 
rs2371121 27850725 50.40 2.20 0.49 2.02 0.44 
rs1609729 28303111 51.13 2.25 0.49 2.07 0.44 





Subfamily contribution to the HLOD scores on chromosome 3p25.1-p23.2 as reported by all 
SNPs identified with near suggestive HLOD scores in MERLIN. SNPs in this region nearly 
achieved significance using MERLIN and were indicated with genome-wide significance by 
McLinkage. The Subfamilies 1 through to 12 constitute Branch 1, subfamilies 13 and 14 
constitute Branch 2 and subfamilies 15 through to 19 constitute Branch 3. Subfamily 17 was 
dropped from the analyses. 
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